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Resumo 
“MODIFICAÇÃO COVALENTE DE PEPTIDEOS ANTIMICROBIANOS E 
ANTICANCERIGENOS PARA A MELHORIA DE SUAS PROPRIEDADES 
FARMACOLÓGICAS. ” 
 Seguindo a informação obtida por um estudo de concepção racional, sintetizaram-se análogos 
estabilizados helicoidais cíclicos, diméricos e lipidados do péptido Cm-p5. O monômero cíclico 
apresentou atividade aumentada in vitro contra Candida albicans e Candida parapsilosis, em 
comparação com Cm-p5. Inicialmente, 14 mutantes de Cm-p5 foram sintetizados seguindo um 
racional de sinal para melhorar a atividade antifúngica e as propriedades farmacológicas. Testes 
antimicrobianos mostraram que a atividade foi perdida em cada um dos 14 análogos, sugerindo 
como uma conclusão principal, que uma ponte de sal Glu-His poderia estabilizar a conformação 
helicoidal de Cm-p5 durante a interação com a membrana plasmática. Um derivado, obtido por 
substituição de Glu e His por Cys, foi sintetizado e oxidado com a geração de um monômero 
cíclico com atividade antifungica melhorada. Além disso, dois dímeros foram gerados durante 
o procedimento de oxidação. Os dímeros mostraram uma estrutura secundária helicoidal em 
água, enquanto o monômero cíclico mostrou apenas esta conformação em SDS. Além disso, o 
dímero antiparalelo apresentou moderada atividade contra Pseudomonas aeruginosa e 
atividade significativa contra Listeria monocytogenes. Nem o monómero cíclico nem os 
dímeros eram tóxicos contra macrófagos ou células humanas THP-1. 
Continuando com as modificações covalentes da estrutura do Cm-p5, no capítulo 2 se descreve 
o desenho, síntese e caracterização de 15 análogos lipídicos e cíclicos/lipidados doCm-p5. 
Estudos anteriores mostram que a N-lipidação do Cm-p5 pela reação de Ugi-4C aumenta 
notavelmente a atividade antifúngica. Nosso teste biológico inicial mostra que a lipidação com 
ácido decanóico não mostrou nenhum efeito na atividade do Cm-p5, enquanto o ácido 
pentadecanóico o diminuiu. Esse resultado não está de acordo com o aumento da atividade no 
caso do análogo lipidado da reação de Ugi-4C. A reação de Ugi-4C não apenas introduz uma 
cadeia lipídica, também produz uma N-substituição que pode alterar o comportamento 
conformacional da cadeia lipídica. Para determinar a influência da N-substituição, três análogos 
contendo Ala, Gly ou Pro entre a cadeia lipídica e a sequência normal de Cm-p5 foram 
sintetizados. Gly e Pro estão implicados em várias mudanças conformacionais em proteínas ou 
peptídeos. Gly possui alta flexibilidade enquanto a Pro é o único aminoácido N-alquilado e 
participa na formação de giros ou estruturas rígidas. Adicionalmente, seguindo o esperado 
aumento de actividade por formação de ponte disulfeto, foram preparadas variantes 
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semelhantes possuindo Ala (introduzida como comparação), Gly ou Pro entre a cadeia de 
decanoilo e o peptídeo CysCysCm-p5 cíclico/dimérico. Finalmente, a lipidação por reação Ugi-
4C com n-dodecilisonitrila e posterior ciclização entre Cys produzem versões cíclicas e 
diméricas de ciclopeptídeos Ugi lipidados. Todos os compostos estão sob avaliação biológica 
que permitirá obter uma conclusão sobre o motivo estrutural necessário para produzir o análogo 
cíclico e lipidado do Cm-p5 mais antifúngico. 
 No capítulo 3, usamos a combinação de métodos de fase sólida e fase líquida para a síntese da 
droga anticâncer, carfilzomib (CFZ). A via convergente compreende a construção de 
tetrapéptidos em fase sólida seguida de acoplamento do epóxido preparado previamente. Os 
efeitos colaterais da CFZ incluem a insuficiência cardíaca e a falta de ar, de modo que o 
desenvolvimento da bioconjugação ou da entrega direcionada é realmente desejado. Com este 
objetivo, nós preparamos um ligante que não deixa resíduos, carbonilacrilic-Val-Cit-PABna 
forma de álcool em fase sólida usando a resina especial DHP em alto rendimento. Este ligante 
na forma de álcool foi tosilado e iodado com o objetivo de melhorar os rendimentos da reação 
de substituição com CFZ. Os peptídeos de inserção a pH baixo (pHLIPs) visam a acidez nas 
superfícies das célulascancerígenas e apresentam utilidade numa vasta gama de aplicações, 
incluindo imagiologia de tumores e distribuição intracelular de agentes terapêuticos. Neste 
trabalho, pretendemos fundir a capacidade de seletividade de células tumorais do peptídeo 
pHLIP com a libertação sem resíduos, estabilidade e seletividade do novo ligante 
carbonilacrílico. Finalmente, a bioconjugação de CFZ com o peptídeo pHLIP através do ligante 
carbonilacrílico-Val-Cit-PAB, para a libertação sem resíduos e distribuição direcionada para 
tumores poderia melhorar significativamente a efetividade deste fármaco no tratamento do 
câncer. 
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Abstract 
“COVALENT MODIFICATION OF ANTIMICROBIAL AND ANTICANCER PEPTIDES 
FOR THE IMPROVEMENT OF THEIR FARMACOLOGICAL PROPERTIES.” 
Following the information obtained by a rational design study, cyclic and dimeric helical 
stabilized analogues of the peptide Cm-p5 were synthetized. The cyclic monomer showed an 
increased activity in vitro against Candida albicans and Candida parapsilosis, compared to 
Cm-p5. Initially, fourteen mutants of Cm-p5 were synthesized following a rational design to 
improve the antifungal activity and pharmacological properties. Antimicrobial testing showed 
that the activity was lost in every of these fourteen analogues, suggesting as a main conclusion, 
that a Glu-His salt bridge could stabilize Cm-p5 helical conformation during the interaction 
with the plasma membrane. A derivative, obtained by substitution of Glu and His for Cys, was 
synthesized and oxidized with the generation of a cyclic monomer with improved antifungal 
activity. In addition, two dimers were generated during the oxidation procedure, a parallel and 
anti-parallel one. The dimers showed a helical secondary structure in water, whereas the cyclic 
monomer only showed this conformation in SDS. In addition, the antiparallel dimer showed a 
moderate activity against Pseudomonas aeruginosa and a significant activity against Listeria 
monocytogenes. Nor the cyclic monomer nor the dimers were toxic against macrophages or 
THP-1 human cells. 
Continuing with the covalent modifications of the Cm-p5 structure, in chapter 2 is described 
the design, synthesis and characterization of 15 lipidated and cyclo-lipidated analogues of Cm-
p5. Previous studies showed that N-lipidation of Cm-p5 by Ugi-4CR increase notably the 
antifungal activity. Our initial biological test showed that lipidation with decanoic acid did not 
display any effect inthe activity of Cm-p5, while pentadecanoic acid decreased it. These results 
are not in accord with the increased activity in case of the Ugi lipidated analogue. The Ugi-
4CRdo not only introduces a lipid chain, also produce N-substitution that can alter the 
conformational behavior of the lipid chain. To determine the influence of N-substitution, three 
analogues containing Ala, Gly or Pro between the lipid chain and the normal sequence of Cm-
p5 was synthetized. Gly and Pro are implied in several conformational changes in proteins or 
peptides.Gly possesses high flexibility while Pro is the only N-alkylated aminoacid and 
participate in loop or rigid structure formation. In addition, following the expected increase of 
activity by disulfide bridge formation, similar variants possessing Ala (introduced as a 
comparison), Gly or Pro between adodecyl chain and cyclic/dimeric CysCysCm-p5 were 
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prepared. Finally, lipidationby Ugi-4CR with n-dodecylisonitrile and subsequent cyclization 
between Cys produce cyclic and dimeric versions of Ugi lipidated cyclopeptides. All 
compoundsare under biological evaluation thatwill permit to gainconclusion about the 
structural motif needed to produce the more antifungal cyclic and lipidated analogue of Cm-p5. 
In chapter 3, we used the combination of solid phase and liquid phase methods for the synthesis 
of the anticancer drug, carfilzomib (CFZ). The convergent route comprises the tetrapeptide 
construction in solid phase followed by coupling with the previously prepared Leu-epoxide. 
Side effects of CFZ include the heart failure and shortness of breath so that the development of 
bioconjugation for targeted delivery is desired. With this aim, we prepared a traceless 
carbonylacrylic-Val-Cit-PAB linker as an alcohol in solid phase using the special DHP resin in 
high yield. This alcohol linker was tosylated and iodinated with the aim of improve the yields 
of the substitution reaction with CFZ (substitution of tosylate need heating). The pH (low) 
insertion peptides (pHLIPs) target acidity at the surfaces of cancer cells and show utility in a 
wide range of applications, including tumor imaging and intracellular delivery of therapeutic 
agents. We pretend to merge the capacity of tumor cell selectivity of pHLIP peptide with the 
traceless, stability and selective delivery of the new carbonylacrylic linker. Finally, the 
bioconjugation of CFZ to pHLIP peptide through the carbonylacrylic-Val-Cit-PAB linker, for 
the traceless release and targeted delivery to tumors could significantly improve the 
effectiveness of this drug in cancer treatment. 
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Chapter 1 
1 Introduction. Chapter 1 
The global levels of fungal infections continue in rise,1 but treatment options that can be used 
to treat these pathologies remain limited to only three classes of antifungal drugs: polienes, 
azoles and equinocandines. The high toxicity of the existent antimycotics in the market and the 
increase of the resistance of these pathogenic microorganisms are the fundamental factors that 
motivate the need for development of new types of drugs, to be employed as internal,oral and 
less toxic antifungals.2 
The AMPs (antimicrobials peptides) may have fungicidal or fungistatic activity, and may or 
may not have antibacterial activity at the same time that they exert their action against fungi. 
Isolated or synthetic antifungal peptides may be effective candidates in the treatment of 
systemic or superficial mycosis. There are different types of classifications for them that include 
defensins, -barrelins, thionines, among others antifungal peptides and have activity against a 
variety of fungi such as Candida albicans, Candida kefyr, Candida tropicalis and 
Saccharomyces cerevisiae, responsible for recurrent diseases in plants and animals.3 
Cm-p5 (SRSELIVHQRLF-NH2) is a peptide derived from the coastal tropical snail Cenchritis 
muricatus (Gastropoda: Littorinidae) that showed antifungal activity against the human 
pathogens Candida albicans, Candida parapsilosis, Cryptococcus neoformans, Trichophyton 
mentagrophytes and Trichophyton rubrum. This peptide did not exhibit any toxicity against the 
mammalian cell line in vitro. It was structurally characterized by CD Polarimetry and NMR 
Spectroscopy,4 revealing an α-helical structure under membranolitic conditions, and a tendency 
to a random structure in aqueous solution.5 
Cm-p5 is not a suitable therapeutic agent due to its easy proteolytic degradation. The presence 
of two Arg residues in the structure probably facilitates trypsin degradation and free N-terminal 
can be targeted by aminopeptidases. The covalent modification of this peptide could improve 
themetabolic stability, once determined the significance of each aminoacidfor the biological 
activity. 
Cm-p5 showed a fungistatic action in the 10-40 μg/mL (6,7-26,9 µmol/L) range against 
Candida albicans, in a similar fashion observed by the conventional antifungal fluconazole 
(MIC= 8-16 µg/mL (16-32 µmol/L), against Candida albicans) but different of the 
amphotericin B, which exhibited a fungicidal character eliminating the microbial population in 
24 h.6 Due to the low hemolytic6 and cytotoxic activity of Cm-p5, the simplicity of its synthesis 
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and covalent modification and the similar antifungal activity compared to conventional 
fungistatics like fluconazole, we selected Cm-p5 for our investigation.7 
The biological action mechanism of Cm-p5 is currently unknown. However, this molecule 
interacts preferentially with fungal phospholipids, does not interact with ergosterol (unlike 
amphotericin B)8 and, to our knowledge, there is no information regarding whether is possible 
or not penetration in to cytoplasm. Based on the previous aspects four action mechanisms can 
be hypothesized: i. destabilization of cellular membrane,9ii. inhibition of cell wall synthesis 
(like echinocandins),10 iii. inhibition of ergosterol synthesis11 (like clotrimazole and 
fluconazole) or iv. intracellular enzymatic inhibition.12 In any case, helical stabilization of Cm-
p5 should play an essential role in the biological activity because permit the adoption of an 
amphipatic structure posesing the positively charged Arg residues toward one face and 
hydrophobic residues opposed in the other face. 
1.1 Objectives of our work. 
This chapter focuses on the development of better pharmacological active versions of the 
antifungal peptide Cm-p5, in an attempt to demonstrate the potential of the concept of 
secondary structure stabilization by disulfide bridges in AMPs of -helical acyclic 
conformation. Cm-p5 is prone to proteolytic degradation in-vivoand by determining the 
importance of all aminoacids in the sequence would be possible to know the structural features 
needed for the adoption of an -helix at contact with membranes and for the exertion of 
biological activity. For this aim, we present a general study of the relevance of several 
aminoacids in the biological activity of Cm-p5.  The conclusions of this rational design of the 
Cm-p5 structure will permit to change the correct residues by Cys and produce the 
corresponding cyclic and helical stabilized analogue.  
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2 Bibliographic Revision. Chapter 1 
2.1 Peptides as drugs 
In recent years, peptides have received an increasing attention as potential pharmaceuticals, 
despite their intrinsic drawbacks in terms of pharmacological properties. The attractiveness of 
peptides as drugs is mainly due to their high degree of specificity in comparison with 
conventional drugs. Furthermore, massive peptide synthesis can be performed in a cost-benefit 
manner and more effective ADME (administration, distribution, metabolism and excresion) 
parameters can be obtained with rationally designed peptide derivatives.13At present, more than 
20% of the current drugs are of peptide structure thanks to the development of combinatorial 
chemistry, the obtention of libraries in filamentous phages, the techniques of controlled release, 
the isolation of natural peptides,14 the use of recombinant methods and the strategies for the 
introduction of covalent modifications.15 
Solid phase and solution peptide synthesis technologies have advanced significantly, thus 
improving the availability of therapeutic peptides from an economic perspective. Previously, 
there were negative perceptions about the quality and scale achievable by the synthetic 
methodologies for the development of therapeutic peptide candidates. The production of tons 
of the peptide Fuseon (Enfuvirtide, 36 aminoacids), inhibitor of the human immunodeficiency 
virus (HIV), revolutionized the SPPS and turned it into the standard technology for obtaining 
these compounds in research and production stages.16 
Peptides are used in the treatment of diabetes, malaria, arthritis, cancer, allergies, obesity and 
cardiovascular diseases.17 They have great advantages as therapeutic and prophylactic agents 
due to their low drug-drug interaction and poor cytotoxicity.15Peptide drugs are quite common 
nowadays,18 however, their usage is limited due to their low metabolic stability,low oral 
absorption, rapid excretion through the kidney and liver, low immunogenicity and high 
hemolytic activity.19 
Peptides have a low half-life in-vivo because they are usually degraded by proteases.20Proteases 
are specific for L-aminoacids and are classified in endopeptidases and exopeptidases (amino or 
carboxypeptidases). The formers produce the hydrolysis of non terminal peptide bonds and the 
latter hydrolyze the residues of the N and C ends. Endopeptidases such as chymotrypsin rapidly 
degrade amide bonds where Phe, Trp or Tyr (slowly to His) participates and trypsin affects Arg 
and Lys. Aminopeptidases and carboxypeptidases are nonspecific in their action.21 
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To overcome these drawbacks, current research on peptides is aimed primarily at improving 
the pharmaceutical formulation to promote the release process, and the design of new 
methodologies for covalent modifications that enhance their properties. 
2.2 Antimicrobial peptides. Characteristics and biological importance. 
AMPs (Antimicrobial Peptides) are a widely distributed defense mechanism in plants, insects, 
vertebrates, unicellular organisms and even mammals.22 They present a broad spectrum of 
activity against fungi, bacteria, viruses and protozoa,23so they have an important protective 
action in organisms that lack an immune system while in vertebrates they are part of the innate 
immunity.22b In addition, they are not affected by mutations that cause resistance to classical 
antibiotics.24 
The AMPs were discovered more than 90 years ago, with gramicidin being one of the first 
reported, since its discovery occurred in 1939 and its effectiveness in protecting against 
pneumococcal infection was demonstrated. In 1941, another AMP, tirocidine, was discovered 
and found to have activity against gram-positive and gram-negative bacteria. In the same year, 
it was also isolated from the plant Triticuma estivum, the AMP purotionina, which was effective 
against fungi and pathogenic bacteria.25 
Although the first AMPs were discovered several years ago, research on this topic did not 
become relevant until 1980when cecropins and magainins were found, mainly due to 
difficulties in the large-scale production. Since then, more than 5000 AMPs have been isolated 
from various natural sources and others have been synthesized by chemical methods.25 
They are generally hydrophobic and amphipathic at physiological pH,26characteristics that 
favor their interaction with lipid bilayers, mainly those that form the membranes of 
pathogens.22a The structure of the AMPs is diverse, so numerous classifications have been 
published taking into account the organismproducer, cell type, mechanism of action, etc. One 
of the more used criteria is based on the secondary structure, by which the AMPs have been 
divided into 4 groups: α-helix, -sheet stabilized by two or three disulfide bridges, extended 
structures with one or more predominant residues (such as Trp and Pro) and in the form of a 
loop due to the presence of disulfide bridges.26 
AMPs have been found in a wide range of organisms. They can act as part of the innate defense 
system of plants, vertebrates and invertebrates, against infections.27 In general, they have the 
ability to directly killmicrobes. However, in recent years, the concept for this heterogeneous 
group has been extended to host defense peptides. This is due to their abilities to disturb growth 
and also to modulate the immune system.28Immunomodulation and, in some cases, “beneficial 
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immunogenicity” are extraordinary features which are not reachable by traditional antibiotics, 
because their chemical nature is functionally incompatible with the immune system. 
AMPs can be used in the treatment of infectious diseases and/or complement the therapy with 
conventional antibiotics, since they show synergism.29 In studies conducted by Nuding and 
others30 it was demonstrated that the peptides HBD1, HBD3, HNP1, HD5, and LL-37 when 
combined with the antibiotics tigecycline, moxifloxacin and meropen have synergistic effect, 
which favors the antimicrobial activity against toxigenic and non-toxigenic strains of 
Clostridium difficile. Bacitracin has also shown this behavior in combination with topical 
antibiotics such as neomycin and polymyxin B.31 
It has recently been shown that the peptide Ib-AMP-4 (derived from the plant Impatiens 
balsamina) has a potent activity against different gram-positive and gram-negative bacteria. In 
studies conducted by Fan and others,32 it was shown that when combined with vancomycin, it 
inhibits the growth of Vancomycin-resistant Enterococcus faecalis (VRE). The effectiveness 
of other AMPs such as LZ1 has also been demonstrated. This peptide inhibits the growth of 
Propionibacterium acnes as well as Staphylococcus epidermidis and Staphylococcus aureus. 
In addition, it has been shown to inhibit the secretion of proinfalammatory cytokines such as 
interleukin 1-β (IL 1-β).33 
Notably most AMPs are very hemolytic and toxic to mammalian cells (mellitin,34guavanin 2,35 
etc.) avoiding their use orally, therefore, only topical formulation is possible in the majority of 
cases (commercial triple antibiotics).36 
2.3 Resistance to antibiotics. Antifungals AMPs and Cm-p5. Commercialization of 
antifungal peptides. 
Giving the lack of new classes of conventional antibiotics is necessary the development of new 
therapeutic principles and/or complements for infectious diseases.37 Bacterial and fungal 
resistance to antibiotics is a great issue for medicine nowadays, not only due to the expected 
consequences of microbial resistant strains,38 but also because of the unexpected effects in 
brain, neurons39 (Alzheimer, ME or ALS conditions),40 and biofilm formation in ear canal and 
teeth.41 
In addition, abuse in the usage of antibiotics has been proposed as a drawback for natural 
microbiota, causing many and unexpected immunological, gastric, neurological, and 
opportunist microorganism disorders. In the same sense, antifungal or antibacterial drugs for 
systemic treatment are always accompanied by many side effects, making necessary the 
hospitable monitoring.42 
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Since 2000, 20 new antibiotics have been launched on the market and approximately 40 
compounds are in clinical trials.43 Of these, at least 15 are AMPs or mimetics that act directly 
as antimicrobial or immunomodulatory agents. 
At the same time, the speed in the approval of new antimicrobial drugs remains in continuous 
decline,44with regulatory control criteria much more demanding than those that are necessary 
for any new drug to be licensed for human use.45 
For example, peptide hLF1-11 (composed of the last 11 aminoacids of the N-terminus of human 
lactoferrin) is in phase I/II clinical trials. This peptide acts indirectly on infections through a 
mechanism of immunopotentiation of the host response against Candida and other non-fungal 
pathogens,46and it was found to be safe and tolerable when is administered intravenously.47 On 
the other hand, PAC-113 is one of the most advanced peptides, currently developed for the 
treatment of oral candidiasis and for vaginal, dermatological and ophthalmological 
applications.45 
2.4 Peptide Synthetic Methods 
Peptides can be obtained by chemical synthesis, recombinant deoxyribonucleic acid 
technology, transgenesis and enzymatic synthesis.48There is great interest in obtaining peptide 
structures either by extraction from natural sources or by chemical synthesis. In living 
organisms, peptides appear in minimal quantities and the extraction is costly and complicated. 
In addition, the modification of natural structures is a complex process (possibility of chemical 
modifications). Synthetic molecules are more robust, easy to transport and store, and their 
production is more economical and flexible.49 
Pharmacologically active peptides such as oxytocin (hormone produced by the pituitary and 
which determines the contraction of the uterus and accelerates labor in mammals), corticotropin 
and secretin, have been synthesized since the 50s of the last century with optimization and 
automation improving year after year.50 
To synthesize a peptide, two synthetic procedures are considered: synthesis in solution and 
synthesis in solid phase (SPPS).51Synthesis in solution is cheaper if it is used to obtain small 
peptides; but the mandatory purification of the obtained intermediates is a tedious and slow 
process that requires high specialization, a disadvantage with respect to the SPPS in the case of 
larger sequences.52SPPS requires a shorter reaction time, peptides are obtained with a high 
degree of peptidic purityand do not produce mechanical losses.50 
There are two strategies of peptide synthesis: linear or steps synthesis in which each aminoacid 
is sequentially coupled53 and it is used for small oligopeptides; and the convergent synthesis, 
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where short fragments are grown separately, which are then purified and assembled with high 
yields, more useful in the synthesis of large peptides and proteins.54 
For the formation of the amide bonds by aminoacid binding, it is necessary to activate the 
carboxylate and selectively protect, temporarily and orthogonally, the functional groups outside 
to the coupling. The activation must guarantee high yields and low levels of racemization of 
the Cand is done by introducing an electroaceptor group by means of: a) activation in situ 
(carbodiimides, uronium salts and phosphonium salts) or b) preparation and previous isolation 
of the active species (acyl chlorides, acylazides, anhydrides, active esters).49b The in-situ 
activation methods with carbodiimides (DIC, DCC, EDC) are more used due to their lower cost, 
although, the salts of uronium (HATU) and phosphonium (PyBOP) are more efficient and less 
toxic (Figure 1). 
 
Figure 1: Common coupling reagents for peptides, a) carbodiimides, b) phosphonium salts and c) 
uronium salts. 
During activation with carbodiimides (Scheme 1),55 the protonation and the formation of an ion 
pair with the carboxylate (slower process in the presence of bases) generates O-acylureas which 
are potent acylating agents, not only of the amine (Scheme 1A), but of another carboxylate 
(Scheme 1B) and can cyclize to form the oxazolones (Scheme 1C). The formation of N-
acylureas (Scheme 1D) is a frequent cause of diminution of yields, but can be avoided 
maintaining a low temperature or using apolar solvents. All postulated intermediaries are 
attacked by nucleophiles with decreasing reactivity in the O-acylurea series (Scheme 1A), 2-
alkoxy-5(4H)-oxazolones (Scheme 1C) and symmetrical anhydrides (Scheme 1B). Which of 
the three is involved in the formation of the peptide bond depends on the presence, availability 
and reactivity of the amino component. The apolar solvents (DCM) and to a lesser extent the 
aprotic polar (DMF) favor the formation of O-acylureas. 
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Scheme 1: Peptide coupling with carbodiimides and racemization inhibitor. 
The O-acylureas, the anhydrides and the 5(4H)-oxazolones in the presence of strong bases can 
cause the enolization of the C of the aminoacid following three mechanisms (Scheme 2): a) 
basic enolization, b) oxazolone formation in dipeptides (it causes that peptides should be always 
grown from the C-terminus to the N) and c) oxazolone formation in aminoacids protected as 
carbamates (less important due to the lower basicity of NH).55 
 
Scheme 2: Racemization mechanisms. Act: activating. 
The use of the nucleophiles HOBt, HOAt, HOSu, HOOBt, Oxyma Pure and OxymaK (Figure 
2) diminishes the occurrence of collateral reactions (Scheme 1, B, C, D) during coupling and 
especially racemization. These substances are N-substituted oximes with electroaceptors groups 
that reinforce the alpha effect present between the N and the OH, turning them into excellent 
nucleophiles (HOMO of greater energy) and at the same time very good leaving groups. These 
compounds react quickly with the O-acylureas forming the corresponding activated esters 
(Scheme 1E), which are less reactive and more stable in presence of the bases.55 Inconveniently 
benzotriazols as HOBt, HOAt and HOOBt are explosives and especially Oxyma Pure have been 
developed to substitute them, showing inclusive more efficiency in terms of coupling times and 
diminutions of racemization. On the other hand, OxymaK increase the yield when Cl-Trt-
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Chloride resin is used by avoiding early cleavage of the peptide due to acidity of the Fmoc-Aa-
OH (pKa= 2-3) and any other racemization inhibitor (pKa= 4-5). 
 
Figure 2: Most common racemization inhibitors. 
To protect selectively, orthogonally and temporarily the functional groups other than the 
coupling, different protective groups and different protection schemes have been developed. 
After each coupling, the N-terminus which will participate in the formation of the following 
peptide bond is deprotected, so that orthogonal protective groups are used, meaning that they 
can be selectively eliminated in the presence of others, according to the reaction conditions.55 
The amines are mostly protected in the form of carbamates, the most common being Fmoc, 
Boc, Cbz or Alloc and the carboxylic acids are commonly protected in the form of methyl, 
terbutyl or benzyl esters (Figure 3). The Fmoc, MeO and BzlO groups are sensitive to basic 
conditions, Boc and tBuO to moderately acidic conditions, Cbz and BzlO to strongly acidic 
conditions or hydrogenolysis and Alloc is eliminated with Pd(0) catalyst.50 The protection 
schemes are classified according to the difference of conditions to eliminate the N-end 
protective groups with respect to those of the side chains, the most used are the Boc/Bzl56 and 
the Fmoc/tBu.57 
 
Figure 3: Some amino and carboxylate protecting groups. 
2.5 Solid Phase Peptide Synthesis. Polymeric Supports. 
SPPS was developed by Merrifield in 1963 (Boc/Bzl methodology) and its name is due to the 
fact that the peptide sequence grows anchored to a polymeric support insoluble in any of the 
solvents used.58Among its main advantages is the ease of purification of the final product, the 
possibility of reusing the polymer matrix and the stability of these polymers at different 
conditions. In 1978 Sheppard incorporated the Fmoc/tBu protection scheme that has practically 
replaced the original Boc/Bzl methodology.49b 
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The SPPS is carried out by the covalent assembly of the selected aminoacid (C-terminal 
deprotected) to an insoluble support. Consecutive steps of deprotection of the N-terminus and 
coupling of the desired aminoacids, after activation, allow the peptide anchored to the support 
to grow by means of a linear synthesis strategy.50 
In each coupling a complete and rapid conversion is necessary, which is achieved with an 
efficient reaction based on the combinationof a carboxylic acid activator, an inhibitor of 
racemization and the use of an excess of reagents, which are eliminated with washed and 
vacuum filtration. 
The completion of each coupling step is checked by the ninhydrin test, a sensitive and efficient 
colorimetric method that allows the detection, even in small amounts, of primary amines. The 
pale yellow ninhydrin reacts at 100°C in the presence of Py, phenol and KCN causing an O-
phenylcyanohydrin and a purple complex, indicative of the presence of primary amines 
(Scheme 3, Reverse Strecker reaction).59 
 
Scheme 3: Proposed mechanism for the reaction of primary amines with ninhydrin in solid phase. 
The anchoring to the resin is achieved with bifunctional molecules, which are permanently 
linked to the resin at one end, and on the other, they temporarily bind to the aminoacid that will 
start the peptide to be synthesized. These molecules are called linkers and have a functional 
group capable of reacting orthogonally during the final step of cleavage, in conditions that may 
or may not affect the protective groups of the side chains of the aminoacids, and which are 
responsible for selectively breaking the temporal link with the peptide (Table 1).60 
A suitable synthetic strategy allows the preparation of diverse peptide structures and even 
introducing covalent modifications by combining the principle of orthogonality between the 
protective groups of the side chains, the -amino protector and the linker.61 
The first solid supports were based on polystyrene (first generation resins) and are still the 
type of polymeric support most used in SPPS. This support is highly stable in the working pH 
range, is mechanically stable under vacuum filtration conditions, swells with solvents such as 
DMF, DCM and THF, and can be obtained with a substitution level of 0.3 to 1.2 mmol/g of 
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resin. Polyamide or second generation resins swell better in polar solvents and are more flexible 
than polystyrene resins.54 PEG (third generation) resins can be of two types: with embedded 
PEG, which were developed to obtain more stable resins, swell in polar and non-polar solvents 
and present substitution of 0.15 to 0.5 mmol/g. The resins composed of a PEG/PPG network; 
which are compatible with polar and non-polar solvents, prevent the peptides from aggregation 
and favor the speed of the coupling reactions.54 
Table 1: Some characteristics of the most used polymer supports. 
Resin MBHA Rink or Am Wang HMBA Trt DHP 
Methodology Boc/ Bzl Fmoc/tBu Fmoc/tBu Fmoc and Boc Fmoc/tBu Fmoc/tBu 
Linker 
Structure 
  
  
 
 
Extreme C Amide Amide Acid Acid Acid Alcohol 
Cleavage HF 95% TFA 95%TFA  NaOH (1M) 1% TFA PPTS 
Lateral Chain Unprotected Protected 
 
2.5.1 Boc/Bzl Chemistry 
The Boc/Bzl protection scheme presented by Merrifield upon introduction of the SPPS is 
based on the use of the Boc group as temporary protector of the -amino and benzyl groups 
(Bzl and Cbz, orthogonal to Boc) as protective groups of the side chains.62 Glu(OBzl), 
Asp(OBzl), Lys(Cbz(2-Cl)) and Arg(Tos), His(Cbz), Cys(Acm), Ser(Bzl), Thr(Bzl), Trp(6-
Dcb) and Trp(Cbz(2-Br)); that resist the deprotection conditions of Boc (TFA 40% in DCM). 
The treatment of Boc-Aa-Resin with TFA liberates isobutylene, CO2 (causes an increase in the 
entropy that favors the reaction) and the amine remains protonated, so it must be neutralized 
before the next coupling. These groups are labile in acidic conditions (95% TFA) but can be 
selectively eliminated if necessary. For example, Cbz and OBzl are removed by hydrogenation 
or alkaline hydrolysis and the Acm is released with I2. In this protection scheme, the MBHA 
resin (Table 2) is used, whose connector is sensitive only to extremely acidic conditions, 
achieving the de-anchoring and the elimination of all the protective groups of the side chains 
by treatment with HF.53 
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2.5.2 Fmoc/tBu Chemistry 
Many peptides are not stable to the vigorous cleavage conditions (HF) used in the Boc/Bzl 
methodology. Most suitable conditions to carry out the SPPS were accessible in 1978, when 
Sheppard developed the chemistry Fmoc/tBu.49b 
The Fmoc/tBu protection scheme is based on the use of the Fmoc group as temporary protector 
of -amino and of tertbutyl and benzyl groups (tBu, Boc, Bzl) as protective groups of the side 
chains.62 Glu(OtBu, OBzl), Asn(OtBu, OBzl), Lys(Boc), Arg(Pbf), His(Boc), Cys(Trt), 
Ser(tBu), Thr(tBu), Trp(Boc) are used; also Tyr(tBu), that resists the conditions of deprotection 
of the Fmoc (Pip 20% in DMF). These groups are labile under strongly acidic conditions (95% 
TFA), but they can be selectively eliminated if necessary. For example, Bzl is removed with 
hydrogenolysis and Trt is released with 1% TFA. Rink resin (Table 2) is used for this 
methodology; its connector is sensitive to acidic conditions, achieving the de-anchoring of the 
peptide by treatment with 95% TFA, which at the same time eliminates all the protective groups 
of the side chains.53 
2.6 Peptide characterization 
In the state of art, synthetic peptide characterization is a constituted science and it is not 
necessary a dept characterization in investigation stages. Peptide synthesis at the CIGB is 
relized under high quality control conditions due to the regulatory agencies controls that permit 
the use of these molecules in medical application. The synthetic procces is sequential (you have 
a register with the order of each aminoacid in the sequence) and include a previous checking of 
the enantiomeric purity and quality of all the commertial reagents, spetially the aminoacids. 
The stages of synthesis are register manually in time of coupling reaction, batch, quantity and 
type of regents, laboratory temperature, etc, a notably different approach when compared with 
isolated peptides from natural products. This permit to analice and correct instaintainly any 
problem that could be occur during the manufacturing proceces. 
That quality control guaraticees the necessary reproducibility, reliability and exactitude in 
peptide characterization during investigation stage that could be realized only knowing the 
purity by RP-HPLC, the molecular mass by ESI-HRMS and if necessary, the secondary 
structure by CD. In investigation stages, biopharmaceutical industries need a rapid 
characterization methods for many peptidic analogues or covalent modifications of a drug 
candidate, validated with the experience and science and only the more active versions are 
charactericed depper because should pass to production stages. 
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Peptide characterization during production stage are realized knowing the purity by RP-HPLC, 
the yield of each batch (only a control of reproducibility because the purity is more important 
in solid phase synthesis), the molecular mass by ESI-HRMS, the sequence by ESI-HRMS-MS 
(only for the three first batch), the total structure and conformation by NMR (only for validation 
and registry, first batch). 
Peptide sequenciation by ESI-HRMS-MS is more accurately for acyclic peptides, with the N-
terminal deprotected and normaly only discret sectors of the sequence are sequenced. Many 
times, peptide sequenciation or NMR is not sufficient for the total structure elucidation and the 
use of many complementary tecniques is desired. 
An important aspect in the analysis of peptides with ESI ionization source is the tendency to 
produce multi-charged ions, which benefits the accuracy of measurements of high molecular 
masses such as those of peptides and proteins and, on the other hand, originates spectra of 
complicated masses. For peptides and proteins, the spectrum actually consists in series of 
quasimolecular ions that have multiple charge (M+nH)n+, appearing in the spectra double (A2) 
and triple (A3) charged peaks, from which we can determine the molecular mass of the 
synthesized compound. This is a technique that is characterized by a high accuracy, which is 
due to the redundant m/z information that originates, corresponding to the different states with 
multiple charge of each species.63  
The ESI-HRMS equipment at the CIGB have a QTOF-2 analyzer that only have exactitude in 
the second digit. On the other hand the resolution of the equipment is independent of the 
exactitude and QTOF-2 permit determine differences of masses between 0-1 Da, enabling the 
determination of the isotopic distribution and the corresponding multiple charge (M+nH)n+ 
peaks. The error in the second digit is not resolution of the equipment, is exactitude. For 
determine a major exactitude with the QTOF-2 analycer is necessary to use an internal standar 
for the calibration. In investigation stages or quality controls, normaly is not used the internal 
standar.  
2.7 Salt bridge stabilization of secondary structures of peptides and proteins 
In the stabilization of secondary structures of peptides and proteins, are involved factors such 
as hydrophobicity, van der Waals forces, hydrogen bonds, dipole-dipole and ion pairs 
interactions.64 The ion pairs are formed between residues with charged side chain, as is the case 
of the oxygens of the carboxyl groups present in residues D or E, and the nitrogen atoms of the 
residues of Arg, Lys or His, when they are present at a distance less than 4Å.65 Negative 
residuesAsp and Glu favor the -helix when they are located near the N-terminal and in the 
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first turn. On the contrary, positively charged residues, Lys and His, stabilize the -helix when 
they are in positions near to the C-terminal.65 
Several types of electrostatic forces favor the enthalpy component of the overal energy and 
balance the loss of conformational entropy by formation ofan -helix.66 These include the 
hydrogen bonds formed between COi---NH (i+4) and the interactions between the side chains 
spaced at i, i+3 and i, i+4and with the ends of the -helix (Figure 4).64b 
 
Figure 4: Stabilization of the -helix of a peptide by salt bridge interactions of the residues Glu(E) red 
and Lys(K) blue of the side chain spaced at i, i+3 and i, i+4 and by hydrogen bonds formed between 
COi --- NH(i+4) (green).64b 
However, peptides, unlike proteins, are normally small molecules that do not have a secondary 
structure well defined in solution, and it is only by interaction with the active site or with a 
membrane (intermolecular interactions) that a defined conformation is induced. To achieve that 
a peptide sequence adopts a defined conformation or at least a 3D energy closer to that present 
in the parent protein, it is often necessary to form disulfide or lactam bridges that generate a 
certain conformational constraint.67 
The introduction of a structural constraint by cyclization, although does not make the peptide 
adopt a defined secondary structure in solution, can decrease the degrees of freedom (accessible 
microstates, entropy of the system), making easier the interaction with the active site.67 
2.8 Covalent modifications of peptides 
The covalent modification of peptides by cyclization, polymerization, conjugation to carrier 
proteins,68 introduction of N-substitutions or peptoid residues, variation of the N and C 
terminals,69 peguilation,70 change of aminoacids in the sequence, phosphorylation, 
glycosylation, lipidation71 or the synthesis of peptide-steroidal hybrids72 have been important 
ways in obtaining drugs within the fields of combinatorial chemistry and biotechnology. These 
changes give to the peptides a greater selectivity and resistance to proteases, and increase 
conformational rigidity or immunogenicity, each case accordingly. 
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2.8.1 Structural constraints by cyclization 
The introduction of structural constraints into a synthetic peptide is one of the modifications 
that have been used to improve the therapeutic properties67or to mimic the secondary structure 
they present in a native protein.73 
Cyclization can decrease the conformational flexibility of the linear peptide, improve 
membrane permeability and thermodynamic stability and metabolic stability,74 besides 
increasing the stability to proteolysis by endo and exopeptidases.75 This translates into an 
improved resistance of the peptide to extreme environments such as high temperatures, media 
with low or high pH values and high concentration of organic solvents. Cyclization can be 
achieved by formation of disulfide bonds, cyclic amide (lactam), ester, hydrazine, among 
others.76 
The most accepted method to achieve specificity in the formation of intramolecular bridges is 
the use of an orthogonal protection system for the aminoacids that form the cycles.77 Different 
protective groups have been developed to selectively obtain disulfide bridges by combining the 
cyclization reaction in solid phase and in solution.78 The synthesis of peptides with one or more 
intramolecular bridges containing up to three disulfide bonds has been described.79 The 
synthesis of four disulfide bonds is rarely reported.80 However, Fangzhou Wu et al. reported 
recently the sequential synthesis of four disulfide bonds in insulin analogues with the use of six 
different protective groups of Cys.74 
2.8.2 Formation of disulfide bridges 
The formation of a single disulfide bond in peptides is generally carried out from the free thiol 
groups present in the aminoacid residues. It can also be carried out by the 
deprotection/oxidation method from the peptide with the protected thiol groups.81 
The formation of several disulfide bridges can be achieved by the method of randomization of 
disulfide bridges in solution,82 by a regioselective formation83 or by the combination of both.84 
With the use of the method of randomization of disulfide bridges multiple products are obtained 
and those thermodynamically more stable prevail.74 For the regioselective formation of several 
disulfide bridges, different groups are used to protect the pairs of cysteines that will be linked 
together.74, 85 This is the method of choice to ensure the desired formation of the bonds, since 
an analytical control of the oxidation of the cysteines can be carried out as the disulfide bridges 
gradually form.86 The formation of the disulfide bridges can be carried out both in solution and 
in solid phase. When the cyclization is carried out in solid phase, resins with a low substitution 
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level must be used to favor the intramolecular reaction by the phenomenon known as "pseudo-
dilution".81 
The most common oxidation method of thiol groups present in free Cys is using oxygen from 
the air as oxidizing agent, in an aqueous solution, at basic pH. This method is very simple, but 
it can take several days.75 Oxidation of Cys residues present in peptides can be mediated by 
substances with low molecular weight with disulfide bonds or two free thiol groups such as 
cystine, cystamine, dithiothreitol, dithiobis-2-nitrobenzoic acid, or by other electroaceptor 
substances such as diiode, dimethylsulfoxide (DMSO), diamide and potassium ferrocyanide.75 
The competition between the formation of intramolecular disulfide bonds (cyclization) or 
intermolecular (oligomers) is mainly governed by the concentrations of the Cys pairs. Thus, to 
obtain the intramolecular bridges diluted solutions are used and to obtain dimers or oligomers, 
oxidation is carried out in concentrated solutions.81 The formation of disulfide bridges can be 
verified by the Ellman colorimetric test (for oxidation from free thiol groups),87 by RP-HPLC88 
and by mass spectrometry.89 Characterization by RP-HPLC is based on the change in the 
retention time of the oxidized species with respect to its precursor. However, the retention times 
of the cyclic and acyclic species often coincide, and in order to distinguish them, it is necessary 
to carry out the iodoacetamide test in which the free thiol groups are protected and their 
retention time is different fromthe disulfide bridged cyclic compound. 
It has been observed that Cys residues can be desulfurized during cyclization in slightly basic 
medium (pH 8-9). This process occurs by extraction of the C proton from the Cys and 
elimination of H2S by an E1-Cb mechanism, with the formation of dehydroalanine. Then an 
intramolecular Michael addition with the free thiol of another Cys generates a thioether bond 
with the C of the desulfurized residue, however, if the Cys residues are very close (i, i+2) or 
sterically hindered, the intramolecular addition does not happen and the peptide remains in the 
form of dehydroalanin.90 
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3 Results and discussion. Chapter 1 
3.1 Design of Cm-p5 mutants 
Normally, an Ala scanning is conducted for estimating the relative importance of each 
aminoacid in the biological activity of peptides.91 However, a simpler and faster approach is 
the rational change of aminoacids92 according to the natural structures currently found in AMPs, 
like the presence of many Arg, Lys, Cys and Trp residues (His in case of histatins),93 and 
alternated positive charges to form a facial amphiphilic -helix or -sheet. This is a 
fundamental structural principle that works well in many cases. AMPs possess a shape in which 
cationic and hydrophobic aminoacids organize spatially in discreet sectors of the molecule, 
forming an amphipathic pattern.94 
Tryptophan is frequently found in interaction with the interfacial region of the lipid 
membrane,95 Arg and Lys, have positive charge at physiological pH permitting the selective 
interaction with microbial membranes and Cys, in certain conditions, stabilize secondary 
structures by formation of disulfide bridges.96 
Based on a simple electrostatic interaction model between cationic AMPs and negatively 
charged bacterial/fungi membranes, are notable several structural features in the helix 
projection of Cm-p5. This peptide presents hydrophobic residues at the C-terminus, a free N-
terminus (positively charged), and an amphipathic helical structure with positive charges 
concentrated towards one side of the helix, but less defined hydrophobic region.  
By analyzing the Schiffer-Edmundson (wheel) projection of Cm-p5 (Figure 5d), it is possible 
to notice that the polar side of the helix contains an unexpected hydrophobic Ile residue. In 
addition, polar residues, such as Glu and His, are curiously present in the putative hydrophobic 
face. 
Previous research,19 have demonstrated that inserting Arg-Cys (forming Cm-p3) or Met-Lys 
(forming Cm-p4) in the C-terminus of the mollusk derived peptide Cm-p1 did not improve 
antimicrobial activity, however Leu-Phe (forming Cm-p5) insertion gives rise to high 
antifungal activity (Figure 5). 
Using the online server http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py, helical 
parameters97 of helicoidal peptides were obtained. Hydrophobicity (H, intrinsic capability of a 
peptide to move from an aqueous into a hydrophobic phase), frequency of polar residues (Freq. 
Polar), relative hydrophobic moment (μHrel, quantitative measure of peptide amphipathicity,98 
defined as the vector sum of the hydrophobicities of the individual aminoacids) and the angle 
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moment (angleM: angle in radians between the horizontal plane and direction of Hrel) are 
listed inTable 2.99 
These parameters do not indicate in any sense that these peptides have helicoidal behavior and 
is not our interest to demonstrate that they form helix. All calculations were realized supposing 
-helical structure and as an explanation of the loss of antifungal activity for all these analogues 
of Cm-p5.  
Table 2: Helical parameters for non-amidated Cm-p1, Cm-p3, Cmp4 and Cm-p5 
 Helix H μHrel z FreqPolar angleM 
Cm-p1 SRSELIVHQR 0.18900 0.05685 1 0.700 5.18806 
Cm-p3 SRSELIVHQRRC 0.20167 0.21172 2 0.667 5.35967 
Cm-p4 SRSELIVHQRMK 0.17750 0.09499 2 0.667 1.98272 
Cm-p5 SRSELIVHQRLF 0.44833 0.19215 1 0.583 0.24380 
H represents hydrophobicity, Hrel: relative dipole moment of hydrophobicity, z: total charge, FreqPolar: 
frequency of polar groups, angleM: angle in radians between the horizontal plane and direction of Hrel 
a)  b)  c)  d)  
Figure 5:Schiffer-Edmundson projections of the antifungal peptides Cm-p1 (a), Cm-p3 (b), Cm-p4 (c) 
and Cm-p5 (d). 
When analyzing in detail the effect of these C-terminal modifications in the Cm-p1 activity, it 
is observed that addition of Arg-Cys (forming Cm-p3) do not considerably change the 
frequency of polar groups, hydrophobicity or orientation (arrow inFigure 5b) of relative 
hydrophobic moment, but significantly alters the μHrel magnitude (Table 2). In contrast, the 
insertion of Met-Lys (forming Cm-p4) turn the direction of μHrel (arrow in Figure 5c), but 
poorly increases its magnitude (Table 2). Addition of Leu-Phe (forming Cm-p5), greatly 
modifies all the parameters, especially, H and μHrel (arrow in Figure 5d and Table 2). In this 
case, Phe is located in a i,i+4 position respect to His, therefore there may occur a --interaction 
between the phenyl and imidazole groups of these residues, which could have some effect in 
helix stabilization. Based on a previous article,5 Cm-p4 is a more active version of Cm-p1 than 
Cm-p3, which may indicate that the variation of the direction of μHrel is more relevant than the 
variation of its magnitude, particularly in Cm-p5, where μHrel is almost directed from the 
hydrophilic to the hydrophobic face (arrow in Figure 5d). 
These previous results, apparently suggest that magnitudes of H, Hrel or its direction, are 
fundamental for activity, favoring sequences with elevated H (intrinsic capability of a peptide 
to move from an aqueous into a hydrophobic phase) or Hrel (quantitative measure of peptide 
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amphi-pathicity) and direction of Hrel from hydrophobic phase to hydrophilic to promote 
membrane interaction. 
Regarding these results, 14 analogues of Cm-p5 (Figure 6and Table 3) were designed based on 
SAR. The experimental strategy of this work pretends, with a minimal use of resources, to gain 
an insight on how the antifungal activity of the Cm-p5 is affected by the change of aminoacids. 
Arg residues remained in almost all cases since positive chargesin the polar face of the helix 
are essential for membrane interaction and biological activity. 
The fundamental modifications introduced in the sequence of Cm-p5, based on aminoacids 
charge at physiological pH, were: i. change of the negative Glu residue, ii. introduction of 
another positive charge by mutation of Lys or Arg by Ile; iii. change of His by a positively 
charged Arg; iv. change of Leu5 by another positively charged residue (Lys) and v. truncated 
versions, where residues such as Leu, Arg, Ser, Glu or His were eliminated.  
All the performed changes will assist in evaluating the contribution of each mutated residue to 
the helical stabilization and therefore, to the biological activity of the peptide. Glu was modified 
by the similar but neutral Gln (peptide 3 in Table 3), in the case of Asp (peptide 2 in Table 3), 
the negative charge was maintained but the length of the lateral chain was modified. The charge 
was also eliminated by mutation by Ala (peptide 4 in Table 3) and -Ala (peptide 5 in Table 3), 
simulating the classical alanine scanning. Changing His for Arg (peptide 1 in Table 3), we will 
assess the role of the neutral His residue at physiological pH and the effect of a permanent 
positive charge. Further changes, such as Ile for Lys (peptide 7 in Table 3) or Arg (peptide 6 in 
Table 3) will introduce another positive charge within the hydrophilic face. Truncated analogues 
could indicate, for example, if the activity is influenced by the interaction of Glu and His in i+3 
(peptide 9 in Table 3) or Glu and Lys in i,i+2 (peptide 10 in Table 3). 
Dimeric MAP (Multi Antigenic Peptides) type peptide was synthesized, since, activity 
improvement in those cases was reported.100 N-terminal acetylated Cm-p5 was produced to 
evaluate if the positively charged free N-terminus contributes to the antifungal activity. 
Chemical synthesis is a valuable tool to obtain analogues of biologically active peptides found 
in natural sources. The experimental feasibility of SPPS allowed us to introduce rational 
changes to the peptide sequence, in order to generate several diverse structures. Fmoc/tBu 
chemistry is preferred and more useful if the peptide does not aggregate. Rink-MBHA-Resin is 
useful for the production of amidated and deprotected peptides and is a first generation 
polystyrene support, adequate for short sequences. The robust characterization of the produced 
peptides in this investigation step could be effected only by ESI-HRMS and RP-HPLC. 
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Monodimentional RMN determination is not sufficiently to differentiate simple aminoacid 
changes (Annex 3). 
Table 3: Helical parameters of Cm-p5 analogues. 
Peptide Helix H μHrel z FreqPolar angleM 
Cm-p5 SRSELIVHQRLF 0.44833 0.19215 1 0.583 0.24380 
 Change of His 
1 SRSELIVRQRLF 0.35333 0.09818 2 0.583 0.14196 
 Change of Glu 
2 SRSDLIVHQRLF 0.43750 0.18479 1 0.583 0.20159 
3 SRSQLIVHQRLF 0.48333 0.21791 2 0.583 0.35966 
4 SRSALIVHQRLF 0.52750 0.25359 2 0.500 0.47042 
5 SRSALIVHQRLF - - - - - 
 Change of Ile 
6 SRSELRVHQRLF 0.21417 0.41547 2 0.667 0.49375 
7 SRSELKVHQRLF 0.21583 0.41384 2 0.667 0.49293 
 Change of Leu 
8 SRSEKIVHQRLF 0.22417 0.19104 2 0.667 1.49355 
 Truncated and change of Leu by Lys 
9 SRSE-IVHQRLF 0.33455 0.18199 1 0.636 2.44770 
10 SRSEKIVHQ-LF 0.33636 0.46847 1 0.636 2.52341 
11 -RS-LIVHQRLF 0.6060 0.33231 2 0.500 3.41529 
12 SRSE-IV-QRLF 0.35500 0.42451 1 0.600 4.21201 
 Additional variants      
13 Ac-SRSELIVHQRLF - - - - - 
14 (SRSELIVHQRLF)2K - - - - - 
1) 2) 3) 4)   
6) 7) 8)  9)  
10) 11) 12)  
Figure 6: Schiffer-Edmundson projection of peptides analogues of Cm-p5. 
3.2 Results and discussion regarding Cm-p5 peptide mutants. 
Fourteen peptides were synthesized based on the previous design (Table 3). All the C-terminals 
of all the peptides were amidated (-NH2) since an Fmoc-Rink-MBHA resin was used. The Rink 
linker and the side-chain protecting groups were stables (orthogonals) functional groups toward 
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the Fmoc elimination treatment (Pip 20% in DMF) and coupling conditions. DIC/Oxyma 
combination (less than 1% of racemization)101 was used for every manual coupling, showing 
an excellent efficiency due to simplicity of the synthetized sequences. Final cleavage and side 
chains deprotection, ether precipitation, centrifugation and lyophilization produced the crude 
product, ready for analytical mass determination and purification process. The functional 
screening of the designed peptides, based on antibacterial and antifungal activities, are listed in 
Table 4. Amphotericin B and Ampicillin were used as control for fungal and bacteria strains, 
respectively. 
Table 4: Biological activity measured as Minimal Inhibitory Concentration (MIC) against different 
bacteria and fungi for each synthesized peptide. (NT: not tested) 
 MIC (g/mL) 
 Peptide Sa Ec Ca Cp Tr 
1 SRSELIVRQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
2 SRSDLIVHQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
3 SRSQLIVHQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
4 SRSALIVHQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
5 SRSALIVHQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
6 SRSELRVHQRLF-NH2 NT NT ˃ 400 ˃ 400 NT 
7 SRSELKVHQRLF-NH2 NT NT ˃ 400 ˃400 NT 
8 SRSEKIVHQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
9 SRSE--IVHQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
10 SRSEKIVHQ--LF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
11 -RS--LIVHQRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
12 SRSE--IV--QRLF-NH2 ˃ 400 ˃ 400 ˃ 400 ˃ 400 ˃ 400 
13 Ac-SRSELIVHQRLF-NH2 NT NT 10 10 10 
14 (SRSELIVHQRLF)2K-NH2 NT NT ˃ 400 ˃ 400 NT 
 Ampicillin 0,02 0,1953 NT NT NT 
 Amphotericin B NT NT 0,25 0,25 0,125 
Ca= Candida albicans, Cp= Candida parapsilosis, Tr= Trichophyton rubrum, Sa= Staphylococcus aureus, Ec= 
Escherichia coli 
To our surprise, no aminoacid change, maintain or improve the antimicrobial activity of Cm-
p5, indicating essential sequence characteristic needed to exert the biological activity. 
Substitution of His by Arg (peptide 1 in Table 3) involved a change in the protonation state of 
the aminoacid at position eight, increases the lateral chain length (reduces distance to the 
negative Glu), decreasesHrel to half and its direction change slight with respect to Cm-p5 
(Table 2, Figure 5). Decreasing Hrel, changing the length of the lateral chain and/or the 
presence of permanent positive charge at the His position does not improve theantifungal 
activity. Similarly, modification of Glu residue by Gln, Ala, βAla or Asp (peptides 2-5, Table 
3), resulted in loses of antimicrobial activity. Apparently, the negative charge in the Glu residue 
(changing Glu by Gln) and the distance to this one (changing Glu by Asp) are essential for the 
activity; even more if we consider that magnitude of Hrel and valor of H are practically the 
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same when Gln or Asp is present instead of Glu. Modification by Ala (peptide 4, Table 3), as 
expected, alter the H and magnitude of μHrel but especially its direction, indicating some 
additional effects. Ala (peptide 5, Table 3) has a similar behavior. 
 In order to increase the amphipathicity we added a positive residue (Arg or Lys) in the 
hydrophilic face, instead of Ile. In these cases, the change in direction of Hrel is higher 
(increased angle between the horizontal plane and direction of Hrel), compared to any 
previous analogue, while H is half, but Hrel duplicates (as expected, increase the 
amphipathicity). However, the original Arg apparently generates such repulsion with the 
additional Arg or Lys (peptides 6-7, Table 3) residues located in the same face that may destroy 
the helical conformation. Actually, this additional positive charge in the hydrophilic face 
originates several changes (repulsion, change in helical parameters) and a conclusion could not 
be established easily in order to explain the loss of activity.  
 Peptide eight in Table 3 was also inactive. The change of Leu5 by Lys produces a major 
increase in the angle between the horizontal plane and the Hrel but its magnitude is maintained 
and H is the halved. In addition, unfavorable electrostatic interaction between Glu and Lys 
residues could be implicated in the inactivation of this analogue. 
 The behavior of truncated versions of Cm-p5 in terms of biological activity was mostly random 
and more difficult to understand, but remarkably all these peptides change dramatically the 
direction of Hrel when compared with Cm-p5.  
 Direction ofHrel can be more important for the correct interaction with the membranes that 
its magnitude (amphipathicity), taking into account that during Arg contact with negative 
phospholipid, only the vertical component of this vector, that split in half the helix from Arg to 
the opposed face (helix axis), is in cooperation with the dipole moment vector of the membrane. 
If the Hrel direction have more horizontal component (perpendicular to the axis of the helix), 
its real magnitude is neglected and repulsive forces are implicated in an increased instability of 
the peptide bounded to membrane system even if positively charged residues, concentered in 
one face, are present (Figure 9a in Experimental Section, Chapter 1). 
Acetylated Cm-p5 maintains fungistatic properties (peptide 13 in Table 3), therefore, free N-
terminal is not needed for activity, enabling the total protection of peptide toward 
aminopeptidase degradation in future research. The dimeric version (peptide 14 in Table 3), 
like MAP, did not show any activity. This may be due to steric hindrance between C-terminal 
joined chains, which would imply helix destruction. 
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In general, our results suggest four determinant structural factors in order to maintain the 
biological activity of Cm-p5. Glu and His residues must be in the i,i+4 positions, Hrel vector 
must be close to a parallel direction respect to the membrane pointing in the opposite direction 
of the hydrophilic face (Arg residues), and any repulsive interaction that could interfere in 
helicity should be diminished. 
3.3 Salt bridge and helical stabilization. 
Based on the previous modifications (Table 3), we considered that the most remarkable finding 
was the relative position of His and Glu (pKaR= 4.25, (dissociation grade)= 99,97 %) 
(analytical calculation based in concentration of g/mL of Cm-p5 and physiological pH) in 
Cm-p5. These residues could be participating in helical stabilization by forming salt bridge 
(defined as the combination of two non-covalent interactions: ion pair interaction and hydrogen 
bonding).102 For Cm-p5, the modification of these residues (peptides 1-5 in Table 3), or the 
distance between them (peptide 9 in Table 3), involve the loss in biological activity. Recently, 
it has been revealed the role of salt bridge interaction in secondary structure stabilization of 
single -helix of peptides.64b 
In proteins, such as T4 lysozyme, a salt bridge was identified between Asp (pKaR= 3.65, = 
99,93 %, supposing 10 g/mL), at residue 70 and a His at 31. Although the imidazole ring of 
His31 is not protonated at physiological pH (pKaR= 6.8, 79,85%, supposing 10 g/mL), it 
has been demonstrated a shift of its pKaR (protonated imidazole) to 9.05 (= 2.19% at 10 
g/mL), in the folded protein that simulate a protonated His at pH= 7.4, due to salt bridge 
formation.103 
Cm-p5 changes to helical conformation only by interaction with membranes. In internal protein 
media or under membranolitic conditions, water content is low,104 solvation of negative Asp or 
imidazole ring is not effective and the salt bridge can be spontaneously formed by negative 
enthalpy and entropy (hydrophobic effect). A possible mechanism in which this process could 
take place is the formation of a hydrogen bond between neutral imidazole (pKaR= 13.1)
105 and 
negatively charged Asp residue. This donation of negative charge by Asp to the imidazole ring, 
increases the basicity, in consequence the pKbR (from 7.2 to 4.95)(pKaR: from 6.8 to 9.05) and 
its protonation grade from 20.25% to 97.81%.103 In principle, the hydrolysis pKhR= pKbR of 
imidazole decreases (pKaR increases) because of the effect of the negative charge of Asp at 
pH= 7.4 (Figure 9b in Experimental Section, Chapter 1).  
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Weak acids anions as phosphate, water solvation or mono-positive cations (Na+ or K+) do not 
favor salt bridge formation (Figure 9b, Experimental Section, Chapter 1). On the other hand, 
di-positive cations (Ca2+ or Mg2+, present as counter ions of phosphate in membranes) could 
reinforce the interaction (Figure 9c in Experimental Section, Chapter 1). This is the first time 
that a salt bridge between His and Glu in i,i+4 position is proposed and further investigation is 
needed to confirm the implication in helical stabilization and, consequently, in the biological 
activity of Cm-p5. 
 If this salt bridge is essential for the antifungal activity of Cm-p5, in environments such as 
mucosa, skin or tumors, where pH is 5-6, the biological effect will be enhanced due to alteration 
in the dissociation degree of Glu (85% at pH= 5) or protonation degree of His (96.89 % at pH= 
5). Also, the influence of the ionic strength or type of ions may alter this non-covalent 
interaction.93, 100 We assume that covalent cyclization between these residues by substituting 
them with cisteine should stabilize the helical secondary structure, energetically favoring the 
action mechanism. A disulfide bridge (or any other covalent stabilization) should overcome all 
drawbacks related with the physiological behavior of this salt bridge and make peptides more 
resistant to proteolysis.  
 
 
 
Peptide H Hrel z F. Polar angleM 
CysCysCm-p5 0.74750 0.45805 2 0.417 0.56152 
Cm-p5 0.44833 0.19215 1 0.583 0.24380 
 
Figure 7: Designed cyclic analogues of Cm-p5. Helical wheel projection of CysCysCm-p5 and 
helicoidal parameters. 
It is currently known that cyclization in i,i+3 or i,i+4 positions can stabilize an -helix.106 In 
order to know whether Cys residue has the suitable length for maintaining a helical 
conformation without further deformation, we made a molecular dynamic study of mutated 
Cm-p5 (E4C and H8C) to estimate the covalent distance between thiol groups in i,i+4position. 
The analysis of distance between sulfur nuclei showsthat they are located in the edge (2-10 Å) 
of the sulfur covalent radius (1.05 Å) necessary for a bond distance S-S of 2.10 Å (Chart 3, 
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Experimental Section, Chapter 1). This result also points that using homo-cysteine residues 
(Hcy) or a combination of Cys and Hcy could improve the cyclization process and, 
consequently, helical stabilization. With these results in mind, we synthesized three new 
peptides, placing two Cys, two Hcy or one Cys and one Hcy instead of the Glu and His pair 
(Figure 7). It is important to note that, like in Cm-p5, these analogues have doubled the H valor 
as well as theHrel magnitudes. Also, Hrel has the direction totally opposed to Arg residues, 
without any horizontal component that can repel the membrane relative dipole moment (Figure 
9a, Experimental Section, Chapter 1). 
3.4 Results and discussion regarding salt bridge and helical stabilization 
The synthetic procedure for Cm-p5 cyclic analogues is presented in Scheme 4. Following the 
Fmoc/t-Bu peptide strategy, cleavage in presence of EDT, three new acyclic analogues were 
produced with high peptidic purity and yield.  
 
Scheme 4: Synthesis of disulfide bridged analogues of Cm-p5. 
 
Scheme 5: Synthesis of CysCysCm-p5 parallel dimer using Acm and Trt protecting groups. 
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The three dithiolated peptides were submitted to the cyclization process by oxidations with 
oxygen of air in water, showing some specificity for each compound. Usually, for other peptides 
under similar reactions, all acyclic starting material is consumed in 2-3 h. In the case of 
CysCysCm-p5 analogue, more time (6h) was needed for the consumption of all starting material 
and, coincidently, acyclic and cyclic monomers have the same retention time, therefore, only 
mass analysis or Elman test can confirm the total conversion (Figure 25Figure 29 in 
Experimental Section, Chapter 1). In a first attempt, desulfured impeptidic purity was produced 
due to high pH (above 9). However, this problem was corrected by maintaining the pH strictly 
around 8-8.5. Surprisingly, in the standard cyclization conditions used for commercial peptides 
in our laboratory (0.5 mmol/L), CysCysCm-p5 analogue produced considerable quantities of 
dimeric byproducts (Figure 25Figure 29 in Experimental Section, Chapter 1), probably parallel 
and antiparallel dimers (Figure 8). Similar dimers were reported as impurities of CIGB-300 
anticancer peptide, also produced in our lab.107 Peak 4 (Figure 25Figure 29 in Experimental 
Section, Chapter 1) represents a conformer of peak 3, a dimer, as can be seen in the ESI-HRMS 
spectrum (Figure 25Figure 29 in Experimental Section, Chapter 1) and due to coalescence 
between peak 3 and 4 if the sample is previously stabilized for 2h at room temperature. 
 
Figure 8: Parallel (left) and anti-parallel (right) dimeric CysCysCm-p5 
Only at 0.03 mmol/L is guaranteed, the production of the cyclic monomer without formation of 
dimeric byproducts (Figure 25Figure 29in Experimental Section, Chapter 1). However, this 
concentration is not actually applicable to industrial processes and a better strategy would be to 
perform the cyclization on resin and to make the final cleavage of the cyclic monomer as a 
crude product. 
In order to identify what peak in the RP-HPLC corresponds to the parallel or antiparallel dimer, 
we decided to change the orthogonality of Cys protection, using Cys(Acm) for the His mutation 
and Cys(Trt) for the Glu. With these new protecting groups, peptide cleavage from resin 
produced an acyclic monomer containing Cys(Acm) and free Cys residue. Dimerization of this 
compound at concentrated condition (1 mmol/L) (Figure 31 Figure 29in Experimental Section, 
Chapter 1), solvent evaporation, lyophilization, and finally the Acm deprotection with iodine 
and the concomitant cyclization guaranteed only the parallel dimer production. This 
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unequivocal parallel dimer has the same retention time compared to the first dimer producedin 
the CysCysCm-p5 peptide cyclization (Figure 25 in Experimental Section, Chapter 1), 
confirming the identification of the parallel dimer and its antiparallel counterpart. 
As a comparison, cyclization of the peptide containing both Cys and Hcy has fewer tendencies 
to form both dimeric products in the same conditions (Figure 34Figure 36 in Experimental 
Section, Chapter 1). In the case of the analogue with two Hcy, only cyclic monomer is obtained 
at 0.5 mmol/L (Figure 38 in Experimental Section, Chapter 1). 
In conclusion, intra-chain disulfide bridge between i,i+4 positions (residues 4 and 8) in Cm-p5 
is more feasibly accessible when two Hcy or HcyCys combinations are introduced. On the 
contrary, inter-chain disulfide bridge when CysCys combination is introduced is clearly limited 
by steric hindrance. This type of inter-chain disulfide bridge is similar to the ones that are 
present in insulin and defensins. However, this is the first report, to our knowledge, of disulfide 
dimers between i,i+4 position. 
3.5 Circular dichroism analysis 
The following peptides were submitted to CD analysis in water and 10% SDS-water mixture: 
Cm-p5, CysCysCm-p5 (cyclic monomer), HcyHcyCm-p5 (cyclic monomer) and the parallel 
and antiparallel dimers of CysCysCm-p5. It is evident that a better helical stabilization was 
obtained for the cyclic monomers in a 10% SDS solution when compared with Cm-p5. 
Interestingly, the CysCysCm-p5 cyclic monomer showed a major percent of antiparallel -
structure in water that in the case of HcyHcyCm-p5. It is important to note that dimer 1 (parallel) 
does not have much contribution of antiparallel -strand to the structure under water or SDS 
conditions when compared with dimer 2 (antiparallel). Also, the latter have the same behavior 
in water or SDS, which may be an indication of the double of repulsion between free positive 
N-terminal (with hydrophilic forces) and hydrophobic Leu-Phe at C-terminus (with 
hydrophobic forces) for this antiparallel construction (acetylated version of CysCysCm-p5 
could totally avoid this drawback). Based on the results shown in Chart 1, it is possible to 
conclude that, for the dimers, the inter-chain disulfide bridge is responsible for maintaining 
25% of helical structure in water. Only in case of the parallel dimer (dimer 1) water molecules 
are excluded by SDS, and additionally, hydrophilic and hydrophobic forces at the N and C 
terminals contribute to considerably increase (up to 49%) the total segment of the helix (Chart 
1). At 10% SDS (micellar critic concentration of SDS) and despite the difference in surface 
curvature, these types of micelles are similar or mimetize biological membrane of bacteria and 
fungus, and are also negatively charge. Remarkably, in the case of dimeric compounds, Chart 
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1, interaction with micelles is not needed for helicity induction; these compounds are 
predominantly -helices in water. 
Chart 1: CD analysis in water and 10% SDS. Secondary structure content (in percentage) calculated 
with the online program Bestsel (http://bestsel.elte.hu). 
 
Hcy: cyclicHcyHcyCm-p5, Cyclic: cyclic CysCysCm-p5, Dimer 1: parallel Dimer, Dimer 2: antiparallel Dimer 
3.6 In-vitro anticandidal and antibacterial activity of Cm-p5 and derivatives. 
Antifungal activity was evaluated for Cm-p5, Hcy, Cys cyclic monomers, (HcyHcyCm-p5 and 
CysCysCm-p5, respectively) and the two dimers (dimer 1 (parallel) and dimer 2 (antiparallel)) 
against three fungal and two bacterial species of clinical relevance (Table 5). 
Table 5: Minimal Inhibitory Concentration (MIC) (µg/mL) of Cm-p5 and derivatives against three 
Candidas, a Gram-positive and a Gram-negative bacterial species. 
 Cm-p5 
Cyclic 
CysCysCm-p5 
Dimer 1 Dimer 2 
Cyclic 
HcyHcyCm-p5 
Candida species 
C. auris 11 27 30 31 NT 
C. parapsilosis 32 14 39 >100 10 
C. albicans 10 5 48 29 10 
Bacterial species 
Listeria 
monocytogenes 
> 100 100 50 12.5 
NT 
Pseudomonas 
aeruginosa 
> 100 > 100 > 100 > 100 
NT 
Cyclic: cyclic CysCysCm-p5, Dimer 1: parallel dimer, Dimer 2: antiparallel dimer, Hcy: cyclic HcyHcyCm-p5 
The antifungal Cm-p5 peptide kept the expected anticandidal activity against C. albicans and 
C. parapsilosis, as previously described.5 Interestingly, a relevant activity was also observed in 
the case of C. auris, an emerging nosocomial pathogen. The Hcy cyclic monomer, only 
maintained the activity against C. albicans, but increased it against C. parapsilosis. The 
30 
 
CysCysCm-p5 cyclic monomer even though it was not so effective against C. auris, has aminor 
MIC value against Candida albicans. The two dimers were the least effective against Candida 
species, showing MIC values around the 30 µg/mL or even higher (Table 5). 
To assess if these antifungal peptides also exert antibacterial activity, Cm-p5, the Cys cyclic 
monomer and the two dimers were analyzed in an agar diffusion assay (Table 6 in Experimental 
Section, Chapter 1) and by determination of the minimal inhibitory concentration (MIC). Table 
5shows the antibacterial MIC of Cm-p5 and the derivatives against the Gram-positive specie 
Listeria monocytogenes and the Gram-negative specie Pseudomonas aeruginosa confirming 
the increased anti-bacterial activity of Cm-p5 dimers against Listeria monocytogenes. Cm-p5 
exhibited a moderate antibacterial activity against L. monocytogenes at 1000 mg/L and 
100mg/L, but had only minor effects against P. aeruginosa (Table 6) at 1000 mg/L. The cyclic 
monomer and especially the two dimers were more active than Cm-p5, which showed a 
significant activity at 20 mg/L (Table 6 in Experimental Section, Chapter 1). 
3.7 In-vitro toxicity of Cm-p5 analogues against human cells 
Cytotoxicity of the cyclic monomer and the two dimers of Cm-p5 against macrophages and 
THP-1 human cells were also tested. At 300 g/mL of each compound (a higher concentration 
than the one used to determine MIC against fungal or bacterial species) no toxicity effects were 
observed in terms of percent cell viability (Chart 2).  
Chart 2: In vitro cytotoxicity of CysCysCm-p5 cyclic monomer and dimers against macrophages and 
THP-1 human cells. 
 
3.8 Discussion regarding biological activity 
The cyclization by an intra-chain disulfide bond in cyclic CysCysCm-p5, improved the activity 
against C. albicans down to 5 µg/mL compared to the native Cm-p5 peptide (MIC= 10 µg/mL).5 
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A similar improvement was observed against C. parapsilosis (from 32 to 14 µg/mL) and a 
decreased activity was observed in the case of C. auris (from 11 to 27 µg/mL).  
Possibly, the duplicated H value, Hrel magnitudes and its direction totally opposed to Arg 
residues of the cyclic CysCysCm-p5 (Figure 3) together with the salt bridge substitution by a 
disulfide bond, favored the antifungal activity. In general, these results represent a significant 
improvement, taking in consideration that this derivative has a stable -helix structure, which 
is less dependent on a membrane mimetic environment, and consequently, a more effective 
approach to the fungal membrane. Also, this molecule is less dependent on physiological 
conditions and probably more proteolytically stable.  
This peptide has the ability to change between -sheet and a helical conformation (according 
to CD spectra Chart 1, therefore, it may have the chameleonic possibility to penetrate the 
membrane as a helix and/or interact with another membrane receptor as a -sheet. Since the 
original Cm-p5 acts in a fungistatic manner against Candida albicans,6 a possible 
complementary therapeutic approach could be conceived and implemented, similar to the 
combination of fluconazole and Amphotericin B,108 taking in account that resistance to 
fluconazole increased dramatically in the last years.109 
Antimicrobial peptides are prone to proteolytic degradation110 and MIC determination in 
standard Mueller Hinton broth may not always lead to optimal results regarding the 
determination of their antimicrobial activity.111 To assess the activity of Cm-p5 and 
thederivatives we used a modified agar overlay assay,112 as well as standard MIC 
determinations (Table 5). In these experiments, we observed a notable increase in the 
antibacterial activity against Gram-positive as well as Gram-negative bacteria mostly for the 
antiparallel derivative. 
While the strains included in this investigation (L. monocytogenes and P. aeuginosa) are not 
multidrug resistant microorganisms, it should be noted that L. monocytogenes is a major 
problem in food production, due to the ability to multiply at 4°C and tolerance of high salt 
concentrations. It can reproduce inside eukaryotic cells and it is one of the most serious 
foodborne pathogens. The 20-30% of listeriosis cases are produced by food and fatality for 
high-risk individuals is common.113 On the other hand, P. aeruginosa is an opportunistic 
microorganism causing dangerous infections more often in immune compromised patients or 
patients with pre-existing diseases like severe burns. In these cases, severe infections and sepsis 
may frequently cause fatal outcomes.114 
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Other antibacterial peptides increase their activity when they are cyclic. Bactenecin is a natural 
antibacterial peptide from bovine neutrophils, which contains a disulfide bond due to Cys 
residues.115 This peptide with such cyclic structure showed a relevant activity against the Gram-
negative bacteria, Escherichia coli, Pseudomonas aeruginosa, and Salmonella typhimurium. 
When linear analogues are generated, the antibacterial (Gram negative) activity decreased 
substantially, whereas against Gram-positive microorganisms (Staphylococcus epidermidis and 
Enterococcus faecalis) such peptide versions displayed a positive interaction. Another example 
of cyclic peptides with antibacterial activity is Gramicidin S, a cationic cyclic decapeptide with 
primary structure cyclo-(Val-Orn-Leu-D-Phe-Pro)2, which is secreted by the bacterium 
Bacillus brevis, is a potent antimicrobial agent at μM concentrations, exhibiting high inhibitory 
activity against a broad spectrum of both Gram-positive and Gram-negative bacteria and 
pathogenic fungi.116 
 CysCysCm-p5 cyclic monomer and the two related dimers resulted nontoxic in terms of cell 
viability, as previously evaluated on human cells (Chart 2). Primary macrophages117 and the 
cell lines THP-1118 have been previously used as in vitro cellular models for testing the toxicity 
of antimicrobial peptides and they have been proved being sensitive enough to assess the 
availability of these molecules as potential anti-infection drugs in humans. Further experiments 
with fetal lung cells and determination of percent of cell vitality, certainly will improve this 
analysis, but, for now, is notable that even at the highest tested concentration, the new 
compounds are not cytotoxic for human cells. Besides, Cm-p5 resulted non-hemolytic for 
human and rabbit erythrocytes;6 the absence of such activity for CysCysCm-p5 cyclic monomer 
and the two related dimers, in term of pharmacological and therapeutic standards for a possible 
anti-infective candidates, remains to be confirmed. 
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Conclusions. Chapter 1 
Fourteen mutants of Cm-p5 peptide were synthesized. The magnitudes of H, Hrel or the 
direction if any other factor is not implied, are fundamental for activity, favoring sequences 
with elevated H or Hrel and direction of Hrel from hydrophobic phase to hydrophilic to 
promote membrane interaction. If other factors such as repulsion of positive charges or loss of 
non-covalent interaction are present, maintaining H, Hrel or direction ofHrel is not sufficient 
for maintaining biological activity. Notable examples constitute all the variants where either 
Glu4 or His8 were mutated, in which anti-fungal activity was lost. Substitution of these two 
residues with Cys permitted to synthesize a new cyclic analogue and two dimers that showed 
helix stabilization as indicated by CD analysis, suggesting the essential role of the Glu-His salt 
bridge. For the first time, to our knowledge, is proposed a salt bridge as a stabilizing factor for 
an anti-microbial peptide. CysCysCm-p5 and related dimers were not toxic for human 
macrophages. The cyclic monomer showed an increased activity in vitro agains C. albicans and 
C. parapsilosis but not against C. auris compared to Cm-p5. In addition, the antiparallel dimer 
(dimer 2) showed a moderate antibacterial activity against Pseudomonas aeruginosa and a 
significant activity against Listeria monocytogenes.  
It is important to note that helical stabilization is necessary for biological activity but not 
enough, since dimers (more helical character) have lower antifungal activity than Cm-p5 and 
the parallel version (the most helical stabilized compound) did not show any antibacterial 
activity against the tested microbes. The cyclic monomer changes between -strand and helical 
conformation when submitted to membranolitic environment and antiparallel dimer (dimer 2) 
has an equal population of molecules as -strand besides having a stabilized -helix (as judge 
by CD). Apparently, a constricted helix is not recommended and a -strand/-helix equilibrium 
in cyclic monomers is needed for antifungal activity. This suggests that an induced-fit model 
of action mechanism could be better than the old key-lock model to explain the antifungal 
activity. These peptides may need several conformations to be active, because they have several 
stages in their mechanism of action: interact, penetrate and/or leave the membrane, and/or inter-
act with the active site of several macromolecule targets. 
Finally, the increased capacity of cyclic CysCysCm-p5 for fungal control compared to 
fluconazole7 and low cytotoxicity, together with a stabilized -helix and disulfide bridges, that 
could advance the metabolic stability and in-vivo activity, improve the prospect of this new 
compound as potential antifungal systemic therapeutic candidate. Direct application of cyclic 
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CysCysCm-p5 or in synergy with amphotericin B, should diminish the doses of this fungicidal 
compound, highly toxic, but fundamental for the treatment of internal infections. 
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Future works. Chapter 1 
 Expand the conclusion and methodology of this study to other antimicrobial peptides that 
exists as -helices (melittin,34 guavanin-2,35 etc). 
 Complete the structural characterization of the dimers and cyclic analogues of Cm-p5using 
NMR techniques. 
 Realize a deeper study of the salt bridge stabilization of Cm-p5 between the Glu and His 
residues. 
 Determine the metabolic stability of the cyclic and dimers analogues of Cm-p5. 
 Determine the hemolytic activity of the cyclic CysCysCm-p5 analogue. 
 Determine the in-vitro antifungal activity of the cyclic CysCysCm-p5 analogue in the 
presence of sodium, calcium or phosphate salts. 
 Determine the in-vivo antifungal activity of the cyclic CysCysCm-p5 analogue. 
 Synthetize the N-acetylated versions of the cyclic and dimers analogues of Cm-p5. 
 Evaluate the synergic effect of the cyclic CysCysCm-p5 in combination with fluconazole 
or amphotericin B. 
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4 Experimental Section. Chapter 1 
4.1 General Remarks 
4.1.1 Materials 
All reagents and solvents were obtained from commercial suppliers and used without further 
purification. Fmoc-Rink-MBHA-Polystyrene and Fmoc-Rink-Chemmatrix resins were 
prepared by reaction of Fmoc-Rink-OH linker with commercial MBHA-Polystyrene or 
ChemMatrix resins following controlled acetylation after 0,53 mmol/g or 0.43 mmol/g 
substitution respectively. All the Fmoc-aminoacids, DIEA, I2, ascorbic acid, Ac2O and resins 
were purchased from Merck. Organic solvents (analytical grade) (DMF, DCM, MeOH, Et2O 
and ACN) were purchased from Merck. RP-HPLC quality ACN and ultrapure water quality 
were used for RP-HPLC analysis and purification. 
4.1.2 Peptide synthesis 
All reactions were carried in polypropylene syringes (10 mL) fitted with polypropylene frits at 
room temperature with mechanical shaking. Excess of solvent and reagent was eliminated by 
vacuum filtration. Side chain of aminoacids was protected with Pbf for Arg, Trt for Gln, Cys 
and His, tBu for Ser and Glu, and Acm for Cys in the synthesis of parallel dimer. 
Solid-phase peptide synthesis was carried out using Fmoc/t-Bu chemistry on Rink amide resin 
based in polystyrene or PEG (ChemMatrix). The resin was washed with DMF (2×1 min), DCM 
(2×1 min), MeOH (2×1 min), DCM (2×1 min) and DMF (2×1 min). Fmoc removal was 
achieved with 20% piperidine in DMF (2×10 min), and the subsequent aminoacids were added 
using the following coupling conditions: Fmoc-Aa-OH/DIC/Oxyma (4 equiv. of each) in DMF, 
after negative ninhydrin test (approximately 30 min). Between the different steps, the resin was 
washed with DMF (4×1 min). Acetylation was achieved using the following condition: 
Ac2O/DIEA (8 equiv.) in DMF for 10 min. After the last coupling reaction, Fmoc is eliminated 
and peptide-resin is washed subsequently with DMF (4x1min), MeOH (4x1min) and Et2O 
(4x1min). Peptide-resin is dried in desiccator during three days and finally is frizzed at -20oC 
by 30 min before cleavage. 
All peptides were obtained with more than 95% of peptidic purity as ascertained by analytical 
RP-HPLC. The molecular mass determined experimentally by ESI-HRMS corresponded with 
the theoretically calculated monoisotopic mass for each peptide. 
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4.1.3 Peptide Cleavage 
Cleavage from the resin and global deprotection: (i) analogues 1-15: TFA/TIS/H2O (95:2.5:2.5, 
5 mL/g of resin), (ii) thiolated analogues: TFA/TIS/EDT/H2O (94:1:2.5:2.5, 5 mL/g of resin) 
was added to the frizzing peptide-resin and left for 2h with shaking. Cleavage mixture was 
filtered and added over cold Et2O (50 mL, -70oC), mixed in vortex and centrifuged. The 
supernatant was discarded and the operation was repeated two more times. The solid residue 
was re-dissolved in H2O/ACN (7:3), frizzed at -70oC and lyophilized (LABCONCO, EUA). 
Approximately 70 % of crude peptide respect to the degree of the substitution of the resin is 
obtained. Working with 0.3 g of resin, at 0.53 mmol/g substitution for polystyrene resin, and 
taking in account approximately the range of molar mass of all peptide (1400-1500 g/mol), 70% 
(160 mg) of crude peptides was produce.In case of ChemMatrix dimer synthesis, we use 0.15 
g of resin, yields of crude are only about 60% and given the double Cm-p5 molar mass of 
product, plus Lys residue (3092 g/mol), 119 mg of crude was produce. 
4.1.4 Peptide Cyclization and Dimerization 
Cyclization was conducted by dissolving the peptides crude (approx. 160 mg) in H2O (0.1% 
TFA)/ACN/i-PrOH (1:1:1) at 0,5 mmol/L guarantying e major cone of agitation and ball filled 
only halfway for guarantee a high contact air(O2)-solvent. Normally, 250 mL of solvent mixture 
was used in a necked flask of 1L.NH3 (ac) (25%) was added until pH 8-9 and the reaction was 
stirred 4-12 h (after consumption of staring material, checked by RP-HPLC or ESI-HRMS) at 
room temperature. The pH is brought to 7 and the H2O/ACN/i-PrOH mixture was removed by 
rotary evaporator and residue was lyophilized (LABCONCO, EUA). 
4.1.5 Cyclization of the parallel dimer using Cys(Acm) 
Peptides (150 mg) containing Cys(Acm) and free Cys in the first or the second Cys residue 
were submitted to dimerization at high concentration in 30 mL DMF/H2O (1:1) during 72h (as 
follow by analytical RP-HPLC) in which the formation of white suspension is observed. 
Subsequently H2O (0.1% TFA)/MeOH (1:1) (VT= 250 mL) was added after (0.5 mM). Finally 
1.5 equiv. of HCl (37%) (pH= 3,78) and 5 equiv. of I2 (dissolved in MeOH) by Acm group are 
supplement and stirring is maintained over 3h or until no dimeric staring material was remaining 
by RP-HPLC.  Iodine was removed by adding 1 M aqueous sodium thiosulfate drop-wise until 
the mixture is colorless or by treatment with activated charcoal and centrifugation. The pH is 
brought to 7 and the H2O/MeOH mixture was removed by rotary evaporator and residue was 
lyophilized (LABCONCO, EUA). 
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4.1.6 Analytical RP-HPLC 
Analytical RP-HPLC was performed on an WellChrom HPLC (KNAUER, Germany) using the 
EZChrom-Elite® chromatography software ChromGate v3.1 from Agilent (USA) using a 
Zorbax RP-C18 (5 μm, 4.6×150 mm) column, with flow rate of 0.8 mL/min and UV detection 
at 226 nm. Mobile phase with gradient of 5% to 60% B in 35 min, Solvent A: 0.1% TFA in 
H2O; solvent B: 0.1% TFA in ACN. Chromatograms were obtained at 226 nm and processed 
by the UNICORN 4.11 (GE Healthcare USA) software package.  
4.1.7 ESI-HRMS 
Low‐energy ESI‐HRMS spectra were obtained in the CIGB, La Habana, Cuba (Peptide 
characterization, page 13) by using a hybrid quadrupole time-of-flight QTOF‐2™ instrument 
(Waters, Milford, MA, USA) fitted with a nanospray ion source in positive ion mode. Peptide 
solutions were collected from RP-HPLC, dissolved in 1 mL of 60% (v/v) ACN/water solution 
containing 0.2% formic acid and loaded into a metal-coated borosilicate capillary nanotip 
(Proxeon, Denmark), inserted into the Z‐spray nanoflow electrospray ion source, and slightly 
pressured with nitrogen to guarantee their stable spray during measurement. The capillary and 
cone voltage were set to 900 to 1200 and 5 to 35 eV, respectively. Mass spectra were acquired 
in the m/z range of 400–2000 Th. A solution of NaI and CsI was used as reference for the 
calibration of the spectrometer. Electrospray ionization mass spectrometry spectra were 
processed using the MassLynx version 4.1 program (Micromass, England). 
4.1.8 Semipreparative RP-HPLC 
Crude peptides (directly cleaved or cyclized) (50 mg for run or 100 mg in case cyclized crude, 
because contain approximately 50% of NH4CF3COO) were dissolved in DMSO (3mL) and 
purified on a LaChrom (Merck Hitachi, Germany) HPLC system using a RP-C18 column 
(Vydac, 25×250 mm, 25 μm). A linear gradient from 15%-60% over 55 min or 25%-60% of 
solvent B over 65 min and a flow rate of 5mL/min were used for linear peptides and cyclic and 
dimeric analogues respectively. Detection was accomplished at 226 nm. Solvent A: 0.1% (v/v) 
of TFA in water. Solvent B: 0.05% (v/v) of TFA in ACN. Fractions of high RP-HPLC 
homogeneity and with the expected mass were combined, lyophilized, and submitted to 
antimicrobial testing. All peptides synthesized was purifiedto >95% by RP-HPLC.   
4.1.9 CD spectroscopy 
The CD measurements were made on a J-1500 CD spectrometer (Jasco, Tokyo, Japan) at 24°C 
in a thermally controlled quartz cell with a 1 mm path length over 190 to 250 nm. The samples 
were prepared by dissolving the peptides in water and 10% SDS/water mixture. The final 
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peptide concentration for the CD measurements was ~35-70 M (100 g/mL). Data were 
collected every 0.1 nm, the bandwidth was set at 1.0 nm, and the sensitivity was 10000 mdeg. 
Data integration time was 1 sec, and scanning speed was 100 nm/min. The number of 
accumulations was 18. Percent of secondary structure was calculate with the Bestsel online 
program which are available at the http://bestsel.elte.hu server.119 
4.1.10 Microorganism strains and growth conditions 
Three Candida species were used: Candida albicans (ATCC 24433) was obtained from the 
Institute of Medical Microbiology and Hygiene, University Clinic of Ulm, Germany. Candida 
parapsilosis (ATCC 22019) was obtained from the laboratory of Medical Mycology, “Pedro 
Kourí” Institute of Tropical Medicine, Havana Cuba; Candida auris (DSMZ-No. 21092, CBS 
10913, JCM 15448)120 was obtained from the Leibniz Institute DSMZ-German Collection of 
microorganisms and cell cultures. Yeast Extract–Peptone–Dextrose (YPD) medium (liquid) was 
used for pre-culture inoculum at 70 r.p.m agitated conditions at 37 °C for 24 h. Trichophyton 
rubrum (ATCC 28189) was obtained from American Type Culture Collection and was cultured 
in Potato dextrose agar and for inoculums in Roswell Park Memorial Institute (RPMI) 1640 
Medium.Four bacteria genera were used:  Staphylococcus aureus (ATCC 23235), Escherichia 
coli (ATCC 25922), Listeria monocytogenes (ATCC BAA-679/EGD-e) and Pseudomonas 
aeruginosa (ATCC 27853). Bacteria were cultured at 37 °C and 5% CO2 overnight as pre-
culture inoculum in culture media.  
4.1.11 In vitro antimicrobial testing 
For Candida species and T. rubrum: The minimal inhibitory concentration (MIC) of Cm-p5 
derivatives (cyclic monomer and the two dimers) was determined according to the “Clinical 
and Laboratory Standards Institute” guidelines M27-A3 broth micro dilution assay121 with 
modifications (turbidimetric detection). Based on cell density measurements, the MIC was 
derived from a Lambert-Pearson plot.122 Flat- lowered sterile 96 well plates (SARSTEDT, AG 
& Co KG, Nümbrecht), RPMI 1640 without sodium bicarbonate, MOPS-buffered (Sigma-
Aldrich-Merck, Darmstadt) were used for the test, and readings were performed at λ= 600 nm 
with TECAN infinite M200 microplate reader (Tecan Group Ltd., Männedorf). For filamentous 
fungi the minimal inhibitory concentration was determined according to CLSI guidelines M38-
A2.112 
For bacteria genera: Agar overlay assay: Bacteria were cultured at 37°C and 5% CO2 overnight, 
pelleted by centrifugation and washed in 10 mM sodium phosphate buffer. Following 
resuspension in 10 mM sodium phosphate buffer optical density was determined at 600 nm. 
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2x107 bacteria were seeded into a petri dish in 1% agarose, 10 mM sodium phosphate buffer. 
After cooling at 4°C for 30 min, 3-5 mm holes were punched into the 1% agarose. Peptides 
adjusted to the desired concentration in 10 µl of buffer were filled into the agar-holes. Following 
and incubation at 37°C in ambient air for 3h plates were overlaid with 1% agarose, tryptic soy 
solved in 10mM phosphate buffer. Inhibition zones in mm were determined following 16-18 h 
incubation time at 37°C/5% CO2.112 
Minimal inhibitory concentration (MIC) determination: MIC determinations were performed 
in Mueller Hinton broth according to CLSI reference method M7A9 with modifications for 
bacteria.113 All tests were performed in triplicate. 
4.1.12 Human cells and culture conditions: 
hMDMs (human monocyte derived macrophages): Peripheral Blood Mononuclear Cells 
(PBMCs) were isolated from human buffy coat via high density gradient centrifugation (Ficoll-
Paque Plus; GE Healthcare, Munich). Monocytes were then purified from the PBMCs through 
adherence. Following, the cells were stimulated with granulocyte macrophage colony-
stimulating factor (GM-CSF), 10 ng/mL (MiltenyiBiotec, BergischGladbach) for 6 days at 37°C 
and 5% CO2 in RPMI 1640 medium (GIBCO, Invitrogen, Munich) supplemented with L-
glutamine, 2 mM (PAN Biotech, Aidenbach), HEPES 10 mM (Biochrom, GmbH, Berlin), 
penicillin/streptomycin (100 U/mL-100 µg/mL (Biochrom, GmbH, Berlin). 
THP-1 cell line (ECACC, Porton Down, UK, 88081201): human monocytic cell line derived 
from an acute monocytic leukemia patient was differentiated to macrophage like cells in cell 
culture medium. Mercaptoethanol, 0.05 mM (Sigma, Merck KGaA, Darmstadt), 10% FCS 
(Biochrom, GmbH, Berlin) and Phorbol 12-Myristate 13-Acetatepma (PMA), 1 µg/mL (Sigma, 
Merck KGaA, Darmstadt) were used as supplemented, overnight at 36°C and 5% CO2. 
4.1.13 Toxicity assay: 
THP-1 cells,1x105 macrophages, per well were distributed into a microplate (Nunclon™ Delta 
96-Well MicroWell™ Plates, Sterile, Thermo Scientific, Germany) in cell culture medium 
supplemented with 5% heat inactivated human serum (PAN Biotech, Aidenbach). Controls 
were media control, heat inactivated cells and diluent control, DMSO (Carl Roth, Karlsruhe). 
Cells were then stimulated with the Cm-p5 derivatives in different concentrations overnight. 
20µl PrestoBlue Cell Viability Reagent (Thermo Fisher Scientific Life Technologies GmbH, 
Darmstadt) per well was added for 20 min at 37°C/5% CO2. The fluorescence was measure at 
an excitation wavelength of 560 nm and emission wavelength of 600 nm with the TECAN 
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infinite M200 microplate reader (Tecan Group Ltd., Männedorf). The optical density (OD) of 
the media control was then subtracted from other results. Unstimulated cells were set to 100% 
viability.  
4.2 Additional Figures and Tables 
a)  
Figure 9: Proposed relative orientation of Hrel with respect to the dipole moment of charged residues 
that maximize the resultant dipole moment vector needed for optimal interaction with antimicrobial 
membranes (a). Formation (b), stabilization (c) and destabilization (due to negatively charged sodium 
atom) (d) of salt bridges between His and Glu in i,i+4 positions. 
Table 6: Agar diffusion test (mm) of Cm-p5, CysCysCm-p5 cyclic monomer and dimers against Gram-
positive and Gram-negative bacterial species. 
Bacteria 
→ 
c(mg/L) 
↓ 
Listeria 
monocytogenes 
Pseudomonasaer
uginosa 
Cm-p5 1000 1.1 0.6 
100 0.4 - 
20 - - 
Cyclic 1000 0.9 0.8 
100 0.5 0.4 
20 - - 
Dimer 1 1000 1.2 1 
100 0.7 0.7 
20 0.3 0.3 
Dimer 2 1000 1.2 1 
100 0.8 0.6 
20 0.3 0.3 
 
4.3 General protocol for solid-phase peptide synthesis 
Coupling reactions were performed manually on Rink-MBHA resin (0.3 g, 0.53 mmol/g) by a 
stepwise Fmoc/tBu strategy. Aminoacids were coupled using DIC/Oxyma activation, and 
completion of the coupling reaction was monitored by the ninhydrin test. Fmoc-deprotection 
was carried out using 20% piperidine solution in DMF. All final product were cleaved from the 
resin with the cocktail TFA/TIS/water (95:2.5:2.5), or TFA/TIS/EDT/water (94:1:2.5:2.5) for 
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Cys containing peptides, precipitated from diethyl ether at -70oC, then taken up in 1:2 
ACN/water and lyophilized. All Cm-p5 analogues were analyzed by RP-HPLC, C18 column 
(Vydac, 4.6 × 150 mm, 5μm) (= 226 nm) (linear gradient of 5 to 60% of solvent B for 35 min, 
at 0.8 mL/min flow) (solvent A: H2O, 0.1% TFA; solvent B: ACN, 0.05% TFA) to determine 
peptidic purity and ESI-HRMS characterization. To improve resolution in case of HcyCysCm-
p5 and HcyHcyCm-p5 we use linear gradient of 5 to 60% of solvent B during 50 min, at 0.8 
mL/min flow. In All cases, final products were dissolved in DMSO and purified by preparative 
RP-HPLC, C18 column (Vydac, 25×250 mm, 25 μm) (= 226 nm) (with a linear gradient of 15 
to 80% of B for 60 min, at 5 mL/min flow). 
 Note: Cyclic and dimeric peptides were purified with a different gradient due to the proximity 
in their retention times (linear gradient of 25% to 65% of solvent B for 60 min, at 5 mL/min 
flow) 
4.3.1 Solid phase synthesis of the antifungal peptide Cm-p5: 
 
 
Figure 10: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of Cm-p5 peptide. 
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4.3.2 Solid phase synthesis of SRSELIVRQRLF-NH2 analogue (peptide 1): 
 
 
Figure 11: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 1. 
4.3.3 Solid phase synthesis of SRSDLIVHQRLF-NH2 analogue (peptide 2): 
 
 
Figure 12: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 2. 
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4.3.4 Solid phase synthesis of SRSQLIVHQRLF-NH2 analogue (peptide 3): 
 
 
Figure 13: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 3. 
4.3.5 Solid phase synthesis of SRSALIVHQRLF-NH2 analogue (peptide 4): 
 
 
Figure 14: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 4. 
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4.3.6 Solid phase synthesis of SRSALIVHQRLF-NH2 analogue (peptide 5): 
 
 
Figure 15: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 5. 
1.1.7 Solid phase synthesis of SRSLRVHQRLF-NH2 analogue (peptide 6): 
 
 
Figure 16: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 6. 
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4.3.7 Solid phase synthesis of SRSELKVHQRLF-NH2 analogue (peptide 7): 
 
 
Figure 17: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 7. 
4.3.8 Solid phase synthesis of SRSEKIVHQRLF-NH2 analogue (peptide 8): 
  
 
Figure 18: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 8. 
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4.3.9 Solid phase synthesis of SRSE--IVHQRLF-NH2 analogue (peptide 9): 
 
 
Figure 19: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 9. 
4.3.10 Solid phase synthesis of SRSEKIVHQ--LF-NH2 analogue (peptide 10): 
 
 
Figure 20: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 10. 
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4.3.11 Solid phase synthesis of RSLIVHQRLF-NH2 analogue (peptide 11): 
 
 
Figure 21: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of the peptide 11. 
4.3.12 Solid phase synthesis of SRSE-IV--QRLF-NH2 analogue (peptide 12): 
 
 
Figure 22: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 12. 
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4.3.13 Solid phase synthesis of Ac-SRSELIVHQRLF-NH2 analogue (peptide 13): 
 
 
 
Figure 23: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 13. 
4.3.14 Solid phase synthesis of (SRSELIVHQRLF)2-K-NH2 (peptide 14): 
 
 
Figure 24: RP-HPLC (crude in the left upper panel) (pure in the right upper panel) and ESI-HRMS 
(lower panel) of peptide 14. 
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4.3.15 Synthesis of Structurally Restricted (Cyclic) Peptide (CysCysCm-p5): 
 
Figure 25: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of the acyclic CysCysCm-p5 peptide. 
 
 
Figure 26: Chromatographic evolution of cyclization of CysCysCm-p5 peptide at 0.5 mM. 
 
 
Figure 27: ESI-HRMS of the compounds (ordered by time retention) formed during cyclization of 
CysCysCm-p5 peptide. 
51 
 
 
 
Figure 28: CysCysCm-p5 peptide dimers structure and RP-HPLC of the purified products (left: parallel, 
right: antiparallel) formed by two intermolecular disulfide bridges. 
 
Figure 29: Chromatographic evolution of cyclization of CysCysCm-p5 peptide at 0.1 mM. 
 
 
Figure 30: RP-HPLC (crude at left upper panel) (pure at right upper panel) and ESI-HRMS (lower panel) 
of cyclization of CysCysCm-p5 peptide at 0.03 mM after 24 h. 
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4.3.16 Synthesis of Structurally Restricted Peptide (CysCysCm-p5)2 (Parallel Dimer) 
using Cys(Acm) as mutant of His of Cm-p5: 
 
 
Figure 31: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of acyclic peptide CysCys(Acm)-
Cm-p5 (crude). 
 
 
Figure 32: RP-HPLC evolution (upper panels) and ESI-HRMS (lower panel) of dimerization of 
CysCys(Acm)Cm-p5 (crude) peptide at 5 mM after 72 h. 
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Figure 33: RP-HPLC (upper panel) and ESI-HRMS (lowerpanel) of cyclization of CysCys(Acm)-Cm-
p5 parallel dimer at 0,3 mM after 30 min with I2. 
4.3.17 Synthesis of Structurally Restricted (Cyclic) Peptide (HcyCysCm-p5): 
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Figure 34: RP-HPLC (upper panel) and ESI-HRMS (lowerpanel) of acyclic HcyCysCm-p5 peptide. 
 
 
Figure 35: RP-HPLC evolution (upper panels) and ESI-HRMS (lower panel) of cyclization of 
structurally restricted peptide HcyCysCm-p5 at 0.5 mM. 
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Figure 36: RP-HPLC (left panel) at high resolution (less gradient slope, right panel) and ESI-HRMS 
(lower panels) of cyclic and dimers of HcyCysCm-p5 peptide. 
 
Figure 37: HcyCysCm-p5 peptide dimers (left: parallel, right: antiparallel) formed by two 
intermolecular disulfide bridges. 
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4.3.18 Synthesis of Structurally Restricted (Cyclic) Peptide (HcyHcyCm-p5): 
 
 
Figure 38: RP-HPLC (upper panel) and ESI-HRMS (lowerpanel) of acyclic peptide HcyHcyCm-p5. 
 
 
Figure 39: RP-HPLC (upper panel) after 6h of cyclization (crude), at high resolution (less slope of 
gradient) and the purified product (left lower panel), ESI-HRMS (right lower panel) of cyclic 
HcyHcyCm-p5 peptide.. 
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4.4 Materials and methods. Molecular dynamics simulations 
Peptide (SRSCLIVCQRLF) model was built with the acetylated N-terminal in order to avoid 
electrostatic effects of the terminal amine group.  Model was fully solvated in an octahedral 
box of TIP3P water model with periodic boundary conditions. The MDS (molecular dynamic 
simulation) was performed using AMBER 11 and supposing an initial -helical peptide.123 The 
model was prepared with a 3-steps protocol. First, 2000 steps were ran for side chains 
optimization, second, a 50000 steps of thermalization at 300 K with a Berendsen thermostat at 
constant volume, and third, a 50000 steps at the same temperature with constant pressure 
(isotropic position scaling) of 1 atm. Finally, 50 ns of MDS under the NPT ensemble condition 
were performed. This system remained stably structured along the whole MDS. Results of the 
distance between sulfur atoms are showed inChart 3, supposing an initial helical structure of the 
acyclic peptide CysCysCm-p5. 
Chart 3: Simulation by molecular dynamic of the distance between sulfur atoms in the -helix of acyclic 
peptide CysCysCm-p5. 
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Chapter 2 
 
 
"Synthesis of lipidated and cyclic analogues of Cm-p5 peptide, with 
stabilized -helix and containing different turn motif between the N-
terminal and the lipid" 
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Chapter 2 
1 Introduction. Chapter 2 
1.1 Objectives of our work. 
Previous studies have shown that the lipidation of Cm-p5 by Ugi-4CR in solid phase influence 
the antifungal activity of Cm-p5 in different degrees, depending on the position where the lipid 
is introduced. For example, the lipidation in intermediate position producesanalogues with less 
antimicrobial activity, which should be related with the loss of helicoidal character, due to the 
introduction of N-alkylation by Ugi-4CR. On the other hand, the N-lipidation in the C-terminal 
maintains the activity and in N-terminals produces the most active versions of Cm-p5 known 
until today.  
 For the lipidation by Ugi-4CR in solid phase is needed to produce an isocyanolipid, which is 
in disadvantage with the easy way of coupling fatty acids at the N-terminal of peptides. The 
increase of antimicrobial activity of peptides by fatty acids coupling at the N-terminal has been 
widely described.124 At this stage of our investigation, the synthesis of N-lipidated analogues 
of Cm-p5 by simple coupling of fatty acids is desired and will allowdetermining the optimal 
size of the lipid chain for the antifungal activity. 
 The fundamental structural difference between an Ugi lipidated analogue and a simple 
coupling of lipid chain is the presence of N-substitution at the union point of the lipid. Pro 
residues in proteins have a similar influence that an N-substitution and are implicated in several 
conformational changes, indispensable forthe biological activity. Gly residues are also 
important in those cases and together with Pro are normally present in loops and surfaces of 
proteins, conferring flexibility and conformational freedom. 
 In chapter 1, we demonstrated the effectiveness of the introduction of disulfide bridge 
construction in the stabilization of the -helical secondary structure of Cm-p5. This disulfide 
bridge, between the Glu and His position, produced a more active version of Cm-p5, which 
could be more stable metabolically. In addition, the implication of Glu and His in salt bridge 
interaction was indirectly demonstrated. 
 Ina nutshell, the lipidation at the N-terminal and the cyclization by disulfide bridge produce 
the most active versions of Cm-p5 reported until today. Due to that, the synthesis of N-lipidated 
and cyclic analogues of Cm-p5 is desired for future investigation. With this aim, the objectives 
of this chapter are focused on: 
 SynthesizeN-lipidated analogues of Cm-p5 by fatty acids coupling of different chain 
lengthand evaluate the antimicrobial activity. 
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 Synthesize N-lipidated analogues of Cm-p5 by coupling of a fatty acid after the 
introduction of Ala, Gly or Pro at the N-terminal. 
 Synthesize N-lipidated analogues of CysCysCm-p5 by coupling of a fatty acid after the 
introduction of Ala, Gly or Pro at the N-terminal. 
 Produce the dimers and cyclic analogues of the last three lipopeptides by disulfide bridge 
formation in pseudo-diluted conditions. 
 Synthesize n-dodecylisonitrile by formilation and deshydratation of n-dodecylamine. 
 Synthesize the N-lipidated analogue of CysCysCm-p5 by Ugi-4CR in solid phase with n-
dodecylisonitrile, acetic acid and paraformaldehyde. 
 Produce the dimers and cyclic analogues of the last lipopeptides by disulfide bridge 
formation in pseudo-diluted conditions. 
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2 Bibliographic Revision. Chapter 2 
2.1 Lipopeptides. Importance and characteristics 
The presence of a lipid group in a peptide modulates the hydrophobicity and secondary 
structure, while retaining the ability of binding to designated receptors. Lipidation improves 
metabolic stability, membrane permeability, bioavailability, and changes the pharmacokinetic 
and pharmacodynamic properties of peptides.125 
Lipopeptides have been proven as powerful and versatile alternatives against a wide variety of 
pathogens.126 Natural or synthetic lipopeptides may have surfactant, antibacterial and antifungal 
activity, and have been evaluated as transfer agents for the release of genes. They have 
amphiphilic characterand are used as biosurfactants and antibiotics. Lipopeptides have been 
used in clinical applications, as well as in the preservation of foods and dailyproducts.127 
Bacteria members of the genus Bacillus are considered effective microbial sources for the 
production of these type of bioactive molecules.128 There are three Bacillus lipopeptide 
familiesthat have been studied for their antagonistic potency against several phytopathogens: 
Surfactin, Iturina and Fengycin (Figure 40).129 Also in actinobacteria, species of the genus 
Streptomyces has been reported the production of various antimicrobial lipopeptides with 
application in the pharmaceutical industry.130 These compounds are widely considered as 
potential alternatives for the growing problem of resistance to conventional antibiotics, fungal 
infections and other diseases that threaten life.127 
 
Figure 40: Examples of the Bacillus lipopeptide family, a) Surfactin, b) Iturin, c) Fengycin. 
Lipopeptides such as Polymyxin B (one component of the commercial triple antibiotics) 
interact primarily with the lipopolysaccharide (LPS) component of the bacterial outer 
membrane by electrostatic interaction while the tail of N-terminal fatty acid exerts the 
bactericidal action because it inhibits the synthesis of the outer membrane.131 
Many of these molecules also play an important role in the processes of induction of 
apoptosis132 and are recognized by the TLRs, an essential components of the innate and adaptive 
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immune response, since they are responsible for the recognition of the different pathogens and 
trigger responses aimed at eliminating pathogens anddeveloping immunological memory.133 
Linear lipopeptides (histatins) are applied as transfer agents for the efficient release of genes 
(Figure 41a),134 in the inhibition of proteases and some of them have neurotoxic properties.71  
The growth of the toxic cyanobacterium Microcystis aeruginosa is controlled by the Spiroidesin 
(Figure 41b) synthesized by the cyanobacterium Anabaena spiroides.135 The lipopeptide 
daptomycin (Figure 41c), known as Cubicin, is marketed and applied against infections caused 
by Gram-positive bacteria in USA since 2003.136 
a) b) c)  
Figure 41: Biologically active lipopeptides, a) histatin, b) spiroidesin, c) daptomycin. 
2.2 Structural activity relationship in biologically active lipopeptides. 
Certain lipopeptides can have strong antimicrobial and hemolytic activities. It has been 
demonstrated that their activity is generally linked to interactions with the plasma 
membrane,playing the sterol components a major role in this interaction.127 In general, adding 
a lipid of certain length (typically C10-C12) to a peptide will increase the bactericidal activity. 
Lipopeptides with a higher number of carbon atoms, for example 14 or 16, will typically have 
antibacterial activityin the lipid tail as well as antifungal activity.124 
Lipopeptide detergents (LPDs) are composed of amphiphiles and two alkyl chains, which are 
located on the last part of the peptide backbone. They were designed to mimic the architecture 
of the native membranes in which two alkyl chains in a lipid molecule interact facially with the 
hydrophobic segment of AMPs.137 
After the extraction in 1968 of the first biosurfactant lipopeptide surfactin, produced by the 
bacterium Bacillus subtilis, the extraction and synthesis methods of this type of molecules 
experienced a constant increase, and in 2005, 23 families of compounds were already known, 
of which 21 were cyclolipopeptides.138 
63 
 
2.3 Lipidation of peptides 
The lipidation of peptides and intracellular proteins is carried out by incorporating fatty acids, 
isoprene and glycophospholipids. Such modifications change the flexibility in the position 
occupied by the lipid,139 increase the hydrophobicity and they also contribute to the association 
with the cell membrane.140 The incorporation of the lipid facilitates the interaction with the 
microbial surface, being this an aspect of a great importance because short peptides (less than 
12 aminoacids), without conformational restrictions, do not possess strong antimicrobial 
actions under physiological conditions.141 
The synthetic methods to achieve lipidation depend on the position where theintroduction of 
the lipid is desired. At the N-terminus, it is usually carried out by coupling a fatty acid or a 
phospholipid142 such as myristic and palmitic acids, among others (Figure 42a).132 In 
intermediate positions, it is achieved by using aminoacids derivatizedwith lipids such as Lys, 
Asp, Glu, Ser, Trp, Orn, Thr and Cys138, 143 (Figure 42b). Also, by reduction of Glu or Asp to 
aldehyde (via Weinreb amides) and subsequent reaction with alkyl bromides via Wittig reaction 
(Figure 42c), or by coupling bromoacetic acid followed by substitution (SN2) with lipidic 
amines (Figure 42d).144 Lipidation at the C-terminus is less frequent because it must be 
performed after cleavage, in liquid phase or with the use of special linkers, which are very 
expensive (Figure 42e).145 The use of side chains or the N and C ends to introduce these 
modifications is not possible in peptides where these sites are essential for activity. An alanine 
scanning must be performed in advance to know which residues are essential to maintain the 
biological activity.144 
 
Figure 42: Lipidation of peptides at the N and C ends and in intermediate positions. 
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Recently Morales et al. reported a lipidation method of the N and C-terminus, as well as in 
intermediate positions of the peptide skeleton employing multicomponent reactions (Section 
2.3.2, page 6565).146 
2.3.1 Multicomponent Reaction. Peptide lipidation by Ugi-4CR. 
In 1959 Ivar Ugi described the first four-component reaction, where an amine, a carbonyl 
compound (aldehyde or ketone), an isocyanide and a carboxylic acid gave rise to an N-
substituted dipeptide and water as the only by-product. The general mechanism of the Ugi-4CR 
includes the initial formation of a Shiff base and the protonation by the carboxylic acid 
(activation by increased electrophilicity), which leads to the reversible double addition on the 
isocyanide. The obtained O-acylamine or α-adduct is a powerful electrophile capable of 
irreversibly andintramolecularly acylatingthe N of the amine (Mumm rearrangement) or the N 
of the isonitrile (Scheme 6).147 In excess of acid and at high temperatures the formation of N-
substituted dipeptides is favored but when the isonitrile radical is bulky (eg. R4= t-Bu) the imide 
can be obtained by Danishefsky reaction.148 
 
Scheme 6: Ugi-4C (right down) and Danishefsky (right up) reaction mechanism. 
The variation of the acid and amino component that take part in the reaction gives access to 
great diversity of structures.149 The following can be used as acid components: HN3, RCOOH, 
HNCO, HSCN, H2O, H2S and H2Se, monocarboxylic acid and salts of secondary amines. On 
the other hand, the amino component could be: NH3, primary or secondary amines, hydrazines, 
hydroxylamines and their derivatives.150 
The Ugi-4CR is exothermic and is usually carried out at roomor lower temperature, since the 
increase of that, can inducecollateral reactions. High concentration of the reactants favors the 
speed. However, kinetics of Mumm rearrangement is of 1st order (intramolecular process, not 
influenced by concentration) and when there are substituents in the C of the acid and/or of the 
amine, reaction times close to 24 h or more are needed to achieve high yields. The previous 
obtention of the imine prevents the occurrence ofcollateral processes, such as the Passerini 
65 
 
reaction. The Ugi-4CR should be carried out in protic polar solvents such as MeOH or 
CF3CH2OH, although it has also been reported in THF/MeOH and CH2Cl2/MeOH. This 
reaction can be catalyzed by Lewis acids such as TiCl4 and ZnCl2 and is not stereoselective.
151 
The Ugi reaction has been implemented in solid phase with simple substrates, for which resins 
have been functionalized as isocyanide (Scheme 7a),152 amino (Scheme 7b and 8c)153 or as 
carboxylic acid.154 The yield in most of these cases is good (80-90%) and hydantoin-4-imides 
(Scheme 7b), 1,4-benzodiazepines-2,5-diones, diketopiperazines, cetopiperazines and 
dihydroquinoxalinones have been obtained.155 However, the solid phase Ugi-4CR takes 24 h or 
several days to complete. Nielsen et al. demonstrated that the speed of these reactions in solid 
phase can be increased by irradiation with microwaves during 5 min with 60W of power 
(Scheme 7c).156  
 
Scheme 7: Examples of Ugi-4CRs performed in solid phase. 
2.3.2 Organocatalysis and Ugi reactions in solid phase. 
Organocatalysis is the use of small organic molecules as catalysts. This method makes synthesis 
processes much more efficient.157 Recently, Morales et al. used an organocatalytic process of 
solid phase transimination between piperidine and paraformaldehyde to guarantee the previous 
formation of methylenimines in peptides anchored to resins with the unprotected amino 
terminal. Thepreformed imines reacted easily with carboxylic acids and isonitriles by the Ugi-
4CR, forming the corresponding N-substituted peptides (Scheme 8).146 
 
Scheme 8:  Synthesis of N-substituted peptides by Ugi-4CR in solid phase. 
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2.4 Amide bonds and turn motifs in proteins. Importance of Gly and Pro residues. 
Amide bonds have a significant delocalization of the lone pair of electrons on the nitrogen atom, 
which gives the group a partial double bond character. The partial double bond renders the 
amide group planar, occurring in either the s-cis or s-trans isomers. In the unfolded state of 
proteins, the peptide groups are free to isomerize and adopt both isomers; however, in the folded 
state, only a single isomer is adopted at each position (with rare exceptions). The s-trans form 
isoverwhelmingly preferred in most peptide bonds (roughly 1000:1 ratio in s-trans:s-cis 
populations). However, X-Pro peptide groups tend to have a roughly 30:1 ratio, presumably 
because the symmetry between the C and C atoms of Pro, makes the s-cis and s-trans isomers 
nearly equal in energy (Figure 43).158 
 
Figure 43: a) Representation of s-cis/s-trans isomers of a secondary amide bond. b) alternative transition 
state configurations for peptide bond rotation. c) canonical structures of the amide group structure. 
Gly and Pro residues have a major influence on the kinetics of loop formation in proteins. 
Glycine and proline residues are frequently found in the turn, loop structures of proteins, and 
are believed to play an important role during early chain folding. 
Kriegeret et al., with the aim of triplet-triplet energy transfer (TTET) from xanthone (Xan) to 
naphthylalanine (NAla), measured directly the kinetics of intrachain contact formation in 
polypeptide chains to demonstrate the importance of Gly and Pro residues in loop formation 
(Scheme 9). TTET from a triplet donor to a triplet acceptor group involves the transfer of two 
electrons (Dexter mechanism) and it requires van der Waals interactions between the two 
groups.159 
In the Loops of varying length are used to assess the distance dependence of the effect exerted 
by a single Gly, cis-Pro, or trans-Pro residue. Loop formation is significantly slower around 
trans-prolyl peptide bonds and faster around Gly residues, compared to any other aminoacid. 
Gly showed faster rate constants for contact formation than any otheraminoacid as expected 
from the increased backbone flexibility due to the lack of a C lateral chain.159 
Table 7 the rate constants for end-to-end contact formationare shown, measured by TTET from 
xanthone (Xan) to 1-naphthyl alanine (NAla) in host guest peptides of the sequence Xan-Ser-
Xaa-Ser-NAla-Ser-Gly with varying guest aminoacid (Xaa). 
Loops of varying length are used to assess the distance dependence of the effect exerted by a 
single Gly, cis-Pro, or trans-Pro residue. Loop formation is significantly slower around trans-
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prolyl peptide bonds and faster around Gly residues, compared to any other aminoacid. Gly 
showed faster rate constants for contact formation than any otheraminoacid as expected from 
the increased backbone flexibility due to the lack of a C lateral chain.159 
Table 7: Effect of different aminoacids on local peptide dynamic 
 
 
Scheme 9: Schematic representation of Triplet-Triplet energy transfer measurement in unfolded 
polypeptide chain. a) Loop sequence, X, between the labels for TTET in peptides of the canonical 
sequence Xan-X-NAla-Ser-Gly. 
 
The presence of a Pro residue leads to a more complex dynamic, with a slow and a very fast 
process of contact formation.The most interesting effect is observed for loop formation around 
cis-prolyl bonds (Pro), which shows the fastest kinetics of all sequences despite anincreased 
activation energy. Pseudo-proline (Pro) is known to increase the cis content of a Val-Pro 
peptide bond to about 80% due to steric effects induced by the methyl groups in the s-trans 
conformation (Loops of varying length are used to assess the distance dependence of the effect 
exerted by a single Gly, cis-Pro, or trans-Pro residue. Loop formation is significantly slower 
around trans-prolyl peptide bonds and faster around Gly residues, compared to any other 
aminoacid. Gly showed faster rate constants for contact formation than any otheraminoacid as 
expected from the increased backbone flexibility due to the lack of a C lateral chain.159 
Table 7). The fast loop formation around cis-prolyl isomers is due to the largely restricted 
conformational space and shorter end-to-end distances, compared to trans isomers, which 
results in a drastic increased of pre-exponential factor for loop formation. Further results 
showed that Gly and Pro residues only influence formation of short loops containing between 
2 and 10 residues, the typical loop size in native proteins. The rate constants for formation of 
these loops during protein folding can be modulated by a factor of 10 by the presence of either 
Gly/cis-Pro or trans-Pro.159 
Xaa kc (107 s-1) sequence % cis 
Gly 12+-1 SP 15+-1 
Ala 8.0+-0.7 SPS 17+-2 
Ser 6.7+-0.7 SSS - 
Glu 5.4+-0.2 SGS - 
Arg 5.5+-0.7 VPS 16+-2 
His 4.9+-0.4 V(P)S 72+-5 
Ile 4.4+-0.3 SSPS 18+-4 
Trans Pro 2.0+-0.3 SVPS 18+-2 
Cis Pro 25+-5 SV(P)S 78+-6 
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Finally, in randomiced Pro containing peptides, an equilibrium between trans and cis-prolyl 
conformation is normally present (Studies on model peptides showed that the cis content 
depends on the preceding aminoacid and varies between 7% and 38%, in contrast to about 
0.15%-0.5% cis isomer at nonprolyl peptide bonds (Loops of varying length are used to assess 
the distance dependence of the effect exerted by a single Gly, cis-Pro, or trans-Pro residue. 
Loop formation is significantly slower around trans-prolyl peptide bonds and faster around Gly 
residues, compared to any other aminoacid. Gly showed faster rate constants for contact 
formation than any otheraminoacid as expected from the increased backbone flexibility due to 
the lack of a C lateral chain.159 
Table 7).159 
If cis-Pro has tendency to form loop quickly, the result is a displacement of the equilibrium to 
the formation of more cis conformer and this is the cause of loop, hairpin or any other twisted 
secondary structure induction in peptides and proteinsby Pro.  
2.4.1 Melittin, the honeybee venom peptide. Secondary structure. 
Melittin is the main component (40–60% of the dry weight) and the major pain producing 
substance of honeybee (Apis mellifera) venom. Melittin is a basic peptide consisting of 26 
aminoacids, with no disulfide bridge.34 The N-terminal part of the molecule is predominantly 
hydrophobic, while C-terminal part is hydrophilic and strongly basic (Table 8 and Figure 44b). 
In water, it exists in form of tetramer but monomers also can spontaneously auto-aggregate into 
cell membranes. The peptide is certainly helical, with a bend induced by a Pro residue (or GLP 
residues, Figure 44). This conformation is fundamental for the mechanism of membrane 
insertion as well as the conformation(s) involved in the process.160 
 As we can see in the wheel projection of melittin (and the independent parts of sequence that 
form -helix), this peptide does not have a common/perfect amphipathic helicity (Figure 44a). 
Helix 2 has two Arg and two Lys distributed over the wheel and helix 1 has only one positive 
charged Lys residue and is fundamentally hydrophobic. Residues KRKR in helix 2 are joined 
in the C-terminal, like in model penetrating peptides and the helix one could be responsible for 
the interaction with the phospholipid in the membrane.  
Table 8: Helical parameters for two independent helices and a posible total helix of melittin. 
http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py97 
 Helix sequence Hydrophobicity Hyd.Moment z FreqNoPolar Val_angleM 
Helix 1 GIGAVLKVLTTGL 0.68000 0.48857 1 0.545 4.93691 
Helix 2 PALISWIKRKRQQ 0.28167 0.35356 4 0.417 4.42248 
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ 0.51077 0.39424 5 0.500 4.85721 
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a)                  b)  
Figure 44: a) Monomer of melittin, cut from the tetrameric crystal structure. Polar aminoacids are shown 
in green, aliphatic in white and basic in blue. b) Wheel projection of the two independent helices (helix 
1 and 2) and a posible total helix of melittin. 
2.4.2 The helix-Gly-Gly-helix motif in the N-terminal domain of histone H1e. 
The linker histone H1e has a central role in stabilizing both the nucleosome and chromatin 
higherorder structure. It has also been described as a general transcriptional repressor because 
it contributes to chromatin condensation, which limits the access of the transcriptional 
machinery to DNA. However, recent studies show that linker histones participate in complexes 
that can either activate or repress specific genes.161 
H1e histones have a characteristic three-domain structure. The central globular domain consists 
of a three-helix bundle with a -hairpin at the C-terminus (Figure 45a). The N-terminus and the 
C-terminus are highly basic. The terminal domains are, in general, unstructured in solution. The 
N-terminal domains of H1e histones have two distinct subregions. The distal part is rich in Ala 
and Pro and is highly hydrophobic, whereas the adjacent region to the globular domain is highly 
basic and may be involved in the location and anchoring of the globular domain (Table 9 and 
Figure 45b).162 
Table 9: Helical parameters for two independent helices and a posible total helix of the N-terminal 
domain of histone H1e. http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py97 
 helix Hydrophobicity Hyd.Moment z Freq. Polar Val_angleM 
Distal helix EKTPVKKKARKAA -0.26692 0.17970 5 0.615 5.68730 
Adjacent helix GGAKRKTSG -0.27333 0.13588 3 0.889 2.48578 
N-terminal EKTPVKKKARKAAGGAKRKTSG -0.26955 0.15145 8 0.727 5.43221 
 
a)          b)  
Figure 45: a) Model of the binding of the N-terminal domain of histone H1e to the nucleosome. 
Representation of the N-terminal domain bound to chromatosomal and linker DNA. The chromatosomal 
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DNA is in green, the linker DNA is in red, the histone H1e N-terminal domain is in blue, and the globular 
domain is in green. The globular domain is located according to the model of Zhou et al. (1998). b) 
Wheel projections of the two independent helices (distal and 2) and a posible total helix of histone H1e. 
The conformational properties of the peptide NE-1 (Histone H1e N-terminal fragment, residues 
15–36, positively charged region of the N-terminal domain)(Ac-
EKTPVKKKARKAAGGAKRKTSG-NH2) have been studied by circular dichroism and 
1H-
NMR. NE-1 is mainly unstructured in aqueous solution, but in the presence of the secondary-
structure stabilizer TFE, it acquires two fragments of -helical structure that comprise almost 
all the peptide, namely, from Thr17 to Ala27 and from Gly29 to Thr34 (Table 9 and Figure 
45b). Both helical regions are highly amphipathic, with the basic residues on one face of the 
helix and the apolar ones on the other. The two helical elements are separated by a Gly–Gly 
motif. Gly–Gly motifs at equivalent positions are found in many vertebrate H1e subtypes. 
Structure calculations show that the Gly–Gly motif behaves as a flexible linker between the 
helical regions (Table 9 and Figure 45b). The wide range of relative orientations of the helical 
axes allowed by the Gly–Gly motif may facilitate the tracking of the phosphate backbone by 
the helical elements or the simultaneous binding of two nonconsecutive DNA segments in 
chromatin.163 
A Gly–Gly motif is also found in the porins of Escherichia coli and other bacterial species.164 
The motif confers flexibility to the third loop of the protein, which appears to have functional 
implications.165Another ex ample of structural flexibility associated with a Gly sequence is 
calmodulin-related TCH2 protein from Arabidopsis. The overall structure consists of two 
globular domains separated by a flexible linker region that contains a (Gly)4 motif.
166 
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3 Results and Discussion. Chapter 2 
3.1 Antifungal activity of preliminary lipidated analogues of Cm-p5. Work 
methodology. 
It is known that the lipidation of AMPs slightly increases the biological activity and it is 
common to find natural antimicrobial peptides containing lipid chains (Polymyxin B, 
Actinonin, Surfactin). These natural peptides are usually cyclic and it is apparent the 
conformational restriction of the lipid chain in one side of the cyclic structure, which perhaps 
favors the interaction with biological membranes. In general, the presence of hydrophobic 
aminoacids and lipids in natural peptides has the fundamental objective of increasing the 
amphiphilicity and hydrophobicity, which allows either to penetrate cell membranes more 
easily or to interact with other biological targets of the same nature.167 
Cm-p5 is a linear peptide, without any conformational restriction and perhaps capable of adopt 
several secondary structures during its action mechanism. However, the -helical structure 
could be responsible for the interaction with the negative membranes of fungus and is probable 
that any alterationof this rearrangement, also limits the biological activity. Without -helix, the 
linear peptide loses the preferred orientation of the lateral chain of aminoacids unless a -turn 
or another secondary structure could support the activity. 
In 2015, we synthetized five lipidated analogues of Cm-p5 applying a new methodology of Ugi-
4CR in solid phase (Figure 46). The biological activity results of this analogues indicated that 
the introduction of N-substitutions with lipids at intermediate positions decreased the antifungal 
activity. However, by lipidation of the N or C-terminus using the Ugi-4CR, the activity was not 
affected (lipidation at C-terminal) or was improved (lipidation at N-terminal). The chemical 
derivatives FMV02421 and FMV0451 lipidated at the N-terminal of the Cm-p5 peptide showed 
MICs close to or lower than the parental peptide against different strains of the pathogenic yeast 
Candida albicans, which showed that the modifications have a positive effect on the antifungal 
activity of these peptides.The analogue FMV0451 (MIC= 1.83 mol/L), more active than the 
Cm-p5 (MIC= 6.75 mol/L) (Table 10), was obtained by lipidation at the N-terminal using 
acetic acid as acid component of the Ugi reaction, paraformaldehyde and n-dodecylisonitrile.168 
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Figure 46: Lipidated analogues of Cm-p5. 
Table 10: Antifungal activity of the lipidated analogues of Cm-p5. 
 MIC (g/mL) 
 C. albicans C. parapsilosis T. reesei 
FMV02421 12,5 50 50 
FMV0243 > 100 > 100 50 
FMV0421 50 > 100 50 
FMV0451 3,125 > 100 50 
FMV0462 > 100 > 100 > 100 
Anfo B 0,25 0,25 0,125 
Sa: Staphylococcus aureus, Ec: Escherichia coli, Ca: Candida albicans, Cp: Candida parapsilosis, Tr: 
Trichophyton rubrum, NT: Non tested. 
 N-substitutions of amide bonds, similar to Pro residues, imposea restricted s-cis conformation 
around the amide bond. The intermediate N-alquilations interrupt the -helical backbone, 
favoring the s-cis conformation of the implicated amide bond and should be directly related 
with the loss of activity because the peptide loses the capacity of acquiring helicoidal character 
during the interaction with membranes. The losses of helicoidal character destroys the 
amphipathicity by dispersion of the polar or apolar residues, unless an amphipathic -turn 
structure will be formed, which is not apparently the present case. 
The Ugi-4CR allows generating N-substituted peptides in one-step, however, compared to the 
lipidation method by simple coupling of fatty acids, is experimentally more complex. For this 
reason, it is important to determine if coupling a fatty acid with similar chain size as the one 
obtained by N-terminal lipidation by Ugi-4CR with n-dodecylisonitrile producesthe same 
biological effect. Furthermore, Cm-p5 interacts with the membrane of microorganisms either 
to destabilize it or to penetrate the cell. The increase in activity by lipid binding to the N-
terminus may be due to a stronger interaction with membranes and is necessary to evaluate the 
effect of a larger carbon chain, more similar to the phospholipids present in membranes. 
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The Ugi motifs produced, when formaldehyde and acetic acid are used, have similar structure 
to sarcosine (N-methylglycine), the simplest peptoid monomer. Both cases lack the structural 
restrictions on backbone angles present in the cyclic Pro residue.Sarcosine scanning, similar to 
Ala scanning, is the usual method employed to determine the conformational influence of this 
residue in all the aminoacid position of a biologically active peptide. On the other hand, Gly, 
Ala or Pro residues are in the extremes of amide bond possible conformations. Pro, for example, 
favors the formations of s-cis amide bond, Ala the s-trans and Gly does not have preference 
and, remarkably, has the largest conformational freedom due to the lack of a lateral chain 
(Figure 47). 
 
Figure 47: Structural comparison of Ala, Gly, Pro, Sar and the products of Ugi residues. 
Considering that the lipid motif produced by coupling of fatty acids does not have the 
conformational behavior produced by the Ugi-4CR, we need to study the influence of the lipidic 
chain related conformation in the activity. With this aim, we pretend to compare the influence 
of Ala, Gly or Pro residues, positioned between the lipid and the N-terminal of Cm-p5, in the 
antifungal activity. 
In chapter 1, it is shown that replacing the His and Glu residues of the Cm-p5 sequence, 
eliminates completely the antifungal activity. In contrast, substitution of Glu and His by Cys 
and subsequent cyclization produces an analogue that showed a notable increased antifungal 
activity. To produce a final pharmacological candidate of Cm-p5, is desired the combination of 
this covalent modification: the introduction of lipid at the N-terminal by Ugi reaction with the 
same study of the influence of Ala, Gly or Pro residues between the lipid and the terminal Ser.  
If the effects of disulfide bridge cyclization and lipidation by Ugi-4CR in fungistatic character 
are additive, a cyclic derivative, also lipidated by Ugi-4CR could be the most active version of 
Cm-p5 obtained until today.  
The experimental design of this research has as objective to use a minimum number of variables 
that allowsestablishing generalizable conclusions about the influence of different ways of 
joining the lipids in the N-terminal of Cm-p5 or the cyclic versions in the biological activity. 
For the development of this research, it was necessary to divide the work in four fundamental 
parts: 
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 N-terminal lipidation of Cm-p5 with saturated fatty acids of different chain sizes to 
determine the optimal lipid chain for antifungal activity. 
 The lipidation of Cm-p5 after coupling Ala, Gly or Pro at the N-terminal to evaluate the 
conformational effects of these aminoacids in the biological activity. 
 The lipidation of CysCysCm-p5 after coupling Ala, Gly or Pro at the N-terminal and 
subsequent cyclization to evaluate the conformational effects of these aminoacids in the activity 
of helical stabilized and lipidated analogues of Cm-p5. 
 The synthesis of n-dodecylisonitrile by formylation and dehydration of commercial n-
dodecylamine for using it in the modification of CysCysCm-p5 by Ugi-4CR. 
 The lipidation of CysCysCm-p5 by Ugi-4CR with n-dodecylisocyanide, paraformaldehyde 
and acetic acid and subsequent cyclization to evaluate the conformational effects of these 
aminoacids in helical stabilized and lipidated analogues of Cm-p5. 
The results obtained in each stage of the experimental work are described below and follow the 
methodology of peptide characterization described in the section 3.1 of Chapter 1. The n-
dodecylisonitrile was characterized by FT-IR and NMR. The molecules synthesized in solid 
phase were characterized by analytical RP-HPLC and ESI-HRMS and purified by preparative 
RP-HPLC. 
3.2 Synthesis of lipopeptides analogues of Cm-p5 by coupling of fatty acids. 
The synthesis of Cm-p5 lipopeptides by coupling of fatty acids at the N-terminus was carried 
out in order to determine the importance of the size of the lipid carbonatedchain and the 
structural binding motif in the biological activity (Figure 48). It is also important to determine 
if the coupling of a fatty acid with the same chain size as that obtained by lipidation of the N-
terminal by Ugi with n-dodecylisonitrile gives the same biological effect with a simpler 
procedure. 
The binding of a 15-carbon lipid chain (pentadecanoic acid) to the N-terminus, produce a 
similar analogue to the one obtained by Ugi-4CR using n-dodecylisonitrile. On the other hand, 
by union ofcapric acid to the N-terminal we could evaluate the biological effect of the insertion 
of this minor carbon chain, both in the antifungal action and in the hemolytic character of Cm-
p5 (Figure 48).  
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Figure 48: Similarity in the lipid chain length of C10-Cm-p5 and C15-Cm-p5 lipopeptides synthesized 
by peptide coupling and FMV0451 synthesized by Ugi-4CR. 
To synthesize these two compounds, the sequence of the dodecapeptide Cm-p5 is completed 
by successive coupling of the aminoacids Phe, Leu, Arg, Gln, His, Val, Ile, Leu, Glu, Ser, Arg 
and Ser, on the derivatized MBHA resin with the linker Am (Rink). Subsequently, commercial 
fatty acids are bound to the deprotected N-end using DIC/Oxyma (Section 4.1.2, Chapter 1). 
After the appropriate treatment, the lipidated peptides are cleaved (Section 4.1.3, Chapter 1) 
from the resin and the analytical determination by RP-HPLC showed 80% of peptidic purity, 
tR= 22.1 min for C10-Cm-p5 (Figure 49) and 74% of peptidic purity, tR= 28.8 min for C15-Cm-
p5 (Figure 50). The ESI-HRMS confirms the identity of the synthesized peptides after 
collection of the fraction corresponding to the aforementioned peaks. 
 
 
Figure 49: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C10-Cm-p5. 
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Figure 50: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C15-Cm-p5. 
The antifungal activity of C10-Cm-p5 and C15-Cm-p5 was evaluated (Table 11). It was found 
that theintroduction of a small lipid chain does not modify the activity of Cm-p5. On the other 
hand, the coupling of pentadecanoic acid decrease theactivity; therefore, the size of the lipid 
chain is not the only determining factor in the activity, taking into account that FMV0451 and 
C15-Cm-p5 have the same size of the lipid chain. 
Table 11: Antifungal activity of decanoil and pentadecanoil lipidated analogues of Cm-p5. 
 
MIC (ug/mL) 
C. albicans C. parapsilosis C. krusei 
C10-Cm-p5 10 10 
10 
C15-Cm-p5 ˃ 20 ˃ 20 
˃ 20 
Anfo B 0,5 0,5 
˃ 16 
Cm-p5 10 10 
- 
The fundamental difference between C15-Cm-p5 and FMV0451 is the structural motif that 
produces the Ugi-4CR, an N-substitution that can alter the conformational balance of the lipid 
chain attached to the N-terminus. It is possible that this N-substitution have a similar behavior 
that Pro or sarcosine in peptides, favoring a rigid s-cis conformation of the amide bond.  
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3.3 Synthesis of lipopeptides analogues of Cm-p5 by coupling of decanoic acid after 
Ala, Gly or Pro. 
In natural lipidated AMPs, it is common to find a lipid anchored to cyclic rigid structures that 
restrictthe conformational behavior. A similar effect of restricted conformation could be present 
in FMV0451 due to the N-substitution (that is not present in C15-Cm-p5).  
A good approach to discover the influence of the lipid chain conformation in the activity of 
Cm-p5, using the tools of peptide chemistry, may be the synthesis of lipidated analogues 
containing Ala, Gly or Pro between the lipid chain and the peptide N-terminal (Figure 51). Pro 
should mimic the best the Ugi motif and Gly should permit total free rotation of lipid chain. 
Ala, on the other hand, is totally opposed to the Ugi motif, favoring rigid s-trans conformation 
and could be used as control. 
Considering the new aminoacid residue introduced, the use of decanoic acid reach only two 
carbon less than the Ugi product with n-dodecylisonitrile. Although it provides a smaller chain, 
we prefer to continue using decanoic acid to avoid the possibility of increased hemolysis, as it 
has been reported for many lipopeptides.169 
 
Figure 51: Lipidated analogues of Cm-p5 containing Ala, Gly or Pro. 
To synthesize these compounds, the sequence of the dodecapeptide Cm-p5 is completed and 
Ala, Gly or Pro is finally coupled, on the MBHA derivatized resin with the linker Am (Rink). 
Subsequently, commercial decanoic acids are bound to the deprotected N-terminal using 
DIC/Oxyma (Section 4.1.2, Chapter 1). After the appropriate treatment, the lipopeptides are 
cleaved (Section 4.1.3, Chapter 1) and the analytical determination by RP-HPLC showed 72% 
peptidic purity, tR= 21.5 min for C10G-Cm-p5 (Figure 52), 75% peptidic purity, tR= 26 min for 
C10A-Cm-p5 (Figure 53) and 70% peptidic purity, tR= 27 min for C10P-Cm-p5 (Figure 54). 
The ESI-HRMS verifies the identity of the synthesized peptide after collection of the fraction 
corresponding to the aforementioned peak. These three new Cm-p5 analogues were purified 
and submitted to biological activity evaluation. 
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Figure 52: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C10G-Cm-p5. 
 
 
Figure 53: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C10A-Cm-p5. 
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Figure 54: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C10P-Cm-p5. 
Table 12: Thermodynamical properties of Ala, Gly and Pro containing peptides. 
Cm-p5 
analogue 
 Δ:E(gas) 
(s-trans/s-cis) 
(kJ/mol) 
Δ:Erot‡ 
(s-trans/s-cis) 
(kJ/mol) 
Δ:Erot‡ 
(s-cis/s-trans) 
(kJ/mol) 
Kc 
(s-trans/s-cis) 
C10-Gly Gly-Gly 5.43 96.98 91.54 0.1 
C10-Ala Gly-Ala 23.41 93.63 70.22 7.85*10-5 
  Δ:Go(ac)(s-trans/s-
cis)(kJ/mol) 
   
C10-Pro Gly-Pro -8.4  76.6±10 85±10 29.9 
ΔE (gas, Pro)≈ ΔGo (ac, Pro)= because Pro is hydrophobic, do not form hydrogen bond with water.  
Considering that an amide bond could have similar conformational behavior in gas 
ormembranolitic conditions, we may compare the characteristics of a lipid chain joined after 
Ala, Gly or Pro to the Cm-p5 peptide. According to the thermodynamic parameters in Table 
12, the s-trans orientation of amide bond is more stable in C10G-Cm-p5 and C10A-Cm-p5, but 
some differences are notables. For C10A-Cm-p5, the quantity of s-cis isomer in equilibrium is 
negligible, due to the bigger valor of ΔG and the rotation from s-trans to s-cis is much more 
prohibited (93.63 kJ/mol) that the opposed process (70.22 kJ/mol). For C10-G-Cm-p5 the 
relation s-cis:s-trans is 1:10 and the rotational barrier for any direction of the inter-conversion 
is almost equal, indicating in principle that the two isomers are accessible.170 
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The s-cis conformation is preferred in the C10P-Cm-p5 because the rotational barrier from s-
trans to s-cis isomers is lower that in case of C10A-Cm-p5 and the process is espontaneous. 
The s-cis conformer is favored thermodynamically and kinetically, reaching the equilibrium at 
a 29.9:1 ratio of s-cis:s-trans. This analogue is the most structurally similar to FMV0451 
obtained by Ugi reaction and the lipid chain may have the same preference for the s-cis form. 
Rotation about the Cof Ala, Gly or Pro also could influence the lipid chain conformational 
behavior linked to N-terminal of Cm-p5. Newman projections considering only steric effect 
(nonelectrostatic, dipole moments or hydrogen bonding interactions were taking into account) 
and that Pro has favored s-cis conformation, both Ala trans conformation and Gly are showed 
in Figure 55. Also in that case, Pro orientate s-cis the lipid chain with respect to peptide 
backbone, Ala s-trans and Gly permit both conformations. 
 
Figure 55: Newman projection about the alpha carbon of C10A-Cm-p5, C10G-Cm-p5 and C10P-Cm-
p5. 
3.4 Synthesis of lipopeptides structurally restricted by disulfide bridge formation. 
Taking into account the results of chapter 1, the helical stabilized and cyclic analogue 
CysCysCm-p5 showed more activity against Candida albicans; thus lipidated and cyclic similar 
structures based on this analogue are desired. The same influence of the conformational effects 
of Ala, Gly and Pro could be acceded by the synthesis of C10A-CysCysCm-p5, C10G-
CysCysCm-p5 and C10P-CysCysCm-p5 (Figure 56), followed by the cyclization and 
dimerization by disulfide bond. Since antiparallel dimer and cyclic monomer of CysCysCm-p5 
were active and the simplest way to obtain both is during the cyclization reaction, we decided 
to oxidize the thiol groups of C10X-CysCysCm-p5 in similar conditions. 
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Figure 56: Structures of the acyclic C10A-CysCysCm-p5, C10G-CysCysCm-p5 and C10P-CysCysCm-
p5 peptides. 
To synthesize these compounds, the sequence of the cyclic dodecapeptide CysCysCm-p5 is 
first completed by successive coupling of the aminoacids Phe, Leu, Arg, Gln, Cys, Val, Ile, 
Leu, Cys, Ser, Arg and Ser on the MBHA resin derivatized with the linker Rink and with the 
use of the Fmoc/tBu methodology. The resulting peptide containing resin is divided in three 
equal parts and additionally, Ala, Gly or Pro residues are coupled to the N-terminal. Finally, the 
decanoilation reaction was carried out by normal coupling conditions using DIC/Oxyma 
(Section 4.1.2, Chapter 1). 
The cleavage is then carried out (Section 4.1.3, Chapter 1) in the presence of ethanedithiol to 
avoid collateral reactions of oxidation and dimerization of the thiol groups. Figure 57,Figure 
58Figure 59 show the RP-HPLC chromatograms and the ESI-HRMS spectra of the three 
synthesized lipopeptides. Chomatograms indicate 73% peptidic purity (tR= 27.5 min) for C10A-
CysCysCm-p5, 85% peptidic purity (tR= 27 min) for C10G-CysCysCm-p5 and 90% peptidic 
purity (tR= 28.5 min) for C10P-CysCysCm-p5. 
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Figure 57: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C10A-CysCysCm-p5 peptide. 
 
Figure 58: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C10G-CysCysCm-p5 peptide. 
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Figure 59: RP-HPLC (upper panel) and ESI-HRMS (lower panel) of C10P-CysCysCm-p5 peptide. 
Next, cyclizations (Section 4.1.4, Chapter 1) were carried out in liquid phase and aqueous 
medium with dioxygen of the air as oxidizing agent in high dilution conditions (0.3 mmol/L). 
This simple method is sufficient for these molecules due to the simplicity of the process (small 
peptide chain, formation of a single intramolecular bridge, spatial closeness of the thiol groups 
to be cycled). The freeze-dried crude of the lipopeptides C10X-CysCysCm-p5 wasattempted to 
dissolve in H2O (0.1% TFA)/ACN (3:1) at a concentration of 0.3 mM; however, it was 
necessary to add 30% of iPr-OH to achieve total solubilization. Then, aqueous ammonia (25%) 
was added until pH reached 8. The mixture was stirred, while open to air. Completion of the 
reaction was checked by RP-HPLC until total disappearance of the starting material. The Figure 
60,Figure 61,Figure 62 show the chromatographic evolution during 4-8 h of stirring. During this 
time, a complex mixture of products was formed and the three predominant peaks were 
analyzed by ESI-HRMS (Experimental Section, Chapter 2). 
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Figure 60: RP-HPLC evolution during oxidation of C10A-CysCysCm-p5 peptide at 0.3 mM after 4h 
(upper panel) and 8h (lower panel) and structure of the dimers and cyclic monomer formed. 
 
 
Figure 61: RP-HPLC evolution during oxidation of C10G-CysCysCm-p5 peptide at 0.3 mM after 3h 
(upper panel) and 6h (lower panel) and structure of the dimer and cyclic monomer formed. 
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Figure 62: RP-HPLC evolution during oxidation of C10P-CysCysCm-p5 peptide at 0.3 mM after 5h and 
structure of the dimer and cyclic monomer formed. 
The mass of peaks 1 and 3 doubled the mass of the cyclic peptide suggesting that they are 
dimers. Although it was not proven, like the dimers of CysCysCm-p5 described in chapter one, 
it is likely that peak 1 is the parallel dimer of the molecule which, being more symmetric, 
interacts less with the C18 chains of the stationary phase in RP-HPLC and therefore is less 
retained (smaller tR). Peak 3 should be the antiparallel dimer, but we must confirm these 
assumptions. 
Chromatograms show different behavior for each oxidized analogue. In the case of C10A-
CysCysCm-p5 (Figure 60), we can observe the consumption of the acyclic staring material after 
8h of reaction and the formation of notable quantities of dimers besides the cyclic product, all 
of them with different time retention than starting material. For C10G-CysCysCm-p5 (Figure 
61) and C10P-CysCysCm-p5 (Figure 62) the behavior was similar, but almost all the product 
was cyclic, with less amounts of dimeric analogues.As expected, Gly and Pro have similar 
orientation of the lipid chain, favoring a conformation in which the repulsion between lipids 
avoid the possibility of intermolecular reactions. On the contrary, Ala imposes conformations 
of the decanoil moiety opposed to the thiol group during cyclization, permitting the 
intermolecular contact. 
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For the preparative RP-HPLC, the peptides were dissolved in pure DMSO due to the high 
hydrophobicity that they present. Nine dimeric or cyclic lipidated analogues of Cm-p5 were 
obtained in more than 95% peptidic purity and will be submitted to biological evaluation. 
3.5 Synthesis and characterization of the n-dodecylisonitrile. 
One of the objectives of this work is the synthesis of n-dodecylisonitrile for the subsequent 
incorporation into the peptide sequence of CysCysCm-p5 by Ugi-4CR in solid phase. The 
length of the carbon chain was chosen after a previous work, in which one analogue synthesized 
with this isonitrileshowed a moderate increase in the antifungal activity. Although it is not 
common to find lipopeptides in the nature with very large lipid chains (usually only 8-16 carbon 
atoms) and it is expected that a very extensive carbon chain increases the hemolytic activity of 
Cm-p5, only experimental results would corroborate these hypotheses. 
Isocyanides can be synthesized by different strategies but the most used is the sequential 
formylation/dehydration of amines (Scheme 10). The n-dodecylamine is commercial and it can 
be formilated in several ways. However, due to the high reactivity (nucleophilicity) and low 
steric hindrance of the amino group, the reflux with ethyl formate guarantees complete 
conversion to formamide, without using other stronger formylating agents such as mixed 
formic-acetic anhydride. Experimentally, the amine is dissolved in ethyl formate and heated at 
60°C for 12 h. The reaction proceeds quantitatively, which is corroborated by TLC (n-
hexane/EtOAc, 1:1). After evaporating the ethyl formate, the solid obtained is used in the next 
step without further purification. 
Dehydration can be performed in several ways; a simple option is the use of POCl3 in excess of 
bases. The dried formamide is dissolved in THF and dehydrated with POCl3 and an excess of 
Et3N. The absence of other functional groups in the lipid chain (alcohols, amides, etc.), sensitive 
to the strongly dehydrating action of POCl3, allows it to be used in this procedure, although the 
process must be carried out under very mild conditions to avoid the occurrence of collateral 
reactions. With that purpose, an EtOH/N2 (l) bath is used to keep the temperature below -60
oC, 
inert N2 atmosphere and slowly addition of POCl3 (1M in THF) during 30 min. 
The treatment of the reaction before the purification by column is determinant and somewhat 
cumbersome, but it is essential to do it in this way to obtain as much product as possible. The 
reaction mixture is concentrated to dryness. Unlike other reported techniques, to eliminate the 
POCl3 excess and salts formed, H2O or saturated NaHCO3 should never be added, because of 
the high capacity of the lipids to form stable emulsions that would prevent the separation of the 
phases during the following extractions. Instead, the dry reaction crude is extracted with small 
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portions of n-hexane, which are combined, then concentrated to dryness and finally purified by 
LCC (hexane/EtOAc, 10:1) yielding 71% of n-dodecylsonitrile. 
 
Scheme 10: Sequential synthesis of the n-dodecylisonitrile. 
The n-dodecylsonitrile was characterized by FT-IR, 1H-NMR and 13C-NMR spectroscopic 
techniques. The Figure 63 shows the FT-IR spectrum with signals on the 2911 and 2847 cm-1 
corresponding to valence vibrations νCsp3-H of methyl groups and methylenes. The signal at 1468 
cm-1 corresponds to the double vibration δasCH3 + δsCH2 that is associated with the doubling of 
scissors δsCH2 and usually appears superimposed with the band δasCH3 of the methyl group. The 
rocking band has some diagnostic utility; in this compound, it appears as a weak band at 720 
cm-1 since a carbon chain with 11 consecutive methylene groups occurs. On the other hand, in 
2148 cm-1 a band of average intensity, corresponding to the vibration of stretching of the 
isonitrile triple bond, that appears between 2100-2200 cm-1.63 
Figure 63: FT-IR spectrum of the n-dodecylisonitrile. 
The Figure 64 shows the 1H-NMR spectrum of n-dodecylisonitrile where are observed the 
classic signals of protons linked to sp3 carbons corresponding to the lipid hydrocarbon chain. 
The signals of the protons are deshielded as the proximity to the isonitrile group increases, 
which gives a measure of how the electronegativity of the N-sp of the NC influences the proton 
displacements. Therefore, the signal of the methylene directly attached to the isonitrile group 
appears as a characteristic triplet at 3.37 ppm. 
Signal IR (cm-1) 
Rocking CH2 716.42 
δ:asCH3 + δ:sCH2 1468,53 
ν  NC 2148,28 
ν  Csp3-H 2847,38 
ν Csp3-H 2911.02 
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Figure 64: 1H-NMR spectra of the n-dodecylisonitrile. 
 
Figure 65: 13C-NMR spectra of the n-dodecylisonitrile. 
The Figure 65, shows the 13C-NMR spectrum of n-dodecylisonitrile where we can see signals 
corresponding to the C-sp3 of the aliphatic chain, whose displacement is greater as they get 
closer to the NC group. As characteristic signal, the carbon of the highly deshielded isonitrile, 
is observed at 155 ppm due to thesphybridization that presents.  
3.6 Lipopeptides synthesis by Ugi-4CR in solid phase. 
Lipidation of the N-terminus of Cm-p5 by Ugi-4CR with n-dodecylisonitrile, increases the 
antifungal activity. Ugi reaction allows generating N-substituted dipeptides in a single step, 
however, compared to the lipidation method by simple coupling of fatty acids, this reaction is 
more complex experimentally and the reactants are more expensive.  
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The lipid with fifteen carbons did not maintain the activity of Cm-p5, which indicates that not 
only the size of the lipid chain is determinant. Another factor influences, perhaps similar to 
what occurs in natural lipopeptides because the main difference of the Ugi product with the 
pentadecylated analogue is the N-substitution that changes the conformational equilibrium of 
the lipid chain. It is finally necessary, taking into account the result of chapter 1, to test the 
combination of the covalent modification by cyclization and lipidation at the N-terminal by Ugi 
reaction. 
To synthesize this compound the sequence of the dodecapeptide CysCysCm-p5 is completed 
by successive coupling of the aminoacids Phe, Leu, Arg, Gln, Cys, Val, Ile, Leu, Cys, Ser, Arg 
and Ser, on the MBHA resin derivatized with the linker Rink and with the use of the Fmoc/tBu 
methodology (Section 4.1.2, Chapter 1). The Ugi-4CRon the freeN-teminal of the peptide is 
then carried out with paraformaldehyde, n-dodecylisonitrile and acetic acid, following 
thepreviouslydescribed procedure.150 
After 36 h of reaction, the lipidated peptide is cleaved from the resin (Section 4.1.3, Chapter 1) 
and the analytical determination by RP-HPLC showed 65% peptidic purity and tR= 29 min. To 
verify the identity of the synthesized peptide, the fraction corresponding to the aforementioned 
peak is collected and ESI-HRMS is performed, showing coincidence between the mass 
observed and the expected mass (Figure 66). 
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Figure 66: RP-HPLC (upper panel), ESI-HRMS (lower panel) and structure of C12UgiAc-CysCysCm-
p5 peptide. 
Cyclization (Section 4.1.4, Chapter 1) H2O/ACN/iPr-OH at 0.3 mM, by oxidation with air 
oxygen produces the expected dimeric and cyclic analogues. Similar behavior as in case of 
C10G-CysCys or C10P-CysCys was obtained because the cyclic compound is almost the major 
product (Figure 67). This is an indication of the N-substitution influence in the lipid chain 
conformation and the preference for intramolecular sulfur oxidation. The three synthesized 
compounds were purified by preparative RP-HPLC. It was necessary to dissolve the samples 
in DMSO due to their low solubility in H2O (1% TFA), ACN or in mixtures of these solvents. 
The obtained pure samples are submitted to biological evaluation. 
 
Figure 67: RP-HPLC evolution during oxidation of C12UgiAc-CysCysCm-p5 peptide at 0.3 mM after 
3h and structure of the dimers and cyclic monomer formed. 
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Conclusions. Chapter 2 
 It is possible to covalently modify the Cm-p5 antifungal peptide by cyclization with disulfide 
bridges between Cys and N-terminal lipidation using multicomponent reactions or peptide 
coupling. 
 The coupling of decanoic acid or pentadecanoic acid to the N-terminus of Cm-p5 made 
possible to obtain two lipidated analoguesefficiently. This modification did not improve the 
biological activity of Cm-p5. 
 The cyclization of lipidic analogues of CysCysCm-p5 produces more quantities of dimers 
when it has an alanine residue between the lipid and the peptide and shows a similar behavior 
for Gly, Pro or the Ugi lipidated versions. 
 The formilation with ethyl formate and dehydration with POCl3 of n-dodecylamine is an 
efficient method to obtain n-dodecylisonitrile. 
 By Ugi-4CR using acetic acid, n-octadecylisonitrile and paraformaldehyde on the free N-
terminus of the CysCysCm-p5 peptide anchored to the solid support, an N-substituted analogue 
and N-acetylated lipopeptide was obtained. 
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Future works. Chapter 2 
 Evaluate the antimicrobial activity of the 15 new analogues of Cm-p5. 
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4 Experimental Section. Chapter 2 
4.1 General Remarks 
4.1.1 Materials 
In this section was used the same materials, method of peptide synthesis, peptide cleavage, 
peptide cyclization and dimerization, analytical RP-HPLC, ESI-HRMS and semipreparative 
RP-HPLC as described in sections 4.1.1-4.1.4 and 4.1.6-4.1.8 of Chapter 1. 
4.1.2 Registration conditions of NMR spectra 
The 1H-NMR and 13C-NMR spectra were recorded at the UFSCar, São Paulo, Brasil on a 
Bruker spectrometer, with a resonance frequency of 400 MHz or 100 MHz respectivetly and 
using TMS as an internal reference. The chemical shifts (δ) are reported in ppm and the coupling 
constants (J) in Hz.  
4.2 Synthesis of Structurally Restricted (Cyclic) Peptide (C10X-CysCysCm-p5): 
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Figure 68: ESI-HRMS of the compounds (ordered by retention time) formed during cyclization of 
C10A-CysCysCm-p5 peptide. 
 
 
95 
 
 
Figure 69: ESI-HRMS of the compounds (ordered by retention time) formed during cyclization of 
C10G-CysCysCm-p5 peptide. 
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Figure 70: ESI-HRMS of the compounds (ordered by retention time) formed during cyclization of C10P-
CysCysCm-p5 peptide. 
4.3 Synthesis of n-dodecylisonitrile by formylation and dehydratation of n-
dodecylamine. 
In a 50 mL flask, commercial n-dodecylamine (2.00 g, 10.8 mmol) is dissolved in HCOOEt (20 
mL). The resulting solution is refluxed for 24 h at 60°C in a bath of sand and TLC (n-
hexane/EtOAc, 1:1) checks the quantitative formation of formamide. The reaction crude is 
concentrated to dryness, dried by evaporation with toluene and keep in a vacuum desiccator for 
24 h. Dry formamide (2.3 g, 10.8 mmol) is dissolved in 10 mL of dry THF, in a three-necked 
flask with a droping funnel, 22.6 mL (162 mmol) of Et3N are added and the whole closed system 
is made inert with atmosphere of N2 (g). The reaction medium is cooled with an EtOH/N2 (1) 
bath (-60°C) and 3 mL (32.4 mmol) of POCl3 dissolved in 15 mL of dry THF (approx. 2M) are 
dropped for 30 min. Then the reaction is allowed to reach room temperature for 24 h. After 
checking the formation of the desired product by TLC (n-hexane/EtOAc, 10:1) the mixture is 
concentrated to dryness. The obtained solid is extracted with n-hexane (5×25mL), decanted and 
all fractions are combined. The organic phase is concentrated under reduced pressure and the 
resulting crude is purified by column chromatography (n-hexane/EtOAc, 15:1) to obtain pure 
n-dodecylisonitrile as a light yellow oil (1.50 g, 71%). 
Rf= 0.83 (n-hexane/EtOAc, 10:1). 
FT-IR (KBr) νmax/cm-1: 2927, 2857, 2148, 1460. 
1H NMR (400 MHz, CDCl3) δ: 3.41–3.35 (tt, 2H, J = 1.9/6.7 Hz, CH2NC), 1.73–1.63 (m, 2H), 
1.44 (m, 2H), 1.33–1.22 (m, 16H), 0.88 (t, J = 6.9 Hz, 3H). 
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13C NMR (100 MHz, CDCl3)δ:155.56, 60.53, 41.70, 32.03, 29.73, 29.64, 29.50, 29.46, 29.24, 
28.84, 26.45, 22.81, 14.25. 
4.4 Lipopeptides synthesis by Ugi-4CR in solid phase. 
The Ugi-4CR in solid phase is carried out in a THF/MeOH (1:1) mixture and MeOH alone is 
not used, because it does not adequately swell the commonly used polystyrene resins. In 
contrast, THF is the solvent with the highest swelling power (Annex 2) and has been used in 
reactions of Ugi mixed with MeOH. As in previous works,146, 171 the heterogeneous reaction 
process between the on-resin peptide as the amino component and paraformaldehyde is not 
efficient. It is necessary to perform the imine by organocatalysis using 4 equiv. of piperidine 
and 4 equiv. of (using CH2O)n in dioxane/MeOH for 1 h (paraformaldehyde is partially soluble 
in dioxane). Then, piperidine is removed by washing with THF, the acetic acid (4 equiv.) and 
dodecylisonitrile (4 equiv.) components dissolved in THF/MeOH (1:1) are added, checking the 
occurrence of reaction by ninhydrin test after 1h. However, as it has already been shown, to 
complete the reaction, 36-72 h were needed due to slow Mumm rearrangement (Section 2.3.1). 
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Figure 71: ESI-HRMS of the compounds (ordered by retention time) formed during cyclization of 
C12UgiAc-CysCysCm-p5 peptide. 
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Chapter 3 
 
"Merging peptides and small drugs for traceless release and targeted 
delivery to tumors" 
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Chapter 3 
1 Introduction. Chapter 3 
1.1 Peptide drugs conjugates. Cancer treatments with Carfilzomib and general 
objective of our work. 
For decades,the targeting therapy with antibody-drug conjugates (ADCs) and peptide-drug 
conjugate (PDCs), usually composed of monoclonal antibodies or peptides, toxic payloads and 
cleavable/noncleavablelinkers, has been extensively studied.172 The conjugates enable the 
selective delivery of cytotoxic payloads to targetedcells, which results in improved efficacy, 
systemic toxicityreduced and betterpharmacokinetics (PK)/pharmacodynamics (PD) compared 
with traditional chemotherapy.173 PDCs and ADCsare based in a similar concept, but with 
vastly different structures and properties. Humanized antibodies introduce high specificity and 
prolonged half-life, while small peptides exhibit higher drug loading and enhanced the tissue 
penetration capacity. In addition, the flexible linear or cyclic peptides are also modified more 
easily.174 
There are four ADCs approved by FDA and several under clinical trials. However, preclinical 
and clinical studies found that therapy strategies based on the targeting of specific proteins is 
significantly hampered by tumor heterogeneity, which can promote tumor evolution, leading to 
the loss of cell surface proteins and, eventually, to therapy resistance and disease progression. 
Moreover, targeted cancer biomarkers tend to be over expressed in a tumor-associated, not 
tumor-specific manner. 
Peptide therapeutics has played a notable role in medical practice since the advent of insulin 
therapy in the 1920s. Thanks to the reduction of the main limitations that arose during their 
collection, synthesis and application, over 60 peptidic drugs are approved in the United States 
and other major markets. Peptides continue to enter in clinical development at a steady phase 
and the use of peptides or proteins as drugs has taken a sharp boom. Particularly, membrane 
penetrating peptides or those that can respond to different stimuli, such as pH, redox potential, 
temperature, light and enzymes, may offer controllable actions in specific targeted body 
locations.  
Proteases encompass a broad range of hydrolytic enzymes that catalyze the cleavage of proteins 
and peptides. Deregulated proteolytic activities frequently have causative or exacerbated 
functions in pathological conditions, and therefore many proteases represent important 
therapeutic targets. The generation of small molecule drugs acting as protease inhibitors is a 
successful manner to fight several diseases. Successful examples of therapeutic intervention 
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using protease inhibitors include: angiotensin, converting enzyme inhibitors for the treatment 
of hypertension, HIV aspartyl protease inhibitors to prevent the development of AIDS and 
application of proteasome inhibitors in the treatment of myeloma. Proteasomes are proteases 
complexes which degrade unneeded or damaged proteins by proteolysis, a chemical reaction 
that breaks peptide bonds.175 
The selective proteasome inhibitor Carfilzomib is a tetrapeptide epoxyketone and an analog of 
epoxomicin. It is an anti-cancer drug that inhibits covalently and irreversibly the chymotrypsin-
like activity of the 20S region of proteasome and displays minimal interactions with non-
proteasomal targets. The build-up of polyubiquitinated proteins resulted of the inhibition of 
proteasome-mediated proteolysis, may cause cell cycle arrest, apoptosis and inhibition of tumor 
growth.176 This drug improve safety profiles over many cytotoxic drugs that can escape from 
the targeted cell and, in a process called "bystander killing", attacking neighboring cells.177  
In phase II trials of carfilzomib, the most common adverse events were hematologic 
toxicity with thrombocytopenia, anemia, lymphoenia, neutropenia, pneumonia, fatigue and 
hyponatremia.178 Furthermore, gastrointestinal disturbances, including diarrhea and nausea are 
non-hematologic side effects, commonly reported with proteasome inhibitors. Additionally, 
cardiovascular toxicity is an outcome of Carfilzomib treatment due to the effects on 
proteasomes in the myocardium.179 
The development of targeted delivery strategies for Carfilzomib could eliminate the adverse 
effects, reduce doses and increase effectiveness. The characteristics as a highly selective and 
irreversible inhibitor of the proteasome should make it a special candidate for the 
bioconjugation with peptides sensitive to the acidic pH of the tumor cells. 
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2 Bibliographic Revision. Chapter 3 
2.1 ’,’-epoxyketone peptides as proteasome inhibitors 
The ubiquitin-proteasome pathway of cell-cycle progression is controlled by the multi-enzyme 
complex proteasome and is involved in the termination of signal transduction cascades and the 
removal of mutant, damaged and misfolded proteins. This protease is a promising therapeutic 
target, and a synthetic dipeptidyl peptide boronate, named Bortezomib (Velcade), is the first 
clinical FDA-approved drug that have proteasome inhibition as action mechanism.178 Natural 
products like epoxomicin are microbial metabolites posesing a epoxy-ketone integrated with a 
peptidic skeleton that exhibit anticancer activities as a result of proteasome inhibition (Figure 
72).180    
 
Figure 72: Natural epoxypeptides inhibitors of proteasome as anticancer agents. 
Such epoxypeptides have been naturallydesigned to bind covalently with Thr of proteasome 
20S, thus leading to irreversible inhibitory activity and a potent, but rather selective, 
cytotoxicity to malign cells. Epoxomicin also served as a scaffold for the generation of a 
synthetic tetrapeptide epoxyketone with improved activity (Figure 73), YU-101, which became 
the inspiration for Carfilzomib, the recently approved therapeutic agent for multiple 
myeloma.181 
 
Figure 73: Bortezomib, YU-101 and Carfilzomib proteasome inhibitors. 
 According to the mechanism described by Hubert and Crews, the unique specificity of 
epoxomicin is a result of the irreversible formation of a morpholino ring between the amino 
terminal catalytic Thr-1 of the  proteasome 20S and the ,-epoxy ketone pharmacophore of 
103 
 
epoxomicin (Scheme 11).182 A sequential double nucleophilic attack on the epoxy ketone 
residue of epoxomicin by two nucleophiles of the N-terminal Thr (the hydroxyl side chain and 
the free N-terminal) explains the formation of the morpholino ring. Therefore, it is expected 
that only N-terminal nucleophile proteases, such as the proteasome, can form the morpholino 
ring by reaction with epoxy ketones, thereby rendering epoxomicin a exceptional specificity for 
the proteasome over alternative mechanism-based proteasome inhibitors.183 
 
Scheme 11: Mechanism for the formation of a morpholino adduct from epoxypeptides. 
2.2 Total synthesis of Carfilzomib 
The FDA approved Carfilzomib for relapsed and refractory multiple myeloma is marketed 
under the trade name Kyprolis. It production use general approaches of convergent peptide 
couplings in liquid phase but some differences are observed in the stage of synthesis of the 
epoxide building block that start with a vinylketone.184 
One route leads from the simple Leucine-vinylketone epoxidation, previously synthetized 
through the Weinreb amide of Boc-Leu-OH and subsequent reaction with the 
isopropenylmagnesium or the isopropenyllithium organometallic reagent. The subsequent 
epoxidation of the Boc-Leu-vinylketone with non-stereoselective methods (H2O2 (1.6:1 dr), 
Ca(ClO)2 (2:1 dr), etc) leads to mixtures of diasteromers and implies the final chromatography 
separation of the desired epoxide. Double protection of the Leu-vinylketone, with two Boc, Boc 
and Cbz or two Cbz and subsequent epoxidation render 9-10:1 dr but implies an addition step 
of protection. Theepoxidation of late stage intermediates (Boc-Phe-Leu-vinylketone) with H2O2 
(9:1 dr), Ca(OCl)2 (3:1 dr), mCPBA (1:1 dr), t-BuOOH, lanthanide BINOL complexes 
(96.5:3.5 dr), H2O2 and chiral manganese complex (7:1 dr) have been also implemented.
184 
The other fragment is synthetized by a linear peptide coupling procedure using the Boc/Bzl 
chemistry. The morpholine group may be appended in two steps via acylation with chloroacetyl 
chloride and displacement of chloro with morpholine.184In the final step, a tetrapeptide (Morf-
Ac-Hph-Leu-Phe-OH) is connected to the Leu-epoxide. Different coupling reagents have been 
used, with low racemization of the C-terminal aminoacid (Section 2.4, Chapter 1). The overall 
process is completed in, at least, five days of work and only with 29% yield (Scheme 12).184 
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Scheme 12: Convergent synthesis of Carfilzomib by early epoxidation. 
A second route is a late-stage epoxidation process that includes also the previous linear 
synthesis of the tetrapeptide left-hand fragment, using liquid phase procedures. Next, a 
vinylketone analogue of carfilzomib is synthesized by coupling the tetrapeptide left-hand 
fragment and Leu-vinylketone (Scheme 13). The vinylketone pentapeptide can be epoxidized 
at late-stage by H2O2/KOH with 5:1 dr and yield 60%.
184 However, the diastereomeric mixture 
has to be purified by column chromatography, with the loss of 20% mass of the desired 
diasteromer. Hence, the yield of the epoxide building block with the desired configuration is 
somewhat low. The overall yield after six days of work is only 17%. Further advance of the 
process could be more simple reaction conditions, the use of readily available starting materials 
and reagents, the use of solvents that are easily handled and/or removed, the prevention of the 
use of hazardous and explosive materials and the improvement of stereoselectivity. A Chinese 
patent application describes epoxidation of the vinylketone pentapeptide using NaHCO3, 
oxone, and trifluoroacetone in DCM at -10 oC. After chromatography, carfilzomib is isolated 
in 46% yield and peptidic purity>99%. The dr of the reaction is not provided.184 
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Scheme 13: Convergent synthesis of Carfilzomib by late-stage epoxidation. 
 
2.3 Antibody drug conjugates (ADCs). Linker technologies, maleimido linkers and 
carbonylacrylic acid approach. 
ADCs are examples of bioconjugates, immunoconjugates and are biopharmaceutical drugs 
designed as a targeted therapy for treating cancer because intend to target and kill tumor cells 
while sparing healthy cells. They are complex molecules composed by an antibody linked to a 
biologically active cytotoxic payload or drug. Until the 2019, 56 pharmaceutical companies 
have been working in the developed of ADCs.185 
Antibodies specifically target certain tumor antigen (a protein that, ideally, is only found on 
tumor cells) and trigger a signal in the tumor cell that activates the internalization of the ADC.  
After the ADC is internalized, the cytotoxin kills the cancer cell once released. This kind of 
targeting limits side effects and gives a wider therapeutic window than the traditional 
chemotherapies.187 
Mechanisms of resistance to ADCs include low/loss of antigen expression, masking of the 
antigen, presence of NRG (neuregulins or neuroregulins , part of the EGF family of proteins), 
truncation of the antigen, poor internalization, impaired lysosomal processing, high rate of 
recycling, oncogenic alterations, mutations in cytotoxic drug target, role of cell cycle and 
apoptotic deregulation.189  
In the development of ADCs or PDCs, the linker is of the same essential importance that the 
monoclonal antibodies and the cytotoxic drugs used.187 The linker impacts the efficacy and 
tolerability of the final bioconjugate and ensures that less of the cytotoxic payload falls off 
before reaching a tumor cell, improving safety, and limiting dosages.190 
General linkers are based on chemical motifs including disulfides, hydrazones or peptides 
(cleavable), or thioethers (noncleavable). Cleavable linkers rely on the physiological stimuli, 
which mainly includes chemically cleavable linkers (acid-labile linkers and disulfide linkers) 
and enzymatically cleavable linkers (peptide linkers and β-glucuronide linkers).191 
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Alternatively, noncleavable linkers require proteolytic degradation. They depend on the 
internalization more than cleavable linkers do. Cleavable linkers take advantage of the 
antibody-drug conjugate targeting mechanism which involves sequential binding of the 
antibody-drug conjugate to the cognate antigen on the surface of the target cancer cells, and 
internalization of the ADC-antigen complexes through the endosomal-lysosomal pathway.191 
For acid-labile linkers (hydrazones and cis-aconityl, sometimes with low serum stability), 
intracellular release of payloads relies on the different pH between endosomes/lysosomes 
(pH= 7.3-7.5) and blood (pH= 7.3-7.5) (Figure 74). A cis-aconityl linkage can be used to 
conjugate payloads, such as doxorubicin (DOX) and daunomycin (or daunorubicin). This kind 
of conjugation was achieved through the carbohydrate residues of the mAbs after periodate 
oxidation, which improved the therapeutic index compared to the unconjugated drug. 
Hydrazones utilize aminoacid residues on the antibody instead of the carbohydrate moieties 
for covalent attachment. Gemtuzumab ozogamicin (Mylotarg), the first ADC approved by 
FDA, is an example that uses the hydrazone linker technology.191 
Disulfides (Figure 74) are thermodynamically stable at physiological pH and are designed to 
release the drug upon internalization inside cells by attack/interchange of cytoplasmic thiol 
cofactors, such as glutathione (GSH) or the intracellular enzyme protein disulfide isomerase. 
Each linker has their advantages and limitations. Ultimately, the choice of the linker is 
correlated to the antibody, the drug and the disease to be treated.192 When drugs already 
approved by some regulatory agency are used in ADC construction, an important criterion to 
follow is the use of linkers that not leave traces once liberated from the drug. 
 
Figure 74: General types of cleavable linkers. 
2.3.1 Enzymatically cleavable linkers: Peptide linkers. Traceless linkers. 
Enzymatically cleavable linkers are sensitive to enzymes located in cytoplasm, providing 
ADCs with improved plasma stability, comparable to non-cleavable linkers, while boasting a 
more defined method of drug release. Moreover, the ability to pair these linkers with self-
immolative chemical groups allows the release of free drugs with a minimal derivation 
(traceless procedure). Dipeptide-based linkers Val-Cit and Phe-Lys are examples of them and 
have been used in ADCs under clinical trials. However, the dipeptide Val-Cit combined with 
PAB (p-aminobenzyl alcohol), a self-immolative linker, is the most popular enzymatic 
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cleavage sequence. Cleavage of an amide-linked PAB triggers a 1.6-elimination of carbon 
dioxide and concomitant release of the free drug in parent amine form. Besides peptide 
linkers, some non-peptide cleavable linkers are also being investigated (Scheme 14). 
Glucuronide linkers incorporate a hydrophilic sugar group cleaved by -glucuronidase. Once 
the sugar is cleaved from the phenolic backbone, self-immolation of the PAB group releases 
the free drug.193  
 
Scheme 14: More used enzymatically cleavable linkers containing PAB. Traceless mechanism of PAB 
release. 
2.3.2 Maleimide containing linkers 
Among the 40 ADCs that are in clinical trials (until 2018), only 34 have disclosed the 
structures. Manyof these structures (24 out of 34) utilize attachment of the linker-drug directly 
to cysteine of the antibody and all of these take advantage of the excellent reactivity of 
maleimide with sulfhydryl groups. There are two common maleimide-type linkers: 
maleimidocaproyl (mc) and maleimidomethyl cyclohexane-1-carboxylate (mcc).194 
However, maleimido linkers have two major drawbacks: the possibility of retro Michael 
reaction (avoided if self-stabilizing maleimide construct is used)195 that causes rapid clearance 
in physiological conditions and the rapid exchange reactions with thiols present in plasma (for 
example in albumin) (Figure 75).196 
 
Figure 75: Maleimide containing linkers and low plasma stability test. 
Maleimido-Caproyl-Val-Cit-PAB-O-p-nitrophenyl carbonate (MC-Val-Cit-PAB-PNPC), is a 
cathepsin cleavable ADC peptide linker to attach antibodies by Michael addition of thiol 
groups. The carbonate moiety permits the union of drugs containing alcohols or secondary 
108 
 
amine groups and a release without traces. For example, FDA approved drug, Brentuximab 
vedotin adopts this linker (Figure 76).197 
 
 
Figure 76: Approved anticancer treatment: Brentuximab vedotin (trade name Adcetris). 
Substitutes of maleimidobased linkers include the one-step and irreversible Cys selective 
bioconjugation using simple carbonylacrylic reagents (Scheme 15). These reagents undergo 
rapid thiol-Michaeladdition under biocompatible conditions in stoichiometric amounts. The 
reaction proceeds with a high degree of Cys selectivity using equimolar amounts of 
synthetically accessible reagents under aqueous, biological friendly conditions. The formed 
conjugates are fully stable in plasma and retain their function.198 
 
Scheme 15: Irreversible Cys selective bioconjugation using simple carbonylacrylic reagents. 
Recently, a new maleimide-traceless linker for bioconjugation of tertiary or heteroaryl amines 
containing drugs (a common chemical motif in many anticancer compounds) was developed.199 
The linker possess a chlorobenzyl moiety that reacts with this type of drug by SN2 substitution 
forming a tetraalkylammonium salt in yields ranging 15-35% (Menshutkin reaction)200 (Scheme 
16). 
 
Scheme 16: Maleimide-Caproil-Val-Cit-PAB-Cl linker for the traceless release of tertiary and heteroaryl 
amines from ADCs. 
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This linker is synthetized by a convergent peptide coupling approach and final 
chlorobenzylation with tionyl chloride. The overall procces is tedious and only 44% of yield is 
obtained after at least five days of work (Scheme 17).201 
 
Scheme 17: Reported Maleimido-Caproic-Val-Cit linker synthesis. 
2.4 pHLIP peptides and related pHLIP-drug conjugates. 
Acidity is a general hallmark of tumors.202 While normal tissue pH is about 7.4, pH in tumors 
range from 5.5 to 7. Peptides as GALA,203 ATRAM204 or pHLIP 
(AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) are synthetic pH-responsive 
amphipathic peptide that target acidity in biological membranes by formation of a -helical 
transmembrane at pH less than 7.  
 These peptides can be used to target cancers or conditions as viral infections in the lung, or 
even arthritis in the knee. Unlike other strategies that are developed to target few specific types 
of cancer, the approach is extremely simple and relies on a feature that is common to most solid 
tumors. pHLIP have been used for the release of cargo molecules attached by the C-terminus 
via a disulfide bond, that is cleaved in the cytoplasm. Disulfide reduction could be effected by 
several changes in the tumor metabolism and sometimes does not show good results. pHLIP 
conjugates with DOX,205 Phalloidin toxin206 or Amanitin (Figure 77)207 are recent examples.  
 
Figure 77: Mechanism of target and intracelular release of the anticancer bioconjugate pHLIP-Amanitin 
(SPDP: maleimido disulfide linker). 
Thévenin’s lab uses the pH (low) insertion peptide (pHLIP), a peptide that can selectively target 
tumors in mice, solely based on their acidity rather than on any specific biomarker. pHLIP 
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circulates in the blood supply until it anchors to the cell membrane of acidic tissues. Their recent 
study shows that pHLIP–MMAE combination is effective at killing a breast cancer cell line that 
is resistant to current targeted therapies, after only two hours of incubation without any apparent 
disruption of the plasma membrane.208 
PET Imaging of extracellular pH with 64Cu- and 18F-Labeled pHLIP peptide Variant3 
(ACDDQNPWRAYLDLLFPTDTLLLDLLT) have been used to target tumors (Figure 78).209 
 
Figure 78: PET Imaging of extracellular pH with 64Cu labeled pHLIP-Variant3. 
The pathway of pHLIP entry into the membrane and the translocation of molecules into cells is 
not mediated by endocytosis, but by interactions with cell receptors or by formation of pores in 
the cell membrane. pHLIP demonstrates prolonged circulation in the blood (several hours), 
which is consistent with the ability to bind weakly to membrane surfaces at neutral and high 
pH, preventing the rapid clearance by the kidney expected for a small, soluble peptide.210 
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3 Results and discussion. Chapter 3 
3.1 Our proposal for the peptide conjugation of Carfilzomib 
Peptide conjugation of Carfilzomib could be realized with many types of peptide-based 
biomaterials with stimuli-responsive and membrane-active properties. Within these, the use of 
pHLIP Varian3 is promising because it has been proved to be effective as pH acidity biomarker 
and in PDCs conjugates due to the easiness of synthesis, covalent modification and good 
stability during plasma circulation.   
Peptides can be prepared in a linear stepwisesynthesis in which each aminoacid is successively 
coupled, or in a convergent approach, where short fragments are grown separately, purified and 
connected. Both strategies can be carried out in solution or in solid support, although solution 
and solid‐phase methods can coexist in convergent approaches. The synthesis in solution is 
cheaper if it is used to obtain small peptides, but the requirement of purification for 
eachintermediate obtained is a tedious and slow process that requires time, a disadvantage with 
respect to the solid phase method. Synthesis on solid support is more expensive, so the cost-
benefit ratio should be favorable during the application. However, it requires a shorter reaction 
time, may be automated and peptides with a high degree of peptidic purity are obtained.9 
Reported synthesis of Carfilzomib is carried out mainlyin liquid phase and implies inefficient 
process of aminoacids coupling and intermediate purifications. Solid phase methods for the 
synthesis of the left-hand fragment of Carfilzomib wasrecentlycompletedbut in low yields 
(48%).Currently, the conjugation of pHLIP peptides to drugs uses only cleavable disulfide 
linkers, which sometimes have poor stability in plasma and therefore limited outcomes. The 
application of enzymatically cleavable linkers to pHLIP-Carfilzomib conjugates could improve 
the effectiveness of the new anticancer bioconjugate and could be further implemented with 
other drugs or stimuli-responsive and membrane-active. One of the most used enzymatically 
cleavable linker (MC-Val-Cit-PAB-Cl) is synthetized inefficiently in liquid phase; it contains 
a maleimido group for addition of thiols and a PAB moiety functionalized with chloride for the 
reaction with tertiary amines. Bioconjugates containing maleimido have poor stability in 
plasma and the reaction of PAB chlorides with tertiary amines have low yield. Therefore, the 
use of carbonylacrylic instead of maleimido and PAB-iodides instead of PAB-chlorides should 
be advantageous. The implementation of solid phase peptide synthetic methods in the synthesis 
of this linker is a novel strategy in this research area. 
With these statements in mind, the objectives of this work could be numbered as follow: 
 Developan improved synthesis of Carfilzomib using peptide synthetic methods in solid 
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phase. 
 Develop an enzymatically-cleavable linker containing carbonylacrylic and PAB-iodides 
instead of maleimido and PAB-chlorides to improve both, PDC or ADC effectiveness in-vivo 
and the yield of coupling to tertiary amine-based drugs. 
 Develop a solid phase peptide synthetic protocol to produce linkers like MC-Val-Cit-PAB-
OH. 
 Synthetize pHLIP-Variant3 containing Cys at the N or C-terminal. 
 Synthetize pHLIP Varians3-Linker-Carfilzomib bioconjugates to address biological 
anticancer effectiveness and reduction of adverse effects of Carfilzomib treatments.  
The results obtained in each stage of the experimental work are described below and follow the 
methodology of peptide characterization described in the section 3.1 of Chapter 1. The small 
intermediate molecules were characterized by NMR and ESI-MS or ESI-HRMS in some cases. 
The molecules synthesized in solid phase werecharacterized by analytical RP-HPLC, ESI-
HRMS and NMR in some cases. The small molecules were purified by liquid column 
chromatography and the others bypreparative RP-HPLC. 
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3.2 Carfilzomib Synthesis 
3.2.1 Solid-phase synthesis of the left-hand fragment of Carfilzomib. 
Previous synthetic methods of Carfilzomib include liquid and solid phase approach, some of 
them with a late-stage epoxidation step. The late-stage epoxidation method developed until 
today, even though it has more yield, implies the loss of 20% of important and costly advance 
material during diastereomers separation. For that reason, in this work we decided to use the 
standard approach of epoxidation at early stage, in which only the aminoacid Leu is lost during 
separation of the diastereomeric epoxides.  
 The left hand of carfilzomib is a tetrapeptide containing the non-natural aminoacids Hph and 
morpholino acetic acid. Both are commercially available but rather expensive (Hph in the form 
of Fmoc-Hph-OH) and morpholino acetic acid could be easily prepared by liquid phase 
substitution of the bromo in bromoacetic acid by morpholine. As this peptide have C-terminal 
in the form of carboxylic acid, it is possible to use Wang or Cl-Trt-Chloride resins to carry out 
the synthesis. Taking into account that aminoacids in this peptide do not have protected lateral 
chains, Cl-Trt-Chloride resin is the best option to avoid the extreme cleavage condition of the 
Wang resin (95% TFA). 
 The peptide was grown using Cl-Trt-Chloride resin with 1.47 mmol/g of substitution. The first 
aminoacid (Fmoc-Phe-OH) was coupled in 2 h by unimolecular substitution (SN1) over the Cl-
Trt group in the resin, using excess of DIEA as base. The possible remained active sites in the 
resin ware capped with MeOH washings. Peptide synthesis was carried out by sequential 
deprotection and coupling reaction and checked by ninhydrin test after the final reaction. The 
combination of DIC/OxymaK as has been reported was an excellent coupling agent due to 
eradication of early cleavage of the peptide in the presence of weak acids as HOBt or Oxyma. 
We proved also a reduction in the consumption of aminoacid and OxymaK quantities. The 
combination of 2equiv. of Fmoc-AA-OH and DIC with 3 equiv. of OxymaK produced 
comparable efficiency (time and yields) as the coupling with 4 equiv. of excess of all reagents. 
It also reduced the wasteand cost of the overall synthesis. Cl-Trt-Chloride Resin also represents 
an advance because can be recovered. 
Notably, we developed a new procedure for the synthesis of the morpholino acetic acid moiety 
in the last step. Instead of coupling this compound, we coupled bromoacetic acid and then the 
treatment with morpholine solution (6x10 min) in DMF afforded the expected product by total 
bimolecular substitution (SN2) of the bromo atom. Final cleavage with 1% TFA in DCM 
afforded the expected peptide in the form of TFA salt in almost quantitative yield. The total 
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synthesis of the left-hand fragment of Carfilzomib was accomplished in solid phase in only 6 h 
and with excellent yield (95%) (Scheme 18). Our results are substantially superior to the liquid 
phase procedure that could imply at least one week of coupling reactions, intermediate 
purifications and less than 35% of yield. Compared with the previously solid phase developed 
protocol184 we increased the yield from 48% to 95% due to the use of OxymaK racemization 
inhibitor. The ESI-HRMS (Figure 79) confirms the expected mass of this tetrapeptide and RP-
HPLC the peptidic purity and absence of racemization during the coupling reactions (see 
experimental part for details, Chapter 3). 
 
Scheme 18: Synthesis of the left-hand fragment of Carfilzomib. 
 
Figure 79: ESI-HRMS of the left-hand fragment of Carfilzomib. 
Despite of the use of excess reagents (2equiv.) in the synthesis in solid phase, the gain in time 
and performance implies reduction of operating costs, laboratory material, payment of qualified 
personal, environmental harmful residues, energy consumption and health risks due to working 
conditions. A further improvement may be the substitution of DMF by THF or MeTHF as 
greener solvents. The implementation of coupling conditions that implies the uses of 2 equiv. 
of FmocAa-OH/DIC and 3 equiv. of racemization inhibitor are being investigated on other more 
complex peptides. 
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3.2.2 Synthesis of the right-hand fragment of carfilzomib and coupling to the left-hand 
fragment. 
For the synthesis of the right-hand of carfilzomib we employed a reported procedure that uses 
Weinreb amide and leucine -unsaturated ketone as intermediates before the final epoxide 
synthesis. We started protecting (L)-Leucine with Boc2O using a standard protocol. The 
Weinreb amide of Boc-Leu-OH was prepared in high yield and peptidic purity using TBTU as 
coupling agent. The following Grignard reaction with commercial iso-propenylmagnesium 
bromide afforded the -unsaturated ketone in high yield and in a simpler procedure compared 
with the reported iso-propenyl lithium. Final stereo uncontrolled epoxidation of the enone 
afforded a mixture (3:1 dr as judge by 1H-NMR (Figure 80) and the mass of isolated products) 
of diastereomeric epoxides in 50% yield, which was separated by flash chromatography. The 
TFA salt of the desired Leu-epoxide aminoacid was obtained in quantitative yield after Boc 
deprotection in the presence of TFA/DCM 30% (azeotropic removal of TFA with toluene was 
necessary to get the pure white solid, Scheme 19).  
 
Scheme 19: Synthesis of the righ-hand fragment of carfilzomib. 
The 1H-NMR of Weinreb amide, alkene and epoxide are presented in Figure 80. For the 
Weinred amide, the two singlets in 3.77 ppm (a, s, 3H) and 3.18 ppm (b, s, 3H) indicate the 
formation of the product. Other important signals come from the Boc protecting group in 1.41 
ppm (s, 11H, together with the -CH2 of the leucine) and the two doublets in 0.94 ppm (d, J = 
6.5 Hz, 3H) and 0.91 ppm (d, J = 6.7 Hz, 3H) corresponding to the –CH3 of the leucine 
aminoacid. The ,-unsaturated ketone system is confirmed by the presence of two singlets in 
6.06 ppm (a, s, 1H) and 5.86 ppm (a’, s, 1H), together with the singlet of the -CH3 in 1.88 ppm 
(b, s, 3H). For the epoxide, two doublets in 3.29 ppm (a, d, J = 4.8 Hz, 1H) and 2.89 ppm (a’, 
d, J = 4.8 Hz, 1H) and a singlet in 1.51 ppm (b, s, 3H) corroborated the structure. The other 
isomer of the epoxide was isolated and characterized. The main differences are observed for 
the -CH2O signals of the epoxide in 3.06 ppm (d, J = 5.0 Hz, 1H) and 2.88 ppm (d, J = 5.1 Hz, 
1H) and the -CH3 observed in 1.58 (s, 3H) (Figure 102). The obtained spectroscopic data is in 
accordance with thepreviously described results in the literature.14 
116 
 
 
Figure 80: 1H NMR spectra of the Boc-protected Leu 9, 10 and 11a (CDCl3, 400 MHz). 
The synthesis of the epoxy-drug was finally accomplished by the coupling of leucine-
epoxidewith the MorfAc-Hph-Leu-Phe-OH tetrapeptide in the presence of 
TBTU/HOBt/DIPEA and THF at -20 ºC to room temperature after 12 h (Scheme 20) furnishing 
Carfilzomib in 90% yield as a white solid after purification by flash column chromatography 
using ethyl acetate as solvent. The 1H NMR (CDCl3) spectrum of Carfilzomib is showed in 
Figure 81. The incorporation of the Leu-epoxide in the main tripeptide structure can be 
confirmed by the multiplet in 0.89–0.82 ppm with integration to 12H (2 CH3 from 2 Leu), 
together with the epoxide signal in 2.85 ppm (CH2O, d, 1H, J = 4.9 Hz)/3.22 ppm (CH2O, d, 
1H, J = 5.1 Hz) and the –CH3 of the epoxide in 1.48 ppm (s, 3H).  
 
Scheme 20: Final coupling of the left and right hand fragments of Carfilzomib. 
a-a'
a-a'
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Figure 81: 1H NMR of Carfilzomib in CDCl3, 400 MHz. 
The total synthesis of Carfilzomib was accomplished in an overall yield of only 57% besides 
the improvement in the left-hand procedure of synthesis, fundamentally because the 
epoxidation process used was non-stereoselective. 
3.3 Carbonylacrylic-Caproic-Val-Cit-PABOH linker preparation in solid phase. 
As previously shown, the reported synthesis of Maleimido-Caproic-Val-Cit-PABOH linker 
using convergent solution phase synthesis is laborious and not efficient (5 days and 44% yield). 
A possible solid phase synthesis of this linker or a similar containing carbonylacrylic moiety 
instead of maleimido is desired. Carbonylacrylic moiety is preferred instead of maleimide 
because of the expected physiological instability in biological conditions. Initial attempts 
employing Cl-Trt-Chloride resin were not good enough because the coupling of alcohol (Fmoc-
PAB-OH) to Trt produces only 10% yield (reaction in Py at 60 oC or using AgOTf as 
catalyst).211 Accompanying to this, the subsequent coupling of Fmoc-Cit-OH to the deprotected 
H2N-PAB-O-Trt-Chloride resin was unsuccessful with any coupling reagent, DIC/OxymaK, 
BTC/collidine or EEDQ. This could be due to the early cleavage of the PABOH during 
deprotection of Fmoc with piperidine 20% in DMF or the expected product (Fmoc-Cit-PABOH, 
attached in only 10%). To solve this problem, Fmoc-Cit-PABOH (90% yield) was prepared in 
liquid phase by coupling of Fmoc-Cit-OH with PABOH in the presence of the special coupling 
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reagent EEDQ. The attachment of this compound to Cl-Trt Chloride resin and later coupling of 
Val, 6-aminocaproic acid and carbonylacrylic acid afforded the expected product in less than 
10% yield.  
After a literature review, we found a special resin for the attachment of alcohols, named DHP-
resin. It contains a dihydropyrane linker that after reaction with alcohol in the presence of strong 
acid catalyst (TsOH, 0.1 equiv.) furnishes the alcohol attached to a tetrahydropyrane forming 
acetal in high yield. The cleavage is realized by treatment with the weak acid PPTS at 60 oC 
(pyridinium p-toluensulfonate). The attachment of Fmoc-Cit-PABOH to this resin occurred in 
almost quantitative yield and the following couplings of Val, caproic acid and carbonylacryli 
acid permitted to obtain the expected product (which we will call Linker-OH from now on) in 
more than 95% yield, in only 2 days (Scheme 21). This route represents a great improvement 
in the synthesis of this type of linkers and for the first time includes the introduction of the 
carbonylacryl Michael-acceptor. It is important to mention that the couplings of Val and caproic 
acid were performed using DIC/OxymaK, but in the last step (attachment of the carbonylacrylic 
acid), it was necessary to use DIC/Oxyma coupling agent since OxymaK reacted with the 
double bound of the Michael-acceptor. 
 
Scheme 21: Solid phase synthesis of the Linker-OH using DHP-resin. 
The 1H-NMR spectra of the Linker-OH is presented in the Figure 82. The signals of the 
hydrogens a and b can be confirmed by the presence of two doublets in 7.88 ppm (a, J = 15.4 
Hz, 1H) and 7.01 ppm (b, J = 15.4, 1H), with a coupling constant of 15.4 Hz for the trans 
geometry of the olefin. The two peptidic -N-CH-CO- (c and d) hydrogens can be identified by 
the signal in 4.40 ppm (c, dd, J = 9.0, 4.7 Hz, 1H) and the doublet in 4.19 ppm (d, d, J = 7.4 
Hz, 1H). The two CH3 groups of the Valaminoacid (e) can be confirmed by the doublet of 
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doublets in 0.98 ppm (dd, J = 8.6, 6.8 Hz, 6H). The multiplets from the aminoacids side chains 
(Cit and 6-aminohexanoic) are distributed from 3.6 and 1.4 ppm. The aromatic phenyl rings of 
carbonylacrylic and PABOH appear in 8.08–7.99 ppm (m, 2H), 7.72–7.65 ppm (m, 1H) and 
7.61–7.53 ppm (m, 2H). In the 13C NMR spectra is possible to observe seven carbonyl signals 
between 191.9 and 162.24 ppm, four aromatic and two olefin signals from 138.0 and 129.9 
ppm, two peptidic -N-CH-CO- in 60.5 and 53.4 ppm followed by nine singlets between 40.5 
and 18.8 ppm corresponding to the Cit, Val, and 6-aminohexanoic acid.  
 
Figure 82: 1H-NMR of the Linker-OH in DMSO-d6. 
The ESI-MS of the Linker-OH (crude cleavage product) show masses corresponding to 
thepyridinium charged molecule due to the presence of PPTS in the cleavage crude material 
(Figure 83). 
 
Figure 83: ESI-MS of the crude Linker-OH. 
R2
R1
Ha
Hb
J trans = 15.4 Hz
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We then proceeded to the chlorination reaction using thionyl chloride and DMF as 
solvent/catalyst. This reaction proceeds efficiently (70%) and does not affect the 
carbonylacrylic motif. However, as reported previously,199 the Menshutkin reaction (formation 
of quaternary salts by reaction of benzyl chlorides with tertiary amines) of this linker with 
Carfilzomib gives poor yields (15-30%, in the presence of TBAI as catalyst). It is known that 
bimolecular substitution reactions (SN2) are influenced by the nature of the leaving group. In 
some cases, aniodine source is used as catalyst when bromo or chloro should be substituted. 
The tosylation of the Linker-OH and then substitution with iodide allows to obtain a linker with 
efficient yield in the reaction with tertiary amine and only implies an additional step in the total 
process. Tosylation of the Linker-OH was performed quantitatively with tosyl chloride in Py. 
The ESI-MS of the crude showed the same behavior that in case of Linker-OH, the signal of 
double charged species produces by the simultaneous protonation and pyridinium was present 
(Figure 84). 
 
Figure 84: ESI-MS of the Linker-OTs. 
The final reaction of the Linker-OTs with TBAI afforded the Linker-I in good yield after 24 h 
of reaction. The characterization by 1H-NMR (Figure 85), ESI-MS (Figure 86) and ESI-HRMS 
(Figure 87) validated the structure after purification by flash chromatography. 
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Figure 85: 1H-NMR of the Linker-I in DMF-d7, 400 MHz. 
 
Figure 86: ESI-MS of the Linker-I. 
 
Figure 87: ESI-HRMS of the Linker-I. 
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3.4 pHLIP-Variant3 synthesis containing Cys at N or C-terminals 
Low pH insertion peptide pHLIP-Variant3 (ACDDQNPWRAYLDLLFPTDTLLLDLLW) is a 
novel marker of acidic malignant lesions. By using 31P magnetic resonance spectroscopy 
(MRS), Tapmeier et al. demonstrated that pHLIP-Variant3 was retained in tumors of pH equal 
to or less than 6.7, but not in tissues of higher pH. Acidic pH may distinguish aggressive from 
more indolent cancers. Using pHLIP Variant3, they showed the ability to detect cancer with a 
low false-positive rate in a genetically engineered model of murine breast cancer, paving the 
way for testing this probe in clinical situations. 
pHLIP-Variant3 peptide possesses a Cys residue at the N-terminal, making it a special candidate 
for the conjugation to anticancer drugs through sulphur addition to carbonylacryl containing 
linkers. This construct could target cancer cells by the characteristic low pH that presents. After 
insertion of the pHLIP-Variant3 peptide into the membrane by the C-terminal, linker-drug at 
the N-terminal stays outside the membrane. Besides the final cleavage of the drug from the 
linker occurs in lysosomes after the total internalization, a pHLIP variant containing Cys at C-
terminal is desired, although that it could affect the insertion of pHLIP into the membrane. We 
decided to synthetize the two variants, Cys at C-terminal or at N-terminal and finally determine 
the bestby biological tests.  
The synthesis was carried out by successive coupling of aminoacids with DIC/Oxyma in the 
Wang-Resin to obtain the free carboxylic acid at the C-terminal of peptides. Cleavage in the 
presence of EDT was needed to avoid oxidation of Cys during concentrated TFA treatment. 
RP-HPLC of the crude product showed more that 80% peptidic purity (70% yield) for both 
cases (Figure 112) and retention times of 33 min for pHLIP-Variant3 containing Cys at N-
terminal and 34.7 min for the variant containing Cys at C-terminal. ESI-HRMS spectra 
indicated the expected molar mass of the products and two fragments due to inevitable 
ionization cleavage at the second Pro of the sequences. MALDI (soft ionization technique) 
analysis corroborated the existence of both structures without fragmentation (Figure 88, Figure 
89). 
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Figure 88: ESI-HRMS (upper panel) and MALDI (lower panel) spectra of the pHLIP peptide containing 
Cys at C-terminal (AADDQNPWRAYLDLLFPTDTLLLDLCW). 
 
 
 
Figure 89: ESI-HRMS (upper panel) and MALDI (lower panel) spectra of the pHLIP peptide containing 
Cys at N-terminal (ACDDQNPWRAYLDLLFPTDTLLLDLLW). 
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3.5 Carfilzomib coupling to Linker-I 
With the pure Carfilzomib and Linker-I in hand, we developed the Menshutkin reaction 
between them in DMF at room temperature (Scheme 22). After 3 h of reaction, we observed 
the total consumption of Carfilzomib in TLC analysis but after precipitation in diethylether, 
only 48 % yield was obtained. This represents a great advance in reaction time and conversion 
when is compared with the previously reported method using Linker-Cl. The ESI-MS 
confirmed the expected molecular mass of the product (Figure 90) and indicate good stability 
when ionization is achieved in presence of HCOOH, besides showed different ionization 
behavior. 
 
Scheme 22: Coupling of the Linker-I to Carfilzomib. 
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Figure 90: ESI-MS of the Linker-Carfilzomib salt in precense of HCOOH (upper panel) or withow 
HCOOH (lower panel). 
3.6 Final coupling of pHLIP to Linker-Carfilzomib by thiol-Michael addition. 
Treating carbonylacrylic derivatives Linker-I in a solution of MeCN/sodium phosphate buffer 
(NaPi) (pH 8.0, 50 mM) at room temperature, for 12 h and inert atmosphere to avoid the Cys 
oxidation by oxygen, gave excellent isolated yield of the desired cysteine-conjugates (Scheme 
23). RP-HPLC analysis (Figure 91) showed more than 60% of convertion and a change in 
retention time (from 39 min to 41 min) of the starting material, pHLIP-Variant3 (Cys at the N-
terminal, B5 in Experimental Seccion, Figure 112). ESI-HRMS (Figure 92), show 
fragmentations similar to pHLIP peptides and MALDI analysis will be performed in future 
experiments. 
 
Figure 91: RP-HPLC of the bioconjugation of Linker-CFZ salt with pHLIP-Variant3 containing Cys at 
the N-terminal. 
The binding of Carfilzomib to pHLIP instead of an antibody eliminates all the disadvantages of 
ADCs, especially those related to the masking of tumor cells. On the other hand, the production 
126 
 
of pHLIP is simpler, less expensive and has shown to be proteolytically stable. The linker 
guarantees, together with pHLIP peptide, the targeted release of the drug, in addition to 
releasing it without chemical modifications (traceless approach).  
 
Scheme 23: Final conjugation of Linker-CFZ salt to pHLIP-Variant3 peptide containing Cys at the N-
terminal. NaPi should cause the interchange of iodo by dihydrogenphosphate. 
 
Figure 92: ESI-HRMS of the bioconjugate pHLIP-Variant3-Linker-CFZ. 
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Conclusions. Chapter 3 
 Carfilzomib was synthesized in 45% yield by combination of SPPS using OxymaK 
(including the synthesis of morpholino acetyl by morpholine bimolecular substitution of 
bromoacetil) and final coupling of Leu-epoxide. 
 A new carbonylacrylic-traceless-linker solid phase synthetic method was developed; in 
which iodo was used as leaving group to improve the yield during reaction with tertiary amine 
drugs (Carfilzomib). 
 pHLIP peptide containing Cys at the C and N terminals was synthesized in solid phase with 
good yield and peptidic purity. 
 For the first time, a PDCs containing pHLIP, Carfilzomib and a carbonylacrylic container 
linker (self-immolative and enzymatically cleavable) were obtained.  
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Future works. Chapter 3 
 Evaluatethe anticancer effectiveness and reduction of adverse effect of Carfilzomib using 
the pHLIP-Variant3-Linker-CFZ conjugate of our work.  
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4 Experimental Section. Chapter 3 
4.1 General Remarks 
4.1.1 Materials 
In this section was used the same materials, method of peptide synthesis, peptide cleavage, 
analytical RP-HPLC, ESI-HRMS and semipreparative RP-HPLC as described in sections 4.1.1-
4.1.3 and 4.1.6-4.1.8 of Chapter 1 and section 4.1.2 for NMR conditions of Chapter 2. 
Cl-Trt Chloride Polystyrene Resin (1.47 mmol/g), Wang Polystirene Resin (1.7 mmol/g) and 
DHP-Polystirene Resin (1.56 mmol/g) were obtained from commercial suppliers. 
4.1.2 MALDI-TOF   
Low‐energy MALDI spectra were obtained in the LaBioMI, UFSCar, Brazil. All spectra were 
obtained with the sample deposited on a MALDI ground steel target plate (MTP 384, Bruker 
Daltonics®) loaded onto a MALDI-TOF MS AutoFlex Speed (Bruker Daltonics®) and α-
cyano-4-hydroxycinnamic acid as matrix. The MALDI-TOF MS equipment was operated using 
Flex Control 3.3 software (Bruker Daltonics®). The positively-charged ions were generated 
with a Smartbeam™ laser at 355 nm, 50 Hz frequency, PIE (Pulsed Ion Extraction) of 120 ns 
and voltage of 2.60 kV lenses. The voltage of the ion sources was 5.99 kV in the first ion source 
and 5.23 kV in the second. The ions were separated using the TOF operating in linear mode. 
The spectra were generated with an average of 10,000 laser shots per spectrum, with power 
ranging between 70% and 90%, with attenuations (laser offset) of 15–28%. For peak position, 
a 75% cut off above the base line level (percent height) was specified. For the exportation of 
the raw spectra, the Flex Analysis 3.3 software (Bruker Daltonics®) was used. The calibration 
was performed using Protein Calibration Standard I (Insulin, [M+H]+ at m/z 5734.51, Ubiquitin 
I, [M+H]+ at m/z 8565.76) from Bruker Daltonics®, in a mass range of 2 to 10 kDa. 
4.1.3 ESI-MS 
Low‐energy ESI‐MS spectra were obtained in the CERSusChem, UFSCar, Brasil, by using a 
time-of-flight TOF instrument (Waters, Milford, MA, USA) equipped with a electrospray ion 
source in positive ion mode. Peptide solutions were prepared dissolving the crude of reaction 
in a solution of HCOOH 1% in MeOH and loaded into a metal-coated borosilicate capillary tip 
(Proxeon, Denmark), inserted into the Z‐spray flow electrospray ion source, and slightly 
pressured with nitrogen to guarantee their stable spray during measurement. The capillary and 
cone voltage were set to 100 to 300 and 5 to 50 eV, respectively. Mass spectra were acquired in 
the m/z range of 200–1000 Th. Electrospray ionization mass spectrometry spectra were 
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processed using the MassLynx version 4.1 program (Micromass, England). Protonated 
molecular ions (M+H)+, sodium adducts (M+Na)+ or potassium adducts (M+K)+ were used for 
empirical formula confirmation. 
4.2 Synthesis of the left-hand fragment of Carfilzomib: Morf-Ac-Hph-Leu-Phe-OH 
4.2.1 Loading of Fmoc-Phe-OH to Cl-Trt Chloride resin (1.47 mmol/g) 
NOTE: It is important to dry all solvents and glassware before use. Fmoc-aminoacids are best 
dried before use by repeated evaporation from dioxane. The carboxylic acid (1.2 eq. relative to 
the resin) and DIPEA (4 eq) is dissolved in dry DCM (approx. 10 mL per gram of resin) 
containing, if necessary, a small amount of dry DMF (just enough to facilitate dissolution of 
the acid). This mixture is added to the pre-swelled resin and stir for 1-2 h. At the end of this 
time, the resin was washed with 3x DCM/MeOH/DIPEA (17:2:1), 3x DCM; 2x DMF, 2x DCM, 
dried in vacuum and weigh to check the quantity of Fmoc-aminoacid loading (95% loading).  
Subsequent couplings of Fmoc-Leu-OH, Fmoc-Hph-OH, BrHAc and substitution of bromo by 
morpholino were conducted followig the general peptide synthesis protocol in Section 4.1.2, 
Chapter 1. The only difference was the use of OxymaK racemization inhibitor instead of Oxyma 
in aim of delimitate the early cleavage from the resin. Bromo substitution by morpholino was 
performed similarly to the deprotection of the Fmoc group by piperidine 20% in DMF.  
4.2.2 Cleavage of Morf-Ac-Hph-Leu-Phe-OH with TFA/DCM 
The peptidyl Cl-Trt Chloride resin was treated at room temperature with TFA 1% in DCM (2:8) 
(10 x 2 min). After the appropriate time, the resin was removed by filtration, washed with 
MeOH and Et2O and dried in vacuum to check the loss of mass (100% losses). Combined 
filtrates are evaporated to dryness. TFA sal of the product is obtained.  
ESI-HRMS m/z: 567.47±0.00 [M+H]+, calcd. for [C31H42N4O6]
+: 567.31 
1H NMR (400 MHz, CDCl3) δ: 7.26 – 7.21 (m, 4H), 7.21 – 7.15 (m, 4H), 7.11 (d, J = 6.9 Hz, 
2H), 4.66 (dd, J = 14.0, 8.8 Hz, 1H), 4.37 (dd, J = 14.2, 8.4 Hz, 1H), 4.26 (dd, J = 13.5, 6.9 Hz, 
1H), 4.03 – 3.86 (m, 6H), 3.49 (s, 2H), 3.23 (dd, J = 14.0, 4.6 Hz, 2H), 3.13 – 3.00 (m, 1H), 
2.94 (dd, J = 13.7, 9.4 Hz, 1H), 2.80 – 2.57 (m, 2H), 2.15 – 1.95 (m, 2H), 1.53 – 1.38 (m, 2H), 
1.37 – 1.21 (m, 2H), 0.78 (d, J = 6.2 Hz, 3H), 0.71 (d, J = 6.0 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ: 174.42, 173.39, 172.93, 164.34, 140.06, 136.22, 129.27 
(2xCH), 128.59 (2xCH), 128.52, 128.35, 127.03, 126.43, 63.61, 63.27, 57.46, 55.80, 53.76, 
53.48, 53.11, 40.42, 37.42, 33.46, 32.12, 24.73, 22.45, 21.55, 17.67 (2xCH3), 12.25. 
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Figure 93: 1H NMR of the left hand fragment of Carfilzomib in CDCl3, 400 MHz. 
 
Figure 94: 13C NMR of the left hand fragment of Carfilzomib in CDCl3, 100 MHz. 
4.3 Synthesis of the left-hand fragment of Carfilzomib 
4.3.1 Synthesis of Boc-Leu-derived Weinreb amide 
To a solution of Boc-Leu-OH (336 mg, 1.26 mmol) and TBTU (497 mg, 1.54 mmol) in THF 
(10 mL) at 0°C was added a solution of HCl salt of N,O-dimethylhydroxylamine (350 mg, 1.26 
mmol) in THF (3 mL) followed by DIPEA (660 L, 3 mmol). The mixture was stirred at -20oC 
to rt for 12h, quenched by the addition of saturated HCl (5% aq) and extracted with EtOAc. The 
organic layer was washed one more time with HCl (5% aq), two times with saturated NaHCO3 
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(aq), brine, dried over Na2SO4 and the solvent was removed under reduced pressure. Column 
chromatography (10:1 to 5:1 Hexane:EtOAc) gave 470 mg (93%) of Boc-Leu-derived Weinreb 
amide.  
Rf= 0.58 (Hexane/EtOAc 8:2) 
1H NMR (400 MHz, CDCl3) δ: 5.06 (d, J = 8.9 Hz, 1H), 4.73 (td, J = 9.2, 2.9 Hz, 1H), 3.79 (s, 
3H), 3.20 (s, 3H), 1.82 – 1.65 (m, 2H), 1.43 (s, 10H), 0.97 (d, J = 6.5 Hz, 3H), 0.93 (d, J = 6.7 
Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ: 173.90, 155.65, 79.46, 61.59, 48.97, 42.09, 32.14, 28.35, 24.72, 
23.35, 21.57. 
 
Figure 95: 1H NMR of Boc-Leu-Weinreb amide derivative in CDCl3, 400 MHz. 
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Figure 96: 13C NMR of Boc-Leu-Weinreb amide derivative in CDCl3, 100 MHz. 
4.3.2 Synthesis of Boc-Leu-derived iso-propenyl ketone 
In a Schlenk tube equipped with septum and magnetic stirring bar, Boc-Leu-Weinreb amide 
(470 mg, 1.71 mmol) was cooled to 0 °C. A solution of isopropenylmagnesium bromide in THF 
(0.5 M, 10.3 mL, 5.14 mmol, 3 equiv.) was added dropwise. The reaction was maintained at 0 
°C for one hour, warmed to rt and stirred for 5-6 hours until full conversion was detected by 
TLC (Hexane/EtOAc 9:1). The reaction was cooled to 0 °C and quenched by addition of 
saturated NH4Cl (5 mL) and water (10 mL). The mixture was extracted with 3x10 mL of Et2O. 
Layers were separated and the aqueous phase was extracted with EtOAc (2x250 mL). The 
combined organic layer was washed with HCl (5% aq), saturated NaHCO3, brine, dried over 
Na2SO4 and the solvent was removed under reduced pressure to afford 500 mg of crude product. 
Purification by flash chromatography using a gradient elution mixture (10:1 to 8:2 
hexane/EtOAc) gave 349 mg (80%) of the product, which solidifies upon standing at 8°C.  
Rf= 0.43 (Hexane/EtOAc 9:1) 
1H NMR (400 MHz, CDCl3) δ: 6.07 (s, 1H), 5.87 (s, 1H), 5.13 (d, J = 8.1 Hz, 1H), 5.05 (td, J 
= 9.2, 2.9 Hz, 3H), 1.89 (s, 3H), 1.78 – 1.66 (m, 1H), 1.42 (s, 10H), 1.36 – 1.28 (m, 1H), 0.99 
(d, J = 6.5 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H). 
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13C NMR (100 MHz, CDCl3) δ: 201.64, 155.55, 142.28, 126.09, 79.57, 52.56, 43.18, 28.33, 
24.95, 23.37, 21.74, 17.84. 
 
Figure 97: 1H NMR of Boc-Leu-Alkene in CDCl3, 400 MHz. 
 
Figure 98: 13C NMR of Boc-Leu-Alkene in CDCl3, 100 MHz. 
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4.3.3 Epoxidation of Boc-Leu-derived iso-propenyl ketone 
349 mg of the vinylketone (1.36 mmol) were dissolved in 10 mL of MeOH and the solution 
was cooled to 0°C. Subsequently 400 L of 30% H2O2 (ac) (2.6 eq) in 1 mL of MeOH and 45 
mg KOH (0.5 eq) dissolved in 1 mL of MeOH was added drop wise. The mixture was stirred 
overnight and then allowsreach room temperature. The mixture was hydrolyzed with 15 mL of 
water and the product was extracted with 2x50 mL of DCM. The combined organic phases were 
washed with 50 mL of 1M Na2S2O3 (ac) and brine. After evaporation to dryness 200 mg (50%) 
of a white solid was isolated, which contain an approximate 4:1 ratio of two diastereomers of 
the desired product as judged by 1H-NMR (Figure 99). Purification by flash chromatography 
using a gradient elution mixture (10:1 to 8:2 hexane:EtOAc) gave 150 mg of the BocLeu-
Epoxide-A (Figure 100,Figure 101) and 40 mg of the BocLeu-Epoxide-B (Figure 102), which 
crystalizes upon standing at 8 °C. 
Rf= 0.4 (Hexane/EtOAc 9:1) 
1H NMR (400 MHz, CDCl3) δ: 4.84 (d, J = 7.7 Hz, 1H), 4.32 (t, J = 8.8 Hz, 1H), 3.29 (d, J = 
4.8 Hz, 1H), 2.88 (d, J = 5.0 Hz, 1H), 1.79 – 1.60 (m, 1H), 1.51 (s, J = 8.2 Hz, 1H), 1.41 (s, 
1H), 1.22 – 1.12 (m, 1H), 0.95 (dd, J = 12.9, 6.6 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ: 209.57, 155.46, 79.74, 58.97, 52.32, 51.40, 40.45, 28.31, 
25.08, 23.39, 16.77. 
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Figure 99: 1H NMR of the crude mixture of diastereomeric Boc-Leu-Epoxides in CDCl3, 400 MHz. 
 
Figure 100: 1H NMR of Boc-Leu-Epoxide-A in CDCl3, 400 MHz. 
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Figure 101: 13C NMR of Boc-Leu-Epoxide-A in CDCl3, 100 MHz. 
 
Figure 102: 1H-NMR of Boc-Leu-Epoxide-B (impure) in CDCl3, 400 MHz. Rf= 0.37 (Hexane/EtOAc 
9:1). 
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4.3.4 Deprotection of Boc-Leu-Epoxy ketone 
To a solution of Boc-Leu-Epoxy ketone (2 g, 7.8 mmol) in DCM (30 mL) at 0°C was added 
TFA (10 mL). The reaction was warmed to room temperature and stirred for 6 h (completation 
checked by TLC). The solvent was removed and the TFA salt precipitated with ter-butyl methyl 
ether (TBME) and hexane at low temperature to give 1.5 g (75%) of the product after filtration 
and drying under vacuum.  
1H NMR (400 MHz, CDCl3) δ: 1H NMR (400 MHz, CDCl3) δ 7.96 (s, J = 37.8 Hz, 3H), 4.08 
(d, J = 9.0 Hz, 1H), 3.11 (d, J = 4.2 Hz, 1H), 2.94 (d, J = 4.4 Hz, 1H), 1.84 – 1.75 (m, 1H), 1.71 
(t, J = 11.8 Hz, 1H), 1.58 – 1.47 (m, 4H), 0.97 (d, J = 4.4 Hz, 6H). 
13C NMR (100 MHz, CDCl3) δ: 205.56, 161.88, 161.51, 58.79, 52.74, 52.49, 39.02, 24.56, 
22.95, 20.63, 16.54. 
 
 
Figure 103: 1H NMR of trifluoracetate salt of Leu-Epoxide-A in CDCl3, 400 MHz. 
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Figure 104: 13C NMR of trifluoracetate salt of Leu-Epoxide-A in CDCl3, 100 MHz. 
 
4.3.5 Coupling of the left- and right-hand fragments of Carfilzomib 
To the tetrapeptide Morf-Ac-Hph-Leu-Phe-OH (100 mg, 0.176 mmol), TBTU (70 mg 0.211 
mmol) and HOBt (29 mg, 0.211 mmol) in THF (2.5 mL) was added DIPEA (90 uL, 0.53 mmol) 
at -20°C. Then the HCl salt of Leu-Epoxy ketone (34 mg, 0.176 mmol) in THF (1 mL) was 
added. After stirring the mixture for 12 h at room temperature, saturated NaHCO3 was added 
and extracted with EtOAc. The organic layer was washed with saturated NaHCO3, brine, dried 
over Na2SO4 and the solvent removed under reduced pressure to give 124 mg (100%) of crude 
product.  
Rf= 0.65 (EtOAc) 
ESI-MS m/z (of the pure product): 720.42±0.00 [M+H]+, calcd. for [C40H57N5O7]
+: 720.43 
1H NMR (400 MHz, CDCl3) δ: 7.29 – 7.21 (m, 2H), 7.19 (dd, J = 7.0, 1.3 Hz, 3H), 7.15 (dd, J 
= 8.1, 3.0 Hz, 2H), 7.13 (dd, J = 6.6, 5.2 Hz, 4H), 7.01 (d, J = 7.7 Hz, 1H), 4.69 (dd, J = 14.8, 
7.0 Hz, 1H), 4.56 – 4.48 (m, 1H), 4.48 – 4.41 (m, 1H), 4.40 – 4.32 (m, 1H), 3.80 – 3.73 (m, 
4H), 3.22 (d, J = 4.9 Hz, 1H), 3.12 (t, J = 16.9 Hz, 2H), 3.03 (d, J = 6.8 Hz, 2H), 2.85 (d, J = 
5.0 Hz, 1H), 2.69 – 2.62 (m, 4H), 2.60 (t, J = 7.5 Hz, 3H), 2.11 – 2.02 (m, 2H), 2.00 – 1.88 (m, 
2H), 1.51 (t, J = 5.5 Hz, 2H), 1.48 (s, 3H), 1.45 (t, J = 6.5 Hz, 2H), 0.89 – 0.82 (m, 12H). 
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13C NMR (100 MHz, CDCl3) δ: 207.91, 171.46, 171.36, 170.57, 170.47, 140.57, 136.34, 
129.28, 128.62, 128.53, 128.32, 126.98, 126.32, 66.88, 61.79, 58.99, 53.89, 53.79, 52.41, 52.28, 
52.17, 49.99, 40.94, 39.95, 37.94, 33.44, 31.94, 25.02, 24.75, 23.31, 22.91, 21.83, 21.27, 16.66. 
 
 
Figure 105: RP-HPLC of Carfilomib. 
 
Figure 106: ESI-HRMS of Carfilomib. 
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Figure 107: 13C NMR of Carfilzomib in CDCl3, 100 MHz. 
4.4 Carbonylacrylic-Caproic-Val-Cit-PABOH linker preparation in solid phase 
4.4.1 Synthesis of Fmoc-Cit-PABOH 
A solution of Fmoc-Cit-OH (500 mg, 1.27 mmol) and PABOH (234 mg, 1.9 mmol) in DCM 
(10 ml) and MeOH (4 ml) was treated with EEDQ (470 mg, 1.9 mmol) and stirred for 15 h. The 
solid product was triturated three times with ether, then filtered and dried. The yield was 570 
mg (90%).  
1H NMR (400 MHz, DMSO) δ: 7.86 (d, J = 7.3 Hz, 2H), 7.74 – 7.66 (m, 2H), 7.54 (d, J = 8.4 
Hz, 2H), 7.38 (t, J = 7.2 Hz, 2H), 7.34 – 7.26 (m, 2H), 7.21 (d, J = 8.1 Hz, 2H), 6.08 – 5.87 (m, 
1H), 5.51 – 5.32 (m, 2H), 5.09 (t, J = 5.6 Hz, 1H), 4.40 (d, J = 5.4 Hz, 2H), 4.32 – 4.05 (m, 
4H), 3.10 – 2.86 (m, 2H), 1.75 – 1.52 (m, 2H), 1.51 – 1.28 (m, 2H). 
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Figure 108: 1H NMR of Fmoc-Cit-PABOH in DMSO-d6, 400 MHz. 
4.4.2 Loading of Fmoc-Cit-PABOH to DHP Polystyrene resin and Linker-OH synthesis 
The resin (1g, 0.7 mmol) is solvated in 7.8 mL of DCE at room temperature for 15 min. The 
alcohol (5 equiv.) is then added and the mixture is chilled to 0 oC, followed by addition of p-
TsOH (134 g, 0.70 mmol) in one portion. The resulting slurry is stirred at 0 oC for 16 h. The 
resin is then washed with DCM (1x), DMF, DCM (3x) and dried in vacuum.Subsequent 
couplings of Fmoc-Val-OH, Fmoc-6-aminohexanoic acid, was conducted following the general 
peptide synthesis protocol in Section 4.1.2, Chapter 1. The only difference was the use of 
OxymaK racemization inhibitor instead of Oxyme to limitate the early cleavage from the resin. 
Final coupling of carbonylacrylic acid was realized with DIC/HOBt because Oxyma or 
OxymaK react with the Michael-acceptor.  
4.4.3 General conditions for cleaving the Linker-OH from the DHP Polystyrene Resin 
Peptide-alcohol derivatized resin (1g, 0.74 mmol) is solvated in 20 mL of 1:1 n-butanol/1,2-
dichloroethane, and PPTS (370 mg, 1.48 mmol) is then added. The flask isstoppered and heated 
to 60oC for 16 h. The solution is isolated by filtration and concentrated in-vacuum. The resulting 
material can be separated from the PPTS by flash chromatography (EtOAc/MeOH 10:1).  
Rf: 0.4 (EtOAc/MeOH 10:1) 
ESI-MS m/z (of the crude product): 730.59 [M+PyH]+, calcd. for [C39H52N7O7]
+: 730.39 
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ESI-MS m/z (of the pure product): 673.5 [M+Na]+, calcd. for C34H46N6NaO7: 673.33 
1H NMR (400 MHz, DMSO) δ: 9.91 (s, 1H), 8.59 (s, 1H), 8.27 (s, 1H), 8.10 – 7.80 (m, 3H), 
7.74 (d, J = 15.3 Hz, 1H), 7.67 (t, J = 7.4 Hz, 1H), 7.56 (t, J = 7.7 Hz, 4H), 7.41 – 7.29 (m, 1H), 
7.21 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 15.3 Hz, 1H), 6.59 (dd, J = 26.5, 9.5 Hz, 1H), 6.16 – 6.01 
(m, 1H), 5.42 (s, 2H), 5.10 (t, J = 5.8 Hz, 1H), 4.38 (d, J = 5.4 Hz, 1H), 4.18 (dd, J = 10.9, 4.2 
Hz, 1H), 3.24 – 3.10 (m, 2H), 3.10 – 2.91 (m, 2H), 2.28 – 2.10 (m, 2H), 2.04 – 1.91 (m, 1H), 
1.81–1.65 (m, 1H), 1.65 – 1.20 (m, 9H), 0.84 (dd, J = 10.2, 6.8 Hz, 6H). 
13C NMR (100 MHz, DMSO) δ: 189.76, 172.38, 171.24, 170.32, 163.25, 162.52, 137.43, 
136.59, 133.58, 131.53, 128.88 (3CH), 128.52 (3 CH), 126.92, 126.82, 118.80, 118.71, 62.60, 
57.65, 52.96, 47.73, 35.72, 35.02, 30.24, 28.56, 26.67, 26.05, 25.05, 19.16, 18.12. 
 
 
Figure 109: 13C NMR of Linker-OH in DMSO-d6, 100 MHz. 
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Figure 110: ESI-MS of the pure Linker-OH. 
4.4.4 Tosylation of Linker-OH 
In a three-neck balloon, 0.6 g (12.8 mmol) of linker-OH are dissolved in 20 mL of Py and 3.68 
g (19.3 mmol) of TsCl are added. The air is removed under reduced pressure, the mixture is 
stirred at room temperature under inert atmosphere (N2) and protected from light until the total 
disappearance of the starting material (approximately 24h, followed by TLC, hexane/EtOAc 
3:7, Rf= 0.9). Some drops of water is added to quench the excess of TsCl. The Py is removed 
by azeotropic evaporation with toluene (3x) to obtain the desired tosylate in 91% yield (0.50 g) 
after flash chromatographic purification (Hexane:EtOAc 1:1).  
ESI-MS m/z (of the crude product): 443.35 [M+PyH]+, calcd. for [C43H59N7O9S]
2+: 855.41 
4.4.5 Iodination of Linker-OTs 
In a small vial, the Linker-OTs (1 equiv.) were combined in DMF (0.25 M) at room temperature 
with 1.1 eq of TBAI and the mixture stirred until all starting material was consumed TLC 
(EtOAc, 24h). The mixture is then treated slowly with water (130 mL) to precipitate a yellow 
solid, which was collected by filtration. The solid was washed sequentially with water, ACN, 
and MTBE. After drying under vacuum, 0.5 g (50% yield) of yellow solid was recovered.  
Rf= 0.8 (EtOAc) 
ESI-MS m/z (of the pure product): 411.23 [M+NaK]2+, calcd. for [C34H45IKN6NaO6]
2+: 822.20 
and 799.46 [M+K]+, calcd. for [C34H45IKN6O6]
+: 799.21 
1H NMR (400 MHz, DMF) δ: 8.09 (d, J = 7.9 Hz, 2H), 7.90 (d, J = 15.3 Hz, 1H), 7.82–7.68 
(m, 2H), 7.64 (t, J = 7.6 Hz, 2H), 7.49 – 7.26 (m, 3H), 7.16 (d, J = 15.2 Hz, 1H), 4.26 (s, 2H), 
3.66 – 3.40 (m, 4H), 3.32 (d, J = 6.4 Hz, 2H), 2.42–2.06 (m, 5H), 1.70–1.51 (m, 4H), 1.40 (dd, 
J = 14.1, 7.8 Hz, 2H), 1.30 (t, J = 5.2 Hz, 2H), 0.94–0.88 (m, 6H). 
13C NMR (100 MHz, DMF) δ: 202.73, 190.29, 179.35, 172.83, 168.86, 164.00, 137.36, 137.02, 
134.00, 132.16, 129.10 (2C), 128.75 (2C), 128.48, 128.39, 126.02, 125.09, 58.27, 57.01, 39.94, 
39.73, 39.48, 38.87, 35.71, 30.72, 28.52, 26.86, 26.67, 25.66, 22.58, 19.25, 17.77, 13.01. 
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Figure 111: 13C NMR of the Linker-I in DMF-d7, 100 MHz. 
4.5 Synthesis of pHLIP-Variant3 peptide containing Cys at C and N terminal. 
4.5.1 Loading of the first aminoacid to Wang-Resin (Steglich sterification) 
The resin (1g) is placed in a clean, dry flask, and sufficient DMF is added to just cover and 
allow swelling for 30 min. If necessary extra DMF is added, just to cover the resin. Fmoc-Trp 
(Boc)-OH (10 equiv. relative to resin loading) is dissolvedin dry DCM. One or two drops of 
DMF may be needed to aid complete dissolution. A solution of DIC (5 equiv. relative to resin 
loading) in dry DCM is addedto the aminoacid solution. The mixture is stirred for 20 min at 
0°C, keeping the reaction mixture free of moisture with a calcium chloride drying tube. DCM 
is removed by evaporation under reduced pressure using a rotary evaporator. The 
residuesdissolved the minimum amount of DMF and the solution is added to the resin. DMAP 
(0.1 equiv. relative to resin loading) is dissolved in DMF and this solution is added to the 
resin/aminoacid mixture. The flask is stoppered and the mixture is allowed to stand at room 
temperature for 2h with swirling. Subsequent couplings of Fmoc-aminoacids and cleavage are 
conducted follow the general peptide synthesis protocol in Section 4.1.2-4.1.4, Chapter 1.  
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Figure 112: RP-HPLC of pHLIP-Variant3 containing Cys at N-terminal (upper panel) or C-terminal 
(lower panel). 
 
4.6 Coupling of the Linker-I to Carfilzomib 
In a small vial, Carfilzomib (40 mg, 1 equiv.) and Linker-I (46 mg, 1.1 equiv.) was dissolved 
in DMF (2.5 M) at room temperature and the mixture is stirred until all starting material was 
consumed, TLC (EtOAc, 3h). The mixture wasprecipitated in freezing Et2O, centrifugated and 
and lyophilized to afford 42 mg (49 % yield) of the desired product (Linker-CFZ-I). 
ESI-MS m/z (of the lyophilized product): 758.33 [M+K]2+, calcd. for [C74H102IKN11O13]
2+: 
1518.63 and 748.69 [M+H2O]
2+, calcd. for [C74H104IN11O14]
2+: 1497.68 
4.7 Conjugation of pHLIP-Variant3 to Linker-Carfilzomib-I 
 To a solution of pHLIP (43 mg, 0.013 mmol, 1 equiv.) in 3 mL of sodium phosphate buffer 
(pH 8.0, 50 mM) containing 30% of MeCN was generated inert atmosphere of N2. Followed, a 
solution of Linker-CFZ-I (20 mg, 0.014 mmol, 1.1 equiv.) in DMF (0.2 mL) was added at room 
temperature. After 12 h of reaction the solvent was removed under reduced pressure and the 
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resulting mixture was precipitated in freezing Et2O, centrifugated and lyophilized to afford 52 
mg (82 % yield) of the desired product (pHLIP-Variant3-Linker-CFZ-I).
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Annexes 
Annex 1: Structure, name and three and one letter code of the 22 essential aminoacids. 
 
 
Annex 2: Relative swelling capacity of some solvents related to poliestirene resins. 
Solvent 
Relative swelling 
capacity 
Solvent 
Relative swelling 
capacity 
THF 5,5 DMA 3,4 
DCM 5,1 Et2O 2,5 
Dioxane 4,6 ACN 2,0 
Toluene 4,5 EtOH 1,05 
DMF 3,5 MeOH 0,95 
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Annex 3: 1H-NMR of peptides 6 (upper panel, FMV025) and 8 (lowerpanel, FMV034)in 
DMSO-d6. 
 
 
